Study of the mechanisms responsible for anemia and thrombocytopenia in an experimental mouse model of visceral leishmaniasis by Preham, Olivier
 Study of the mechanisms responsible for anemia 
and thrombocytopenia in an experimental mouse 
model of visceral leishmaniasis 
 
 
Olivier Yvon Giuseppe Preham 
 
PhD 
 
 
 
 
 
 
 
 
 
 
 
 
 
2016 
  
 2 
Abstract 
Visceral leishmaniasis (VL) is a neglected tropical disease caused by protozoan parasites 
of the Leishmania genus causing between 20 000 and 50 000 deaths per annum. The 
parasites have developed a range of mechanisms to avoid the host’s immunity and 
establish chronic infection of the spleen, liver and bone marrow as intracellular parasites of 
macrophages. The non-exhaustive list of syndromes associated with VL include 
hepatomegaly, splenomegaly, fever and pancytopenia. The causes for the reduction of red 
blood cells, platelets or leukocytes are still unclear. Many studies have focused on the 
immunological aspects of VL, both in humans and experimental models, but the 
mechanisms causing haematological disorders remain unclear. In this study, it is shown 
that mice chronically infected with Leishmania donovani (L. donovani) develop 
haematological abnormalities, namely anaemia and thrombocytopenia. Erythropoiesis was 
quantified in the bone marrow, the main site of haematopoiesis in adult mammals. The 
number of late erythroid precursors was severely reduced in infected animals. Reduction of 
medullar erythropoiesis was associated with a reduction of stromal support in the bone 
marrow shown by a reduction of stromal macrophages expressing high levels of CD169 
and a loss of CXCL12-producing stromal fibroblasts. The granulocyte-colony stimulating 
factor (G-CSF) known to deplete stromal macrophages and inhibit CXCL12 expression 
was systematically up-regulated in infected mice. Splenomegaly correlated with 
compensatory extramedullary erythropoiesis confined to the red pulp. Infection of 
splenectomised mice demonstrated that anaemia was independent of the spleen since 
medullar erythropoiesis was still impaired in these mice. Infection caused an increase in 
CD4 and CD8 T cells in the bone marrow and infected B6 RAG2-/- mice lacking mature T 
and B cells were not anaemic and had no repression of medullar erythropoiesis nor 
splenomegaly. Alterations of bone marrow stromal cells or up-regulation of G-CSF did not 
occur in these mice. Splenomegaly was relevant because it was shown to be responsible for 
thrombocytopenia. Megakaryopoiesis was unaltered by chronic infection and infected 
splenectomised mice had higher platelet counts than their sham-operated counterparts. 
Platelet production could be stimulated by injections of recombinant thrombopoietin 
(TPO) in chronically infected mice. Efficacy of TPO treatment in curing thrombocytopenia 
correlated negatively with the severity of splenomegaly. The original contribution of this 
work is the demonstration of a complex immunopathological mechanism causing 
haematological changes in an experimental model of VL. Better understanding of 
haematological alterations of VL is a step forward for the improvement of VL therapy, in 
which these alterations have been associated with the lethality of the disease.  
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Chapter 1 Introduction 
Visceral leishmaniasis (VL) is a neglected tropical disease responsible for the death of 20 
000 to 50 000 people each year. Visceralising species such as Leishmania donovani infect 
and replicate inside macrophages of the spleen, liver and the bone marrow1. The disease 
causes, among other symptoms, a reduction of circulating blood cells. Anaemia, 
leukopenia, thrombocytopenia – reduction of red blood cells, white blood cells or platelets 
respectively – or pancytopenia – the reduction of all three lineages – are common 
occurrence in patients2. Yet the mechanisms for haematological alterations are still unclear. 
Uncovering these mechanisms would allow improved treatment of patients as well as 
potentially enable better and earlier diagnosis of VL, which is sometimes mistaken for 
other haematological disorders3,4. The epidemiology and immunobiology of visceral 
leishmaniasis have been extensively studied previously and will be discussed in this 
chapter as well as the current knowledge about the haematology of the disease. This study 
focuses on anaemia and thrombocytopenia so the physiological regulation of red blood 
cells and platelets will be described. Finally known mechanisms for haematological 
changes in the context of infectious diseases will be discussed, with a particular focus on 
parasitic diseases. 
 Leishmaniasis 
  Epidemiology 
Leishmaniasis refers to multiple diseases which are caused by protozoan parasites of the 
Leishmania genus1. Cutaneous leishmaniasis (CL) is the most widespread form of the 
disease and associated with many parasites throughout the New World and Old World. CL 
causes nodules (elevated/swollen tissue) on exposed parts of the body. These nodules can 
sometimes evolve into open lesions (ulcers). The lesions appear typically between 1 week 
to 3 months after the initial bites. In most cases, infection does not spread further, although 
satellite lesions can form near the primary lesion and parasites can be found in adjacent 
draining lymph nodes. In immune-competent individuals, lesions spontaneously regress 
after 6 to 12 months but leave scars. Species of parasites are able to cause a diffuse 
cutaneous leishmaniasis (DCL). DCL is most prevalent in the New World although cases 
have been reported in the Old World as well. A primary lesion similar to that of CL 
appears, but secondary parasites-containing lesions develop on other parts of the body. The 
infection however only affects the skin and parasites do not disseminate to internal organs 
Secondary lesions are generally non-ulcerative. Mucocutaneous leishmaniasis (MCL) is a 
mostly New World-disease associated with Leishmania braziliensis, Leishmania 
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amazonensis and Leishmania guyanensis. MCL is characterised by infection and 
destruction of mucosal surfaces on the face (nasal cavity, mouth and throat) and can result 
in severe disfigurement or death from malnutrition or respiratory pneumonia. VL, also 
known as Kala-azar, is the most severe form of the disease. It is caused by Leishmania 
donovani (L. donovani) and Leishmania infantum (L. infantum) in both the Old World 
(mostly Sudan, India and Nepal) and in the New World. Compared to all other forms of the 
disease, VL is characterised by a systemic infection. Parasites are mostly found within the 
spleen, the liver, the bone marrow, the lymph nodes and other atypical locations. VL 
causes multiple symptoms among which hepato- and splenomegaly, weight loss, fever and 
anaemia are the most commonly reported. If left untreated, VL is lethal in close to 100%. 
For reasons still unclear, VL sometimes evolves into a cutaneous disease termed post kala-
azar dermal leishmaniasis (PKDL), causing a rash which usually starts on the face and can 
spread to other parts of the body. PKDL is mainly reported in Sudan and India and appears 
within 6 months or 2-3 years after VL treatment, respectively. The epidemiology of PKDL 
varies between geographical regions. Between 10% to 20% of VL patients will develop 
PKDL in India whereas as many as 50% to 60% of VL patients will develop PKDL in 
Sudan5.  
Altogether, these diseases affect millions of individuals in virtually all continents. 
According to the latest reports, 1 million new cases of CL occur each year. CL being rarely 
lethal, the burden is mostly social. As a result of scars or disfigurements, individuals tend 
to be excluded from society. Most leishmaniasis-related deaths are caused by VL, with 
300,000 new cases each year and an estimated 20,000 to 50,000 deaths annually. However, 
the clinical and epidemiological heterogeneity of leishmaniasis means that the burden of 
the disease is likely to be underestimated6. A certainty is that tropical regions are where 
most of the leishmaniasis cases occur. Epidemiology of leishmaniasis is closely linked to 
the biology of its vector. 
 Vectors of leishmaniasis 
The main natural vector of leishmaniasis is the female of a small insect of the 
Phlebotominae subfamily, commonly called the “sand fly”. Vectors of leishmaniasis in the 
Old World belong to the Phlebotomus genus whereas in the New World, vectors belong to 
genus Lutzomyia. Leishmaniasis transmission occurs during blood meals. Female sand 
flies require blood in order to produce eggs7. They suck blood from a variety of animals, 
including mammals, reptiles and birds. Because they are highly sensitive to temperature, 
sand flies are generally nocturnal in order to avoid dehydration. Blood meals thus usually 
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happen at dusk or during the night. The requirement of humid environments and high 
temperature for eggs to develop results in sand fly habitats to be concentrated in the inter-
tropical regions, which correlates with the distribution of leishmaniasis. Evidence suggest 
the distribution of these habitats is currently ongoing changes, notably in Europe8. In 
Australia, where leishmaniasis is virtually absent, a report of autochthonous infection in 
the red kangaroos was published in 20049. Because the sand fly is not endemic to 
Australia, studies have showed that female midges were potential vectors10,11. This 
evidence is still insufficient to confirm that midges are vectors of leishmaniasis since a full 
infection cycle has not been demonstrated yet in these species12,13. 
 Biology of leishmania parasites 
The Leishmania genus belongs to the group of Trypanosomatidae, which includes other 
notable parasites such as Trypanosoma brucei, the agent of Chagas disease, and 
Trypanosoma cruzi, the agent of sleeping sickness. They are protozoan parasites, i.e. 
unicellular eukaryotes. Leishmania spp. have a dual life-cycle shared between an insect 
host, the sand fly, which is also the vector, and a mammalian host. The parasites present 
two major forms: the promastigote form, an extracellular flagellated form, and the 
amastigote form, the intracellular form with no external flagella1. Promastigotes colonise 
the sand fly’s mid-gut where they proliferate (procyclic promastigotes) until they migrate 
into the proboscis (the tubular mouthpart of the insect used for blood meals) and 
differentiate into the non-proliferating infective form (metacyclic promastigotes). Upon 
transmission to a mammal, metacyclic promastigotes are phagocytised by mononuclear 
phagocytes and differentiate into amastigotes in the phagolysosome of host cells, the latter 
becoming a parasitophorous vacuole (PV). Amastigotes replicate inside phagolysosome, 
either in one communal PV (e.g. L. amazonensis en L. Mexicana) or each in an individual 
PV (e.g. L. donovani and L. major)14. Whereas downward transmission (sand fly to 
mammal) is relatively well understood, upwards transmission is less clear. Models 
generally assume that macrophages rupture when the parasite load is too heavy and that 
intracellular amastigotes are subsequently freed. These free amastigotes are thought to be 
taken up by sand flies during blood meals, after what they differentiate back to 
promastigotes, completing the life cycle. This is accepted as the mechanism propagating 
the infection from one macrophage to others. However, direct evidence for this is still 
needed. Despite the complexity of Leishmania spp. the life cycle, the genome of parasites 
is constitutively expressed15, so genetic regulation is at the post-transcriptional level and 
through changes in ploidy16,17. 
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Figure 1-1. Life cycle of Leishmania spp. parasites. Metacyclic promastigotes are transmitted to 
the host by a female sand fly. Promastigotes are then internalised by mononuclear phagocytes in 
which they transform into amastigotes and proliferate inside parasitophorous vacuoles. 
Transmission from one host cell to another is thought to occur through lysis of the host cell and 
subsequent reinvasion. Uptake of amastigotes by a sand fly can occur during a blood meal. 
Amastigotes differentiate in the sand fly midgut into proliferative procyclic promastigotes then into 
infective metacyclic promastigote, thus completing the life cycle (reproduced from Kaye and Scott, 
Nat Rev Microbiol, Jul 2011).  
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 Host cells of leishmaniasis 
Leishmania amastigotes are obligate intracellular parasites and most parasites reside within 
the vacuole of macrophages. However, many studies have shown that the variety of host 
cells of Leishmania spp. is greater than expected. 
Mononuclear phagocytes, macrophages and dendritic cells (DCs), are where most parasites 
can be found. Within each tissue, amastigotes have a preference for resident macrophages. 
In the spleen they are more readily found within marginal zone macrophages and marginal 
metalophillic macrophages, which are the macrophages forming the marginal zone around 
the splenic white pulp. In the liver, Kupffer cells are the main host cells. In the bone 
marrow, they infect CD169+ stromal macrophages18,19. Dermal DCs take up L. major 
parasites within hours of infection20. More host cells are recruited at the site of infection in 
the form of monocyte-derived DCs (moDCs). Interestingly these moDCs are both host 
cells and protective cells by stimulating interferon gamma  (IFNg) -producing T cells 21,22 . 
Neutrophils have also been reported as host cells of Leishmania spp1. Initial intradermal 
infection by the sand fly or with a needle results in neutrophils swarming towards the site 
of infection23,24. However, neutrophils are not known to be infected in the long-term. 
Parasites only reside transiently in neutrophils, which drew researchers to hypothesise that 
neutrophils are “Trojan horses” for Leishmania spp.25. Infected neutrophils become 
apoptotic and are phagocytised by phagocytic cells, which triggers anti-inflammatory 
mechanisms by autocrine and paracrine mechanisms involving mediators such as the 
transforming growth-factor beta (TGFb) and interleukin-10 (IL-10)26–28. According to the 
Trojan horse hypothesis, engulfment of infected apoptotic neutrophils by macrophages 
enables the safe passage of parasites to their long-term residence inside mononuclear 
phagocytes. It has since been demonstrated in L. major infected mice. Infected dermal DCs 
had reduced activation markers when acquiring parasites through neutrophil phagocytosis. 
Depletion of neutrophils also resulted in higher L. major-specific CD4+ T-cell responses29. 
Recently, recruitment of neutrophils by L. mexicana has been linked to a decrease in 
protective moDCs in lymph nodes. Neutropenic mice ultimately healed while lesions were 
chronic in wild-type mice22. 
L. major has been reported to reside in fibroblasts of the skin and draining lymph nodes30. 
Infected fibroblasts do not express high levels of nitric oxide (NO) that kills intracellular 
parasites. Most persistent parasites are inside fibroblasts, suggesting stromal cells are a 
safe haven for intracellular amastigotes. L. donovani can infect splenic fibroblasts 
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expressing the marker ER-TR731. Infected stromal cells produce higher levels of CCL8 and 
CXCL12. The two cytokines support the development of regulatory DCs which dampen 
the immune response via IL-10 secretion32,33. These studies all point towards a negative 
role of stromal cells in regards to leishmaniasis. 
 The mechanisms for intracellular survival of Leishmania spp. 
Two mechanisms trigger phagocytosis of pathogens by macrophages. Evolutionary 
conserved molecules displayed by pathogens, termed pathogen-associated molecular 
patterns (PAMPs) bind pattern recognition receptors (PRRs). Alternatively, opsonised 
pathogens are also phagocytised. Opsonisation is a process enhancing phagocytosis which 
consists in covering pathogens with antibodies, immunoglobulin G being the most potent 
isotype, or molecules of the complement (C3). Macrophages express antibody receptors, 
IgG- constant fragment receptor, and FcgR, or complement receptors such as CR3. 
Phagocytosis results in the formation of a pathogen-containing intracellular vesicle called 
the phagosome. A complex maturation process follows. The phagosome fuses with other 
vesicles, including highly acidic lysosomes. Matured phagolysosomes have a very low pH, 
many oxidative species and antimicrobial molecules34. Peptides and molecules issued from 
the degradation of the parasites can then be displayed on the surface of macrophages in 
association with the class II major histocompatibility complex (MHCII), inducing adaptive 
immunity specifically targeted against the parasites. 
Despite the hostile environment, phagolysosomes are the subcellular compartments where 
Leishmania parasites proliferate35,36. In order to survive within macrophages, Leishmania 
spp. have developed an arsenal of tools subverting the biology of their host cells. 
Promastigotes cannot survive the conditions inside phagolysosomes and have therefore 
acquired the capacity to delay the maturation of phagosomes. This capacity has been 
attributed to the parasite’s surface lipophosphoglycan (LPG) which inhibits several 
mechanisms of maturation37. The promastigote-derived metalloprotease GP63 cleaves a 
soluble N-ethylmaleimide attachment protein receptor (SNARE) protein called VAMP8, 
which mediates the fusion of phagosomes with late endosome38,39. Promastigotes only 
delay the maturation of phagosomes, which ultimately mature into an acidic 
phagolysosome. Most likely, promastigotes only delay phagolysosome maturation until 
they transform into amastigotes, a form adapted to growth in low pH medium40. 
Amastigotes have defence mechanisms involving the reduction of oxidative stress in 
parasitophorous vacuoles by inhibiting the NADPH oxydase41,42. 
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 Adaptive immunity to leishmaniasis 
Despite the mechanisms deployed to avoid antigen presentation, an immune response 
develops during VL. Efficient adaptive immune response against visceralising Leishmania 
spp. usually has been linked to the expansion of type 1 helper T cells (TH1). TH1 cells 
produce IFNg and promote expansion of CD8 T cells, which also produce IFNg43. IFNg has 
a protective role against the infection as it induces NO production and parasites killing by 
macrophages. IL-12 is a key cytokine for the induction of a TH1 immune response and has 
been linked to control of visceral infections44,45. Despite observations that development of 
VL was associated with a TH2 type immune response46, studies did not report a TH2 
skewing in patients. Together with IFNg, active VL is associated with high levels of IL-
1047,48, which dampens the immune response and participates in chronic disease49,50. 
Active disease is usually associated with hypo-responsiveness of peripheral blood-
mononucleated cells (PBMCs) stimulated with Leishmania antigens50. By contrast, 
PBMCs from cured or asymptomic patients respond to antigenic stimulation51,52. Another 
factor contributing to ineffective control of parasites by the adaptive immune response is 
the exhaustion of effector T cells53. Targeting of the inhibitory receptor expressed by T 
cells has therefore been investigated as a way to enhance the host’s immune response54,55. 
Recently, in a mouse model of CL, it has been shown that innate immune response against 
L. major induces a detrimental TH2 adaptive immune response via activation of the Nod-
like Receptor P356.  B cells are not required for resistance against L. donovani in the mouse 
model, but Immunoglobulins G protect against excessive liver damage57.   
 Current treatments against visceral leishmaniasis 
The complexity of VL makes it a hard disease to cure. Because of the variations in 
Leishmania spp. and the epidemiological complexity, finding a single drug efficient in all 
cases of VL is challenging and seemingly far from reach58. 
Antimony-based treatments have been in use since the 1940s. Antimony is a heavy metal 
which has an antiprotozoal effect. Two formulations of antimony are clinically used: 
sodium stibogluconate (SSG), and meglumine antimoniate. SSG is the most commonly 
used formulation of the two. Clinically, SSG has a good record of effectively curing the 
disease in East Africa. However, clinical treatments with SSG have shown a poor efficacy 
in India. Although the drug is quite cheap, it is absorbed very poorly orally so requires 
administration via daily intravenous (i.v.) or intramuscular injections. This implies the 
need for appropriate infrastructures and trained personnel as well as a necessity for patients 
to move in order to get treated. As VL is prevalent in poor countries, setting the 
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infrastructure can be challenging and patients might not be able to afford going to the 
hospital daily. In addition, the toxicity of antimony is an important disadvantage for this 
drug, especially combined with the relative long treatment needed (20 to 28 days). It 
causes nausea, vomiting, cardiac and liver dysfunctions. Antimonies are still the first line 
drugs used against VL in Africa and South America. 
From the 1990s, reports from multiple regions of India indicated that the efficacy of SSG 
was in decline58. This drove the research of alternative treatments and most new drugs 
were targeted to the Indian subcontinent. Amphotericin B is an anti-fungal drug that was 
shown to be a potent anti-leishmania agent. It is administered i.v. and achieved good cure 
rates in India, including in SSG-resistant infections. However, the elevated cost of 
amphotericin B has limited its use and most studies focus on making it more efficient to 
limit the costs. Lipid formulations of amphotericin B have been shown to be even more 
potent59. Amphotericin B is now the main drug used to treat VL in India. 
Paromomycin, a cheap wide-spectrum antibiotic, has been shown to be efficient against 
VL in India, although clinical trials have so far failed in East Africa. Paromomycin has 
usually been evaluated in combination with SSG when supplies of SSG were low. 
Reconditioning of Miltefosine, an alkyl phospholipid previously used for treatment of 
cancer, occurred after it was shown to have leishmanicidal activity60 . It is a promising 
drug which is administered orally and is the first drug used against both VL and CL61. 
Most drugs used against VL aim at killing the parasites directly, although not all 
mechanisms of action are understood. As this approach is susceptible to resistance, 
illustrated by the inefficacy of SSG in India, alternative approaches are being investigated. 
The design of a vaccine capable of enhancing the host’s immune response to Leishmania 
parasites is privileged by many researchers. The time and investment required to make 
anti-leishmaniasis vaccines a reality means conventional therapies will still be used for 
years to come. 
 Haematological alterations commonly associated with VL 
Alterations of blood cellular components has been reported in human3,62–66, hamster67,68, 
canine69–71 or feline72 visceral leishmaniasis. Cytopenia is a common occurrence in human, 
with anemia being the more frequent, followed by leukopenia and thrombocytopenia64,73,74. 
Retrospective studies have previously linked haematological disorders with the probability 
of death. In particular, haemorrhagic tendencies have been associated with less favourable 
prognosis75–80. Anaemia, while never directly reported as the cause of death in VL patients, 
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is very likely to participate to general fatigue, while leukopenia in conjunction with 
immunosuppression potentially increases the risks of secondary opportunistic infections. 
Pancytopenia is a general reduction of blood cells and is thus associated with mechanisms 
that cause reduction of all lineages non-specifically. Mechanisms responsible for the 
reduction of red blood cells, leukocytes or platelets specifically are described in the next 
chapter. Much of what is known about pancytopenia comes from clinical data or field data 
from naturally infected dogs and cats. Immune-mediated elimination of circulating cells 
has been proposed as a mechanism for pancytopenia. The detection of antibodies against 
red blood cells, platelets and leukocytes suggests that auto-immunity can develop in 
chronic infections81,82. However, other studies report that sustained inflammation can also 
lead to non-specific destruction of blood cells by immune cells. This mechanism is 
supported by frequent observation of haemophagocytosis83,84 (e.g. the presence of 
erythrocytes inside macrophages). Splenomegaly is also cited as one major cause of 
pancytopenia. As in other diseases, increase in spleen size causes an increase in splenic 
capture of circulating cells. While the sequestration and/or destruction of mature 
circulating cells is a possible cause for pancytopenia, it is also very likely that VL results in 
an impairment of haematopoiesis in the bone marrow. Studies have reported 
myelodysplastic features in all three blood cells lineages4,85. Myelodysplasia refers to 
inefficient production of blood cells. The mouse model of VL has previously been 
regarded as too different from the human, canine or feline disease to be used in 
experimental study of haematological disorders. Indeed, chronic infection of mice with L. 
donovani or L. infantum is non-fatal and parasite clearance from the liver occurs typically 
3 to 4-week post-infection. Nevertheless, Cotterell et al. have demonstrated that L. 
donovani infection of BALB/c mice leads to an increase of haematopoietic activity in the 
spleen and the bone marrow86. More specifically, they showed that an infected bone 
marrow stromal macrophage cell line enhances myelopoiesis in vitro by up-regulation of 
the production of granulocyte monocyte-colony stimulating factor (GM-CSF) and tumour 
necrosis factor alpha (TNFa)19. 
Anaemia is the reduction of circulating erythrocytes but can take different forms. In 
addition to the number of circulating cells, two important parameters for the diagnosis are 
the size of erythrocytes and their haemoglobin content. Macrocytic anaemia is 
characterised by enlarged erythrocytes and is associated with multiple conditions such as 
vitamin B12 deficiency, drugs or alcohol abuse and myelodysplastic syndromes87. It is a 
consequence of abnormal erythropoiesis producing bigger erythrocytes and is associated 
with enlarged erythroid precursor (megaloblastic anaemia). Microcytic anaemia is 
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characterised by smaller erythrocytes and occurs most notably in the context of iron or 
vitamin B6 deficiency anaemia88. Reduction in the haemoglobin inside erythrocytes results 
in hypochromic anaemia which refers to their coloration (since the red coloration of 
erythrocytes is related to the concentration of haemoglobin). Iron deficiency anaemia is 
microcytic hypochromic due to ineffective erythropoiesis. A normochromic normocytic 
anaemia (reduced number but normal size and haemoglobin concentration) is often 
associated with a reduced but normal erythropoiesis or increased destruction of 
erythrocytes, such as in chronic inflammation89,90. However, chronic inflammation also 
disrupts the iron metabolism, resulting then in a microcytic anaemia91. Anaemia in the 
context of infection diseases is often multifactorial and complex. Malaria for example 
causes anaemia through multiple pathological mechanisms such as direct lysis of 
erythrocytes by parasites, dyserythropoiesis, splenic removal and immune destruction of 
erythrocytes92. Clinical data from patients indicate that typical anaemia of VL is 
normocytic and normochromic2, although macrocytic anaemia has been observed73,93. 
A few studies have reported mechanisms specific for anaemia. It has been reported that VL 
results in increased sequestration of iron inside macrophages. It is believed to be a 
mechanism favouring the development of intracellular amastigotes since iron is necessary 
for their growth94. Iron is also required for the synthesis of heme during erythropoiesis. It 
is therefore thought that reduction of available iron participates in the dyserythropoiesis95. 
As an alternative rodent model, the hamster has been favoured because the course of 
infection is similar to natural infections and reaches a fatal endpoint. Hamsters chronically 
infected with L. donovani display a severe anaemia67 associated with a higher apoptosis of 
erythroid precursors in the bone marrow and induction of stress erythropoiesis in the 
spleen68. The specific mechanisms of thrombocytopenia are unclear as well. Platelets have 
been shown to be destroyed by immune cells in infected dogs96 but not in humans. Because 
platelet counts return to normal values after splenectomy, hypersplenism is thought to be 
the main cause of thrombocytopenia62,97. No specific mechanism of leukopenia has been 
reported2. 
Overall, there are few mechanistic studies about the haematological changes in VL, 
especially when compared to the extensive knowledge about the immunological aspect of 
the disease. As described above, the prognosis of VL is often linked to haematological 
alterations. Being able to understand the source of these alterations would enable new 
treatments correcting these alterations and potentially reduce the lethality of the disease. 
Visceral leishmaniasis is sometimes misdiagnosed as myelodysplasia because little is 
known about the specifics of haematological alterations3. This emphasises the importance 
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of a better understanding of the haematological aspects of the disease. The development of 
diagnostic tools for VL in endemic areas is slow and challenging98. Being able to detect 
signs of VL in patients not yet diagnosed based on their haematological profile would help 
early detection of VL. To understand how VL affects blood cells, it is first necessary to 
understand the physiology of blood cells production. In this work, the murine model using 
C57BL/6 mice chronically infected with L. donovani presented both anaemia and 
thrombocytopenia (Table 3-1). For this reason, the next part focuses on haematopoiesis 
and the biology of red blood cells and platelets. 
 Haematopoiesis 
 Models of haematopoiesis 
The field of stem cell biology, be it induced pluripotent stem cells, haematopoietic stem 
cells or mesenchymal stem cells, is generating an exploding interest worldwide due to the 
multitude of potential therapeutic applications, such as for auto-immune diseases, 
leukaemia and regenerative medicine. Yet, with the expansion of different studies has 
come the need to define what should be called a stem cell, a progenitor or a precursor99. 
The scientific community has defined a stem cell as a cell that must be capable of 
unrestricted self-renewal, i.e. symmetrical or asymmetrical division generating at least one 
identical daughter cell with the same potential so that the stem cell pool is never exhausted, 
and it must be capable of giving rise to a number of cell types. Totipotent stem cells such 
as embryonic stem cells, can virtually develop into any cell type found in the body while 
multipotent stem cells are more restricted. Thus, haematopoietic stem cells (HSCs) are the 
source of all cells of the haematopoietic lineage. This definition is still ambiguous in the 
sense that “stem cells” such as embryonic stem cells, or short-term HSCs have a limited 
self-renewal potential and will be ultimately exhausted. 
Greater misunderstanding arises from the terms progenitors and precursors which seem to 
be used interchangeably in the literature. In this work, the term “progenitor” is used for 
daughter cells of stem cells whose differentiation potential is more restricted and 
sometimes have a limited self-renewal ability; i.e. can generate a restricted number of 
identical daughter cells before exhaustion. One example of a progenitor cell is the common 
lymphoid progenitor, capable of differentiating into Natural Killer (NK) cells and T or B 
lymphocytes. The term “precursor” is used for cells that are fully committed into a lineage 
and do not replicate, giving rise to a single type of mature cell. For this reason, the pro-
erythroblasts and erythroblasts are called erythroid precursors here, being only able to 
differentiate into erythrocytes. 
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Haematopoiesis refers to the process through which a HSC produces blood cells. HSCs are 
multipotent stem cells capable of differentiating into any type of blood cell. Although 
called blood cells, cells issued from haematopoiesis do not necessarily reside in the 
circulatory system permanently. However, all are released in the blood where they will 
either stay or transition towards another organ. Haematopoiesis is usually described as a 
hierarchical differentiation process in which step-wise differentiation of haematopoietic 
progenitors is associated with progressively restricted differentiation potential (Figure 1-
2). The classical model of haematopoiesis starts with a HSC which can commit either to 
the lymphoid lineage or the myeloid lineage, by differentiating into either a common 
lymphoid progenitor100 (CLP) or common myeloid progenitor101 (CMP) respectively. 
According to the classical model, the differentiation potential of CLPs is restricted to T and 
B lymphocytes as well as NK cells. The differentiation potential of CMPs is restricted to 
erythrocytes, platelets, granulocytes, monocytes/ macrophages and DCs100,101. Although 
still in use, this model has been challenged by multiple studies. Initial commitment has 
been shown to be either myeloerythroid or myelolymphoid, specified by either the 
expression of transcription factors GATA-1 or PU.1, respectively102. Maturation of T cells 
involves precursors leaving the bone marrow (bone marrow) for the thymus, where 
differentiation involves diversification of the T cell receptor (TCR) and negative selection 
of auto-reactive cells. However, early thymic precursors of T cells have been shown to be 
able to differentiate into DCs103 and macrophages104,105, while lacking B cell potential. In 
another study, HSCs were sorted on the basis of the transcription factor Flt3. Flt3+ HSCs 
preserved the granulocytes, macrophages, T and B cells potential but lacked 
megakaryocyte-erythrocyte potential as opposed to Flt3- HSCs106. Commitment to the 
platelet and red blood cell lineages might therefore occur from the HSC stage not from the 
CMP stage as originally described. This shows that the binary model of lymphoid vs 
myeloid lineage is limited in regards to its representation of reality. Other models have 
therefore been proposed to incorporate the complexity of haematopoiesis107. These models 
refute that determination between lymphoid and myeloid lineages occurs at the apex of the 
haematopoietic tree. They illustrate the lack of consensus regarding the map of 
haematopoietic lineages. As a consequence, the classic model is still used, including in this 
work, despite its known limitations107. However, all models agree that haematopoiesis 
originates from a HSC. 
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Figure 1-2. The classical model of haematopoiesis. The classical model of haematopoiesis 
describes a step by step differentation of HSCs towards mature blood cells. According to the 
classical model, the first decision is commitment to the myeloid lineage (platelets, RBC, 
monocytes and granulocytes) or the lymphoid lineage (T and B lymphocytes and NK cells). Each 
decision is associated with a restriction of the differentiation potential, so that myeolid-commited 
cells can’t differentiate into lymphoid cells and inversely. However, this model has been 
challenged multiple time as discussed in 1.2.1. Adapted from Robb, Oncogene, Oct 2007108. 
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 Haematopoietic stem cells 
Till and McCulloch published the first evidence that the mouse bone marrow contained a 
population of radio-sensitive cells capable of forming haematopoietic colonies in the 
spleen (spleen colony forming units, CFU-S) when transferred into an irradiated mice109. 
The number of colonies formed inside the spleen in transferred mice correlated with the 
number of transplanted cells, suggesting that a single colony was the product of a single 
cell clone. These cells also had the particularity of producing heterogeneous colonies of 
blood cells. The concept of HSC was born through the marking and tracking of clones and 
the discovery that all types of mature blood cells could arise from a single clone110–112. 
HSCs are described as cells capable of producing any blood cell type while maintaining a 
stable pool of HSCs throughout the organism’s life. Evidence showed that HSCs are 
heterogeneous in their capacity to repopulate blood cells in the long term113. This 
introduced the concept of long-term HSC (LT-HSC) and short-term HSC (ST-HSC). LT-
HSCs are capable of repopulating blood cells of a recipient in the long term, a capacity that 
is preserved after serial transplantation. ST-HSCs are less persistent and lose their ability 
to repopulate blood cells over time, and the pool is eventually depleted after serial 
transplantation114. The term multipotent progenitors (MPP) is used when the self-renewal 
potential is reduced but the differentiation potential includes all lineages115. Phenotypic 
markers for the purification of HSCs were established116, including for LT-HSC115,117. 
However, subsequent studies showed that LT-HSCs also represent a heterogeneous 
population of cells in regards to their repopulation kinetics and bias towards a particular 
lineage118–120. Indeed, Sieburg et al. have determined, in mice, that long-term repopulating 
cells could be associated to 16 different kinetic profiles of repopulation when transferred to 
a new host. They state that these 16 profiles encompass all possible variations of 
repopulation kinetics observed in HSCs118. However, these profiles do not take into 
account what type of blood cell the HSCs produce. Dykstra et al. have shown that within 
the LT-HSCs, there were some LT-HSC that were skewed towards myelopoiesis or 
lymphopoiesis. They have defined 4 groups of LT-HSC according to their lineage-bias119. 
The LT-HSC population is characterised by a high frequency (»75%) of quiescent cells in 
G0 of the cell cycle at a given time, although all cells will have entered the cell cycle in 
about 57 days121. Control of the cell cycle is crucial to avoid depletion of the HSC 
pool122,123. The quiescence/activation regulation of HSCs is flexible, so that 
haematopoiesis can be adapted to supply more blood cells when a stress occurs124. 
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 Haematopoiesis in its anatomical context 
 Histology of the bone marrow 
The main interest in the study of BM is understanding the relationship between HSCs and 
their environment. Haematopoiesis starts during embryonic life in the foetal liver and then 
migrates inside the bone marrow. The bone marrow is the major site of haematopoiesis in 
adult mammals. The bone marrow is the tissue inside the cavity of long bones (e.g. femur, 
tibia, humerus and hip bone). Most studies of the bone marrow are done in the femur of 
mice, being the most accessible and most abundant source of bone marrow in adults 
(Figure 1-3). The epiphysis is the extremity of the femur forming the joint with adjacent 
bones. The metaphysis sits beneath the epiphysis and is where longitudinal growth of the 
bone occurs. The diaphysis is the largest part of the bone, it is the middle, tubular shaped 
part that contains most of the marrow. The outer shell of the femur is called the cortical 
bone, or compact bone. Projections of the cortical bone inside the cavity form a “spongy” 
bone called the trabecular bone. The epiphysis and metaphysis are filled with trabecular 
bone, whereas the diaphysis is almost devoid of it. The bone is a surprisingly dynamic 
tissue, with cells constantly synthesising new bone and cells degrading it125. The 
endosteum represents the interface between the bone and the bone marrow. It is composed 
of osteoblasts, cells responsible for the formation of new bone, and osteoclasts, which 
degrade it. The coupling of this formation and resorption is key to keeping the bone 
functional. Vasculature is really important in the bone marrow as many cells enter it but 
more importantly many are released. Haematopoiesis also requires a steady supply of 
nutrients and oxygen. Along the diaphysis run central arteries. From these thick arteries are 
derived sinusoids. Sinusoids grow from the centre of the bone marrow towards the 
endosteum and become gradually smaller. Venous circulation takes the form of a central 
sinusoid in which sinusoids coalesce126,127. 
However, until recently the combination of markers that enabled the identification of HSCs 
by flow cytometry was too complex for immunostaining. Breakthrough came through the 
discovery of a small subset of receptors belonging to the signalling lymphocytic activation 
molecules (SLAM) family that helps identify a small fraction of bone marrow cells 
containing all serially transplantable HSCs. The expression of CD150, in conjunction with 
the absence of staining for CD48 and CD41 enabled the in vivo analysis of HSCs. This 
revealed that HSCs were closely associated to the vasculature, as most cells were 
perivascular. In addition, recent transgenic mice expressing fluorescent protein associated 
with markers of stromal cells, such as Nestin, CXCL12, or Leptin receptor (Lepr) have 
provided useful insights into the spatial organisation of the bone marrow128–130. 
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Figure 1-3. Anatomy of long bones. Adapted from Morrison and Scadden, Nature, Jan 2014127. 
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 The haematopoietic stem cell niche concept 
The concept of niche refers to a specific microenvironment that participates in the 
development or normal function of cells. Till and McCulloch demonstrated that the bone 
marrow contained multipotent cells capable of forming haematopoietic colonies in the 
spleen109. However, this ability was lost after serial transplantations131, which conflicts 
with the hypothesis that HSCs are long-term self-renewing cells capable of producing 
blood cells throughout the life of an individual. To reconcile the data from Till and 
McCulloch with this concept, Ray Schofield postulated that  “the stem cell is seen in 
association with other cells which determine its behaviour”132. This initiated the concept of 
HSC niche, a microenvironment in the bone marrow preserving the long-term properties of 
HSCs. Studies of the differentiation and proliferation potential of HSCs confirmed that 
some of the properties that were observed following transplantation were lost in vitro119. 
The presence of haematopoiesis-supporting cells in the bone marrow was confirmed by 
Dexter et al., who successfully established long-term in vitro cultures that could maintain 
haematopoietic cells for several months133. These cultures were derived from the bone 
marrow of mice and made of a heterogeneous population of cells. Dexter noted that “giant 
fat” cells were important in the maintenance of haematopoiesis; these non-haematopoietic 
cells would later be called stromal cells. This initiated the search for bone marrow stromal 
cells and the dissection of the haematopoietic niche in vivo. 
The word stroma comes from the Greek word strōma meaning “coverlet”, referring to a 
fabric used to cover a bed. In animal biology, it has originally been used to describe the 
tissue not directly associated with the function of a given organ, as opposed to the 
parenchyma. In lymphoid organs, the stroma consists of all non-immune cells, such as 
fibroblasts or endothelial cells that support and regulate lymphocyte function. In 
haematopoietic organs, HSCs, haematopoietic progenitors and precursors form the 
parenchyma while other cells form the stromal compartment. 
 Molecular and cellular constituents of the HSC niche 
The identified cellular constituents of the HSC niche so far include fibroblastic cells, 
endothelial cells, osteoblasts and macrophages. The niche acts by secreting factors or by 
cell-cell contacts with HSCs127. It is a complex environment subject to several regulatory 
pathways, including signals from the central nervous system (CNS)134. 
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The secreted stem cell factor (Scf) is one of the first niche-derived cytokines that was 
discovered. The gene encoding Scf is encoded by the SI locus in mice and binds to its 
receptor c-kit135,136, encoded by the white spotting (W) locus137. Before any of these two 
molecules were characterised, evidence showed that mice with a mutation in the W or SI 
loci had a reduced haematopoiesis, measured at the time by the formation of CFU-S138,139. 
bone marrow cells from SI-mutant mice were able to form spleen colonies when 
transferred into irradiated wild-type mice and cure the anaemia of W-mutant mice. By 
contrast, transfer of wild-type bone marrow cells into irradiated SI-mutant mice resulted in 
very little haematopoietic activity139. Scf is produced by radio-resistant stromal cells in the 
bone marrow, while its receptor c-kit is expressed by HSCs. c-kit activation on HSCs 
triggers multiple cell signalling pathways140. Notably, it activates the signal transducers 
and activators of transcription 3 and 5A (STAT3 and STAT5A) via recruitment of JAK2, a 
protein known to be mutated in many myeloproliferative disorders141,142. Ultimately, these 
pathways enhance the self-renewal of HSCs through control of the cell cycle or of the 
viability. Another key factor of the HSC niche is the chemokine CXCL12. CXCL12 
promotes the retention of HSCs in the bone marrow via signalling through the CXCR4 
receptor143,144. Depletion of CXCL12-producing  cells in mice reduces the number of HSCs 
in the bone marrow130. 
The term mesenchymal stem and progenitor cells (MSPCs) is used for a specific 
population of stem cells found in  the bone marrow capable of self-renewal, proliferation 
and differentiation into fibroblasts, osteoblasts, chondrocytes (cartilage cells), adipocytes 
and potentially other cell types145. They are essential constituents of the HSC niche. 
Knock-in of GFP within the gene encoding CXCL12 highlighted a cell population called 
CXCL12-abundant reticular cells (CAR cells). These cells were characterised by long 
cytoplasmic processes and were physically associated with HSCs144. Depletion of CAR 
cells in mice reduces the number of non-haematopoietic multipotent progenitors capable of 
differentiating into osteoblasts and adipocytes in vitro130. This suggests that CAR cells are 
actually MSPCs. Purified Nestin-expressing (Nes+) cells in the bone marrow contain all the 
MSPC activity and express high levels of CXCL12129. However, neither CXCL12 nor Scf 
from Nes+ cells are essential for HSC maintenance in the bone marrow128,146. Lepr is 
another marker of MSPCs in the bone marrow. Lepr+ cells and endothelial cells produce 
both CXCL12 and Scf, the latter being essential since conditional deletion of Scf in Lepr+ 
cells depletes HSCs in the bone marrow128. In most studies, MSPCs are described as 
perivascular cells, which correlates with the localisation of HSCs in the bone marrow126. 
 32 
Evidence has shown that sympathetic nerves in the bone marrow induce the mobilisation 
of HSCs by inhibiting CXCL12 expression134. 
CD169+ stromal macrophages have been shown to regulate the HSC niche in the bone 
marrow. Their depletion causes reduction of HSC-niche genes such as Cxcl12 and Scf in 
Nes+ cells and the depletion of HSCs in the bone marrow147. These macrophages impose 
the circadian rhythm on CXCL12-expressing cells. Aged neutrophils express little CD62-
ligand but up-regulate CXCR4. They are drawn to the bone marrow where they are 
phagocytised by stromal macrophages which in turn inhibit production of CXCL12 by 
CAR cells. CD169+ macrophages therefore synchronise the rhythm of neutrophil clearance 
(a circadian rhythm) with the rhythm of HSCs egress from the bone marrow148. 
 Erythropoiesis 
 Erythropoietic progenitors and precursors 
Erythropoiesis is the process through which erythrocytes or red blood cells (RBC) are 
produced from HSCs. The classical model of haematopoiesis involves a step-wise 
commitment to the erythroid lineage via differentiation into a CMP, then a megakaryocyte-
erythrocyte progenitor (MEP) which can engage into the erythroid lineage or towards the 
production of platelets149. However, it has been shown that progenitors with a potential 
restricted to red blood cell and platelet also derived directly from HSCs150,151. The earliest 
known erythroid-only progenitors are called the erythropoietic burst-forming unit (BFU-E) 
and erythropoietic colony-forming unit (CFU-E)152,153. These progenitors are observed in 
in vitro cultures of bone marrow or peripheral blood cells stimulated with erythropoietin 
(EPO), and can synthesise haemoglobin and mature into enucleated cells. The BFU-E have 
a higher proliferative potential than the CFU-E and are not as discrete as colonies, i.e. 
individual cells are less easy to discriminate from one another. The CFU-E derives from 
the BFU-E. Isolation of murine BFU-E  and CFU-E is still challenging, although they can 
be enriched by negative selection154–156. In contrast, late erythroid precursors are more 
easily purified and morphologically identifiable. Using a combination of glycophorin A 
(Ter119) in conjunction with the transferrin receptor 1 (CD71) or the glycoprotein CD44, 
Chen et al. have resolved the 5 last stages of erythropoiesis157 (Figure 1-4). The earliest 
precursor is the proerythroblast, which derives from the CFU-E. Proerythroblasts are 
characterised by a high expression of CD71 and a low but detectable expression of Ter119. 
Proerythroblasts then mature into basophilic erythroblasts, polychromatic erythroblasts, 
orthochromatic erythroblasts, reticulocytes and finally red blood cells. The expression of 
Ter119 increases from the proerythroblasts and stays high in mature erythrocytes. 
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Maturation of proerythroblasts is also associated with a progressive decline of CD71 and 
steady reduction of cell size. 
Compared to other lineages, the erythroid lineage has been extensively studied because of 
its relative simplicity in regards to the molecular interactions involved in erythropoiesis. 
The earliest factor for the commitment of HSCs towards the megakaryocyte and 
erythrocyte lineage is the transcription factor GATA-1102. GATA-1 is necessary for the 
development of erythroid cells and is antagonised by another transcription factor called 
PU.1102. A single hormone is capable of skewing haematopoiesis towards the production of 
blood cells. This hormone is EPO and is found to be up-regulated during anaemia158. The 
mechanism behind how EPO induces erythropoiesis is still unclear. Some studies suggest 
that EPO acts at the apex of the haematopoietic tree, and induces erythroid differentiation 
in MPPs159 while other have shown that the formation of BFU-Es and CFU-Es was 
independent of EPO160. EPO is also known to prevent cell death in erythroid 
progenitors161. At the molecular level, EPO has been shown to induce GATA-1 
activation162. Studies show that PI3 kinase is an important adaptor in EPO signalling and is 
closely linked to EPO-induced expression of erythroid genes159,162. 
 The niches of erythropoiesis 
Erythropoiesis involves multiple stages of differentiation from the HSC to the mature 
erythrocytes. As erythropoiesis progresses, the cells have shifting requirements and 
therefore rely on different niches at different stages. The ligand of c-kit, expressed by 
stromal cells, is indispensable for erythropoiesis163. In mice, mutations in the W of SI loci, 
respectively coding for c-kit and its receptor, cause anaemia from the embryo stage139,163. 
The interaction of c-kit with its ligand is known to promote survival and self-renewal of 
the erythroid progenitors, in collaboration with EPO164,165. However, c-kit is gradually 
down-regulated in the later stages of erythropoiesis and is not detectable166. The expression 
of c-kit inversely correlates with that of Ter119 and is no longer detectable after the 
basophilic erythroblast stage. Scf has been shown to be expressed by endothelial cells and 
Lepr+ perivascular cells. As a consequence, earlier stages of erythropoiesis are dependent 
on the perivascular niche. 
More than 50 years ago, the French haematologist Marcel Bessis made an observation that 
macrophages from the bone marrow were in close contact with erythroblasts167. He coined 
the term “erythroblastic island” for a macrophages surrounded by erythroblasts and 
described it as a functional unit of the bone marrow.  Macrophages were shown to 
associate with erythroid cells from the CFU-E stage168,169. At the CFU-E stage, erythroid 
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Figure 1-4. Markers of erythropoiesis.  The burst-forming unit-erythroid (BFU-E) is the first 
progenitor restricted to erythropoiesis only. It is followed by the colony-forming unit-erythroid 
(CFU-E). Both can be identified by colony-formation assay and express the c-Kit receptor. CD71 is 
expressed early during erythropoiesis and disappear after the pro-erythroblast stage. Ter119 
expression starts later on but remains on mature erythrocytes. The transcription factor GATA-1 is 
expressed during all stages of erythropoiesis. Reproduced from Dzierzak, and Philipsen, Cold 
Spring Harb Perspect Med, Apr 2013170. 
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 progenitors still respond to Scf derived from perivascular stromal cells,166 suggesting that 
at some stage of erythropoiesis, progenitors are likely to rely on signals from both the HSC 
niche and the erythroblastic island. Stromal macrophages express several molecules 
mediating adhesion with erythroblasts, such as the erythroblast macrophage protein 
(Emp)171, the vascular cell adhesion molecule 1 (VCAM-1) which interacts with the very 
late activation antigen 4 (VLA-4) expressed by erythroid cells172 or the alpha V integrin 
which binds to ICAM-4173. The role of erythroblastic island macrophages is unclear. One 
function appears to be the erythroid precursors’ nuclei phagocytosis 174. Genetic 
inactivation of Emp is lethal in the embryo and associates with an increase in nucleated 
erythroctyes175. Crocker et al. have identified a stromal macrophage-restricted marker 
called sheep erythroid receptor 4 (SER-4) at the time 176,177. It was later re-named 
sialoadhesin or sialic acid-bind immunoglobulin-type lectin 1 (Siglec-1, CD169). The 
deletion of CD169+ cells was shown to dramatically reduce bone marrow erythropoiesis in 
adult mice147. In vitro, stromal macrophages promote proliferation of splenic CFU-E in a 
contact dependent rather than EPO dependent way178. 
 Erythropoiesis and iron homeostasis 
The role of red blood cells is to distribute dioxygen (O2) and collect carbon dioxide (CO2) 
throughout the body. Gas exchange is centralised in the lungs, hence the need for a 
distribution/collection system. RBC encapsulate haemoglobin (Hb), a large polypeptide 
made of 2 a-globin chains and 2 b-globin chains. Each chain is associated non-covalently 
with a heme, a cofactor made of a porphyrin containing ferrous iron (Fe2+). The Fe2+ ions 
are where gases bind, except for CO2, which binds to amino-terminal residues of Hb. Iron 
is therefore essential for the function of RBC. Haemoglobin synthesis starts early during 
erythropoiesis and requires a steady supply of iron. Iron is transported as ferric ions (Fe3+) 
in the blood associated with the protein transferrin179. A key molecule of erythropoiesis is 
the transferrin receptor 1 (TfR1 or CD71)180. It is responsible for the interaction of 
erythropoietic cells with transferrin181. TfR1 is expressed at the surface of immature 
erythropoietic progenitors and precursors from the CFU-E stage to the reticulocyte stage. It 
binds iron-bearing transferrin and is then internalised by endocytosis182. The resulting 
endosome is acidified, iron is freed from the transferrin and  exit the endosome through the 
Nramp2 (DMT1) transporter183. The cytoplasmic Fe2+ will then be used for heme 
synthesis. 
The liver acts as a key regulator of systemic iron availability. Hepatocytes produce a small 
peptide hormone called hepcidin184. Hepcidin has been shown to bind to ferroportin185. 
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Ferroportin exports iron from the cells and animals deficient in ferroportin accumulate iron 
inside macrophages, enterocytes, hepatocytes and adipocytes186 . Binding of hepcidin to 
ferroportin causes internalisation and degradation of the complex185.  Therefore, hepcidin 
induces iron retention in ferroportin-expressing cells, causing a decrease of available 
iron187. Overexpression of hepcidin in mice decreases the stock of available iron187. 
Because of the importance of iron in the biogenesis of haemoglobin and production of 
erythrocytes, as described previously, regulation of hepcidin expression has quickly been 
linked to anaemia and hypoxia188. To compensate for anaemia and hypoxia, the body 
stimulates erythropoiesis, which involves an increase need in available iron. As a 
consequence, hepcidin expression is down-regulated in response to these two stresses188. 
 Platelets and haemostasis 
 Anatomical description of platelets and their origin 
Platelets are anucleate cells that circulate in the blood and are involved in haemostasis. 
Haemostasis refers to the mechanisms through which bleeding is stopped. They are smaller 
than any other blood cell. For example, in this study, the average platelet volume of 10-12 
week old C57BL/6 mice was measured at 4.3femtoliter (fl). As a mean of comparison, the 
volume of RBC was 52fl. Priming towards the production of platelets may occur straight 
from the HSC stage106,150,151. A recent study has demonstrated that a thrombopoietin 
(TPO)-dependent population of HSCs primed for megakaryopoiesis was present in the 
bone marrow of mice150. Platelets derive from megakaryocytes, giant cells found in the 
bone marrow and to a certain extent in the lungs. Megakaryopoiesis refers to the 
production and maturation of megakaryocytes. Thrombopoiesis refers to the production of 
platelets from megakaryocytes. Little is known about thrombopoiesis in vivo but recent 
data have provided valuable insights189. The prevalent model of thrombopoiesis is the pro-
platelet model (Fig 1-5). Megakaryocytes in the bone marrow extend pseudopodial 
processes in the bone marrow vasculature through the endothelium. These cytoplasmic 
processes are called proplatelets and are released into the circulation. However, freshly 
released proplatelets were found to be bigger than blood platelets, indicating that 
proplatelets are further fragmented after release. It is thought that the pulmonary 
vasculature is where the shedding of proplatelets occurs190. 
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Figure 1-5. Mechanism of platelet release from megakaryocytes. Adapted from Thon et 
Italiano, Semin Hematol, Jul 2010190. 
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 The coagulation cascade 
Coagulation is the process aiming at stopping blood leaving the circulation, a 
haemorrhage, following a vascular injury (Fig 1-6). The process of coagulation can be 
divided into 3 steps: the initiation, the amplification and the propagation. The initiation 
phase is triggered by damages to the vasculature and exposition of extravascular cells. 
Most extravascular cells express tissue factor (TF) on their surface. The coagulation factor 
VII (FVII) is usually physically separated from TF-expressing cells by the endothelium. 
Vasculature damage results in formation of the TF:activated FVII (FVIIa) complex which 
triggers a cascade called the extrinsic pathway, resulting in the activation of the platelet-
bound FIXa:FVIIIa complex. The FIXa:FVIIIa complex amplifies the coagulation process 
by activating another platelet-bound complex called prothrombinase. Prothrombinase can 
be activated by an alternative pathway triggered by collagen detection by platelets via the 
glycoprotein VI (GPVI)191. Prothrombinase converts prothrombin into thrombin, an 
enzyme which catalyses the conversion of fibrinogen into fibrin. Molecules of fibrin 
coalesce into a gel that participates in the clot formation. Thrombin further activates 
platelets at the site of injury. During the propagation phase, activated platelets recruit and 
activate more platelets. Coagulation results in formation of a clot mostly made of platelets 
embedded in a fibrin matrix. Importantly, haemostasis is complete by repair of vascular 
damage and lysis of the clot192,193. 
 Homeostasis of platelets 
The number of circulating platelets can vary greatly between individuals. Interestingly, 
individuals with lower platelet counts have higher mean platelet volumes (MPV). 
Throughout life, the platelet count of one individual is constant. However, certain 
conditions can affect the number of circulating platelets. In such events, the body then 
preserves the platelet mass and not the platelet count. Indeed, it has been shown that in 
response to thrombocytopenia, the average volume of platelet increases194. 
TPO and its megakaryocyte-specific receptor myeloproliferative leukaemia protein (Mpl) 
are the main regulators of platelet production195. TPO induces megakaryopoiesis196. 
Regulation of TPO production occurs at multiple levels. TPO is produced in the liver and 
the kidney in a physiological state. The expression of TPO in the steady state is negligible 
in the bone marrow, but it is strongly expressed by bone marrow stromal cells following 
thrombocytopenia197. Platelets are negative regulators of TPO levels. They express the Mpl 
receptor and capture circulating TPO, causing its degradation. The amount of circulating 
TPO is determined by the balance between TPO production and destruction. As a 
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consequence, a decrease in platelet count causes a reduction of TPO destruction and an 
increase of circulating TPO. The balance is re-established when the number of platelets 
returns to normal values. There are exceptions to this model however, in which immune 
destruction of platelets does not increase TPO levels198. More recently, a novel pathway of 
TPO regulation in the liver has been reported. Hepatocytes are known to secrete TPO 
constitutively197 but regulators of steady-state TPO production in the liver are unknown. 
Platelets lifespan is determined by their content in sialylated surface glycoproteins. Sialic 
acid residues are progressively lost on platelets. Desialylated glycoproteins are recognised 
by liver macrophages and hepatocytes, which phagocytise and clear old platelets199. The 
Ashwell-Morell receptor (AMR) is expressed in the liver and binds desialylated platelets. 
Activation of the AMR leads to activation of the JAK2-STAT3 signalling pathway and up-
regulation of TPO production by hepatocytes200. 
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Figure 1-6. The coagulation cascade. The initiation phase starts with the exposure of sub-
endothelial cells expressing the Tissue Factor (TF). The Factor VII (FVII) forms an activated 
complex with TF called the extrinsic tenase. The extrinsic tenase triggers the formation of the 
FIXa:FVIIIa complex (intrinsic tenase) on the surface of platelets. Both tenase complexes 
participate in the activation of prothrombinase. Prothrombinase activates Thrombin, which in turns 
catalyses the formation of Fibrin fibers from Fibrinogen. Thrombine-activable fibrinolysis inhibitor 
(TAFI) protects the clot from fibrinolysis. The clot result from the crosslinking of fibrin fibers. PL 
= platelet. Adams and Bird, Nephorlogy (Carlton), Aug 2009192. 
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 Infectious diseases and haematological disorders 
Very little is known about the pathology of haematological disorders in the context of VL. 
For this reason, it is necessary to look at other models to understand pathological 
perturbations of blood cells and haematopoiesis. In most models, anaemia is the most 
studied haematological disorder. 
Malaria is probably the best known parasitic infection causing anaemia. It is caused by the 
parasite Plasmodium falciparum (P. falciparum), which infects RBC. It is the first cause of 
acquired RBC disorder. Contrary to VL, where macrophages are infected, P. falciparum is 
an intracellular parasite of mature RBC and directly affects their physiology. Notably, the 
P. falciparum modifies the membrane of RBC and is able to translocate proteins from the 
parasite to the surface of the RBC201. The protein P falciparum erythrocyte membrane 
protein 1 (pfEMP1), when expressed at the surface of erythrocytes, causes them to adhere 
to the endothelial cells of the blood vasculature and stop circulating202. Parasites replicate 
inside RBC and cause their direct lysis. Anaemia of malaria is very complex and 
multifactorial92. While parasites cause direct destruction of RBC, erythropoiesis is altered 
as well. Another product of P falciparum, called P. falciparum Hemozoin (pfHz), has been 
shown to to phagocytised by monocytes and causes erythropoiesis suppression in the bone 
marrow203,204. pfHz can induce apoptosis in erythroid precursors205. 
Trypanosomiasis is another infectious disease causing anaemia. Here also anaemia is 
multifactorial. One major cause seems to be the peripheral destruction of RBC by 
macrophages, notably in the spleen206. Trypanosoma cruzi, the causative agent of sleeping 
sickness, secretes a haemolysin, a molecule capable of lysing erythrocytes by forming 
pores in the cell membrane207. In addition to direct lysis of erythroblasts, Trypanosomiasis 
causes auto-immune lysis of RBC and platelets208,209. Incorporation of parasite-derived 
proteins into the membranes of the host’s cells is thought to accentuate destruction of RBC 
by the immune system210. Erythropoiesis in the bone marrow of mice infected with 
Trypanosoma brucei was also suppressed because of local nitric oxide production211. 
Anaemia of trypanosomiasis is linked to up-regulation of TNFa and IFNg while IL-10 has 
protective effect by countering pro-inflammatory cytokines212. 
A non-specific cause for anaemia in chronic infectious disease is iron deficiency. 
Interleukin-6 (IL-6) is a pro-inflammatory cytokine which up-regulate hepcidin expression 
in the liver213. As described above, hepcidin induces internalisation of ferroportin on 
macrophages, causing iron to be sequestered inside these cells and no longer available185. 
Chronic inflammation and chronic IL-6 production can therefore cause anaemia by 
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preventing the synthesis of haemoglobin which requires iron. In addition to IL-6, IFNd and 
TNFa can cause retention of iron inside monocytic cells by up-regulating the expression of 
DMT1 on the cell surface and causing iron retention inside these cells214. Anaemia of 
chronic disease is characterised by altered erythropoiesis producing fewer and bigger 
erythrocytes88. 
The Salmonella Typhimurium murine infection model recently provided further insights 
into inflammation-induced thrombocytopenia. The authors of the study have shown that 
innate inflammation triggers the local formation of blood clots in the liver. This process 
does not depend on the presence of the bacteria but is dependent on IFNd, which induces 
the expression of podoplanin on monocytes and Kupffer cells in the liver215. Platelets 
interact with podoplanin via the C-type lectin-like receptor (CLEC-2), wich induces 
coagulation216,217. This process does not require signalling through GPVI. Thrombosis in 
mice infected with Salmonella correlates with the number of circulating platelets215. 
Thrombocytopenia is also commonly associated with liver dysfunction218. The liver is the 
main source or TPO with the kidney195, and it has been shown to be essential in regulation 
of platelet turnover, by binding and degrading old platelets and producing more TPO 
through the AMR200. Hepatitis C virus (HCV) causes fibrosis of the liver which has been 
associated with thrombocytopenia219,220. 
These infectious diseases provide insights into how parasites can cause haematological 
alterations. Interestingly, anaemia is the most studied haematological aspects in the context 
of parasitic infections. They also highlight how complex haematological studies are, since 
most defects are multifactorial.   
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 Summary and aims 
Visceral leishmaniasis is a complex infectious disease associated with intracellular 
parasitism of mononuclear phagocytes in the spleen, the liver and the bone marrow. The 
immune response to Leishmania spp. is relatively well understood. However, the disease is 
consistently associated with haematological disorders in patients, in dogs, in cats and in 
some experimental models. The disease can lead to anaemia, thrombocytopenia, 
leukopenia or all three deficit combined, pancytopenia. Yet the mechanisms for 
haematological disorders associated with VL are still unclear. They are often linked to 
hypersplenism or dysregulation of iron homeostasis, haemophagocytosis and ineffective 
haematopoiesis. These mechanisms however have not been thoroughly dissected due to the 
lack of an experimental model. Mice, the most commonly used model in biomedical 
research, do not develop overt symptoms when compared to the human disease and has 
hardly been used for haematological studies. Study of other models of infectious diseases 
which commonly cause haematological disturbances, especially anaemia, can provide 
useful insights into potential causes for cytopenia in VL. 
The main hypothesis of this work is that the experimental mouse model of VL can be used 
to provide insights into the mechanisms responsible for haematological alterations in the 
human disease. Despite the absence of clinically relevant symptoms in mice chronically 
infected with L. donovani, we aim at improving the knowledge about haematological 
aspects of VL using this model. A better understanding of the haematological aspects of 
VL would help a) improve treatment of patients b) recognising signs of VL from blood 
analysis. The latter would be useful as sometimes not yet diagnosed patients with VL have 
haematological disorders and are treated for something else (e.g. myelodysplasia3). 
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Chapter 2 Material and methods 
 Mice 
All animal procedures were performed under UK Home Office License (Ref # PPL 
60/4377) in accordance with the Animals (Scientific Procedures) Act 1986 (revised under 
European Directive 2010/63/EU). All regulated procedures received approval from the 
Animal Procedures and Ethics Committee of the Department of Biology, University of 
York. Mice were housed in a pathogen-free Category 3 facility with an artificial 12-hour 
day/night cycle and fed a standard diet for rodent and water ad libitum. Unless stated 
otherwise, experiments were performed using C57BL/6 mice bred in-house. Experiments 
were performed on 6-8 week old animals.  
Cxcl12tm2.1Sjm/J221 (CXCL12DsRed reporter) mice were purchased from The Jackson 
Laboratory as heterozygotes and were crossed with C57BL/6 because homozygotes are 
non-viable. This is due to the insertion (knock-in) of the DsRed-encoding cassette within 
the endogenous CXCL12 locus, rendering this copy of the CXCL12 gene non-functional. 
Litters were genotyped after weaning by a qPCR reaction amplifying the DsRed gene from 
a digested ear tissue sample. 
Fluorescent reporter mice for in vivo analysis of T cells were kindly provided by Mark 
Coles. Expression of the green fluorescent protein (GFP) and DsRed is restricted to T cells 
and NK cells in the hCD2.GFP and hCD2.DsRed, respectively222. 
Splenectomised C57BL/6 mice were purchased from Charles River. Mice were 6-7 week 
old at the time of surgery. The wounds were closed with clips and mice were kept in 
Charles River for two weeks post surgery to allow wound healing and clip removal before 
shipment. Mice were placed into the Category 3 facility on delivery and were allowed 1 
week to adapt to their new surroundings before starting a procedure. 
Because haematopoiesis is highly regulated under the circadian rhythm, all animals were 
killed between 7am and 9am in order to obtain consistent results. 
 Experimental Visceral leishmaniasis 
All experiments were performed with the Ethiopian strain of L. donovani (LV9 and LV9-
tdtomato223). Amastigotes were maintained by passage in B6 RAG2-/- mice deficient for the 
recombination-activating gene 2 (RAG2). Passage mice were euthanized by CO2 
asphyxiation before dissection. Freshly isolated spleens were crushed using a sterile glass 
homogeniser into a single-cell suspension and washed in Roswell Park Memorial Institute 
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medium (RPMI, Thermo Fisher Scientific, Waltham, MA, USA). The suspension was 
transferred into a 50ml falcon and dense debris were pelleted by centrifugation at 140g for 
5min. The supernatant containing splenocytes was incubated in Saponin (0.125% (w/v) in 
RPMI) for 5min at room temperature (RT) with regular agitation. This step induces 
permeabilization of cell membranes and allows parasites to leave the host cells. Parasites 
were pelleted by centrifugation at 2000g for 10min, the supernatant was discarded and they 
were washed another three times in RPMI. Parasite number was evaluated using a Thoma 
counting chamber. Freshly isolated L. donovani amastigotes were suspended at a 
concentration of 1.5x108 amastigotes/ml in RPMI. Mice were injected with 200µl of 
parasite preparation (3x107 amastigotes) intravenously via the lateral tail vein.  
 Estimation of parasitemia 
Spleens freshly isolated were cut in half and dried on paper. Imprints were performed on 
Superfrost slides (Thermo Fisher Scientific). Slides were air-dried, fixed in methanol and 
stored in dry conditions until further use. For estimation of parasite load, the slides were 
stained for 30mins in a Giemsa solution, rinsed in tap water and air-dried. For each sample 
1000 nuclei were counted on random fields of view. Amastigotes were counted in each 
field of view based on their morphology. Splenic parasitemia was expressed in Leishman-
Donovan units (LDU) where LDU=number of amastigotes/1000 nuclei x spleen weight (in 
grams). 
 Administration of granulocyte-colony stimulating factor-neutralising antibody 
Mice were infected with L. donovani for 6 weeks. Each mouse received a daily dose of 
25µg of anti-granulocyte-colony stimulating factor (G-CSF) antibody (cat no. MAB414, 
R&D Systems, Minneapolis, MN, USA) diluted in phosphate buffered saline (PBS). The 
antibody was administered by intra-peritoneal injection. 
 Administration of thrombopoietin 
 Randomisation of mice 
All experimental mice were tagged with p-Chips (PharmaSeq, Monmouth Junction, NJ, 
USA) to avoid selection bias. The chips were implanted subcutaneously in the tail prior to 
the experiment. The chips are identified by the PharmaSeq Wand which activates the chips 
with a 660nanometer (nm) laser and returns unique 9-digit numbers. The tag number of 
each animal was recorded in an electronic spreadsheet. Randomisation of treatment was 
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performed as described in Figure 2-1. At the time of treatment, each mouse was picked 
individually, identified by its tag number and administered the treatment accordingly. 
 Injection of recombinant human thrombopoietin 
Recombinant human thrombopoietin (rhTPO; ZymoGenetics, Seattle, WA, USA) was 
provided by Dr Ian Hitchcock, University of York. rhTPO was diluted in PBS in 
concentrations ranging from 5µg/ml to 10µg/ml, and mice were treated for 5 consecutive 
days (100µl administered by intraperitoneal injection). Naïve or infected mice, treated or 
not with TPO as above, were killed 5 days after the end of rhTPO administration, and 
parameters associated with blood and splenic response were measured as described in 
Chapter 4. 
 Blood collection and analysis 
Mice were anaesthetised by inhalation with isoflurane prior to blood collection. After 
induction of anaesthesia in a closed chamber, mice were placed on their back. A mix of 
isoflurane and oxygen was continuously supplied through a mask attached to the nose of 
the animal. Deep anaesthesia was confirmed by absence of withdrawal reflex when gently 
pinching the hind feet. 1ml syringes with 19-gage needles were coated with a Citrate-
dextrose solution (ACD, Sigma-Aldrich Company Ltd., Dorset, UK). A negligible amount 
(<50µl) of ACD remained in the dead volume of the syringe. Blood was collected from 
terminally anaesthetised mice by insertion of the needle into the heart and slowly drawing 
back blood. When no more blood could be withdrawn, the needle was removed and the 
syringe depressed slowly to transfer the blood into EDTA-coated Vacutainer (BD, Franklin 
lakes, NJ, USA). Because the blood was used for platelet counting, caution was taken not 
to cause too much shear stress, which can activate platelets and make the counts 
inaccurate. The whole blood was kept in the Vacutainer at RT until analysis since cold 
temperatures can also alter the platelet counts. The blood analysis was performed with a 
Hemavet 950FS (Drew Scientific, Miami Lakes, FL, USA). To assure accuracy of the 
device, a blank (empty) sample and a control of known values were analysed before each 
experiment. 
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Figure 2-1. Workflow for the randomisation of mice prior to rhTPO administration. Random 
numbers were generated with the function RAND integrated in the Excel software (Microsoft, 
Redmon, CA, USA). 
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 Plasma collection 
Blood was collected as described previously. It was decided to use plasma rather than 
serum since blood samples were used for haematological analysis and should not be 
clotted. The fraction of whole blood for plasma preparation was kept on ice until use. 
Plasma was separated from the cellular fraction by centrifugation for 10min at 1500g. The 
clear supernatant was transferred to a separate tube and kept at -80°C until use. 
 Isolation of bone marrow cells 
After killing mice, the hind legs were thoroughly washed with 70% ethanol. An incision 
was made from the ankle upwards and the skin was peeled back. Muscles and ligaments 
were removed with scissors and the feet cut off. The femurs were gently pulled from their 
socket at the hip joint. Femur and tibia were separated by cutting the knee joint and opened 
at both ends to expose the bone cavity. The bone marrow plug was flushed with the wash 
buffer made of PBS 1% foetal calf serum (FCS) using a 25-gauge needle through a 70µm 
cell strainer. Cell strainers were thoroughly rinsed with wash buffer. Single cell 
suspensions were washed by centrifuging 5min at 300g and suspending the pellet in fresh 
buffer. Red blood cells were lysed with Ammonium-Chloride-Potassium (ACK, Sigma-
Aldrich) buffer for 5min at RT, nucleated cells were subsequently counted using a Vi Cell 
XR Cell Counter (Beckman Coulter, Pasadena, CA, USA). 
 Isolation of splenocytes 
Spleens were removed and cleaned from any surrounding adipose tissue. They were placed 
on 70µm cell strainers and crushed though with the plunger of a syringe. The strainers 
were washed thoroughly with PBS 1% FCS (wash buffer) and the cell washed by 
centrifuging 5min at 300g and suspending the pellet in fresh buffer. Red blood cells were 
lysed with ACK buffer for 5min at RT, nucleated cells were subsequently counted using a 
Vi Cell XR Cell Counter (Beckman Coulter). 
 Fluorescence microscopy 
 Preparation of femurs for immunohistochemistry 
Femurs were isolated and cleaned to remove excessive tissue then fixed overnight at 4°C 
in Periodate-lysine-paraformaldehyde fixative (10mM sodium Periodate dissolved in three 
parts 0.1M lysine-HCl 0.1M Na2HPO4 and one part 20% (w/v) paraformaldehyde) and 
decalcified for 3 days at 4°C with slow agitation in 10% EDTA, 0.1M Tris, pH6.95. Bones 
were transferred in 30% sucrose in PBS for a final overnight incubation at 4°C then 
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embedded in Optimal Cutting Temperature (OCT™) compound (Sakura Finetek Europe, 
Alphen aan den Rijn, The Netherlands) in Cryomolds® (Sakura Finetek Europe) and snap-
frozen on dry ice. Frozen bones were kept at -80°C until required. Femoral 5µm-sections 
were cut using a CM1900 cryostat (Leica Microsystems, Wetzlar, Germany) onto 
Polysines® slides (Thermo Fisher Scientific), air-dried for at least 30min at RT and stored 
a -20°C until further use. 
 Preparation of spleens for immunohistochemistry 
To avoid an anatomical bias between samples, a transversal fragment of the spleen was cut 
from the middle of the organ. They were placed into Cryomolds® and covered in OCT™. 
The samples were frozen on dry ice and transferred at -80°C until further use. Transversal 
5µm spleen section were cut on a CM1900 cryostat and onto Polysines® slides (Thermo 
Fisher Scientific), air-dried for at least 30min at RT and stored a -20°C until further use. 
On the day of the staining, the slides were thawed and covered in ice-cold acetone for 
10min to fix the tissues then air-dried. 
 Immunohistochemistry 
Sections were blocked in staining buffer (PBS, 0.05% (w/v) bovine serum albumin (BSA), 
5% serum of the same source as the secondary antibody) for 1h at RT. Excess buffer was 
removed from the slides before adding primary antibodies at the appropriate dilutions in 
staining buffer for 1h at RT or overnight at 4°C. Slides were washes three times 5min in 
washing buffer (PBS 0.05% (w/v) BSA) and secondary antibodies or streptavidin 
conjugates were applied in staining buffer at the appropriate dilutions for 1h at RT. Slides 
were washed three times 5min in washing buffer, counterstained with 4',6-diamidino-2-
phenylindole (DAPI; 1µg/ml in washing buffer) and wash one more time when necessary. 
Section were mounted in ProLong® Gold antifade reagent (Thermo Fisher Scientific), 
cured overnight and sealed before imaging. Antibodies for immunohistochemistry are 
listed in Table 2-1. 
 Confocal imaging 
Confocal images were obtained using LSM780 or LSM710 systems (Leica Microsystems) 
using the ZEN software. Tissues were scanned sequentially with different lasers (405nm, 
488nm, 561nm, 633nm) to avoid any emission overlap between fluorochromes. The 
pinhole was set to 1 airy unit in the highest-wavelength laser and adjusted for the other 
lasers in order to capture the same thickness in each channel. The images were taken at 
optimal resolutions where the size of a pixel corresponds to the smallest object that can be 
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resolved, as determined by the software. Contrast levels were adjusted post-acquisition to 
enhance images. The same post-treatment was applied to all images within one 
experiment. 
 Epifluorescence imaging 
Imaging of whole spleen sections was performed with an automated AxioScan.Z1 slide 
scanner (Zeiss). The optimal focus was determined based on the DAPI staining. To ensure 
a sharp image and correct potential inclination of the slide or sample, the optimal focus 
was re-measured regularly throughout a scan. Tissues were illuminated sequentially with 
LEDs and reflected fluorescence was recorded by an Orca Flash 4 camera (Hamamatsu, 
Hamamatsu City, Japan) through a 20x objective. 
 Whole-mount microscopy 
A femur from a mouse infected with the LV9-tdTomato strain was prepared as described 
previously until the sectioning step. A femur embedded in OCT™ was cut longitudinally 
using a cryostat until the bone marrow cavity was visible on both sides. The femur was 
then washed in PBS to remove the excess of OCT™. All following steps were performed 
at 4°C. The thick section was incubated overnight in blocking buffer (PBS 0.2% Triton 1% 
BSA, 10% goat serum). The following day, it was transferred in blocking buffer containing 
a rabbit anti-laminin antibody (Sigma-Aldrich) diluted 1/50 and incubated for 3 days. After 
primary antibody labelling, the sample was washed overnight in PBS. It was then 
incubated with the secondary antibody (Alexa Fluor® 488 goat anti-rabbit IgG), at a 1/50 
dilution in blocking buffer overnight. It was washed 3 times for 10min in PBS with 
agitation and transferred to an 80% (v/v in water) glycerol solution for a final overnight 
incubation. The glycerol solution acts as a clearing agent, allowing light to penetrate 
deeper into the tissue as well as more light out of the tissue. It was chosen over different 
clearing agent such as benzyl-alcohol benzyl-benzoate (BABB) because the latter can 
reportedly cause reduction of emission from fluorescent proteins, although it is more 
efficient in clearing tissues. The sample was sealed between two glass coverslips in 80% 
glycerol and imaged on a Zeiss LSM780 confocal microscope. To allow deeper 
penetration, a multiphoton laser was used with an excitation wavelength of 870nm. 
 Haematoxylin-eosin staining 
Sections were prepared as described for immunochemistry. They were air-dried for several 
minutes to remove moisture. The slides were immerged in a filtered Harris Haematoxylin 
solution for 5min at RT and rinsed in cool running H20 for 5min. They were then placed in 
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a tray and dipped in 0.5% Eosin (dissolved in 95% ethanol) 12 times. The excess eosin was 
removed by dipping in distilled H20 repeatedly until no more eosin could be seen 
dissolving into the water. The tray containing the slides was dipped into a bath of 50% 
ethanol 10 times, then 70% ethanol 10 times. Slides were finally left in 95% ethanol for 
30sec and pure ethanol for 1min. Slides were left to air-dry then mounted in DPX 
mounting medium (VWR) under glass coverslips. 
 Flow cytometry 
 Sample preparation 
Cells were prepared as described previously. They were then concentrated or diluted to a 
concentration of 2x107 cells/ml in PBS 1% FCS (staining buffer). Unspecific binding of 
antibodies to Fc receptors was blocked by incubating cells with a purified anti-mouse 
CD16/32 antibody (Fc Block, eBioscience Ltd., Hatfield, UK) for 10min on ice (1/500 
dilution in staining buffer). Cells were washed and plated in a round-bottom 96-well plate. 
A 2X antibody mix was prepared in staining buffer. The 2X mix was added to the cells at a 
1:1 ratio for a final concentration of 1x107 cells/ml. The plates were placed in the dark at 
4°C for 30min. Cells were then spun for 10min at 300g at 4°C and suspended in 200µl 
fresh staining buffer. The operation was repeated twice to thoroughly wash the unbound 
antibodies. In cases where cells fluorescence was not acquired on the same day, cells were 
fixed with 100µl 2% paraformaldehyde (PFA) in PBS. Plates were incubated for 10min at 
4°C and an additional washing step was done. Cells were washed and analysed on a Cyan 
flow cytometer (Beckman Coulter). 
 Flow cytometry data analysis 
For all experiments, only single events were included. Other events were discriminated on 
the basis of the pulse width plotted against forward scatter height (FSC). There is a relation 
between the size of cells and the pulse width, which measures the time it takes to a particle 
to flow through the laser beam. Doublets tend to be orientated lengthwise and have a larger 
pulse width with the same height of FSC as individual cells. As such, doublets can be 
excluded. Dead cells were labelled with Fixable Viability Dye eFluor780 or eFluor450 
(eBioscience). Cells positive for the dye were excluded from analysis. 
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 Fibroblastic colony-forming unit assay (CFU-F) 
 Sample preparation for CFU-F 
Femurs and tibias were isolated as described previously. Femur and tibia were separated 
and cut at both ends to expose the bone cavity. The bone marrow was flushed with PBS 
2% FCS (wash buffer) using a 25-gauge needle through a 70µm cell strainer. Cell strainers 
were thoroughly rinsed with wash buffer. Cells were washed and suspended in PBS 2% 
FCS. Only nucleated cells were counted by diluting a small aliquot in 3% Acetic Acid with 
Methylene Blue and counting the nuclei with a haemocytometer. Cells were left on ice at a 
final concentration of 107cell/mL until use. 
 CFU-F assay 
Complete MesenCult® medium (STEMCELL technologies, Grenoble, France) was 
prepared one day prior to the assay. The MSC stimulatory supplements were thawed at RT 
and added to the MSC basal medium at a 1/5 ratio to make complete MesenCult® medium, 
according to the manufacturer’s instructions The bone marrow cell suspensions were 
mixed with the complete medium (1/20 dilution) and 2ml of the dilution was added to each 
well in 6-well plates (Nalge Nunc, Rochester, NY, USA). A total 1x106 cells were plated 
in each well. Individual samples were platted in duplicate or triplicate. Cells were 
incubated for 10 days at 37°C in 5% CO2. 
 Staining and enumeration of CFU-F 
After 10 days in culture, medium was removed from each well by aspiration. Each well 
was washed twice with 2ml PBS and left to air-dry at RT for 5min. To fix the cells, 2ml of 
methanol was added to each well. After 5min, the methanol was aspirated and the plates 
left to air-dry for 5min at RT. 1ml of Giemsa staining solution was added to each well and 
incubated for 5min. The staining solution was removed and excess stain was washed with 
ddH2O until the water was clear. The plates were finally left to air-dry and stored at RT 
until further use. Colonies were counted microscopically. One CFU-F was defined as a 
colony comprising more than 10 fibroblast-like cells (spindle shape) as shown in Fig 2-2. 
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Figure 2-2. Identification of CFU-F from the bone marrow. (A) Macroscopic visualisation of 
colonies. bone marrow cells were culture for 10 days in MesenCultÒ medium and stained with 
Giemsa. (B) Representative example of a CFU-F, visualised under a microscope, characterised by 
the presence of elongated fibroblast-like cells. (C) Example of a non-fibroblastic colony which 
looks similar to a CFU-F macroscopically but different when studied under a microscope.  
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 Quantification of G-CSF and TPO in plasma 
 Enzyme-linked immunosorbent assay (ELISA) 
Plasma was used for the measurements of circulating G-CSF and TPO. Collection and 
storage of plasma were described previously. Samples were thawed on ice before the 
assay. Two ELISA kits were used, pre-coated with capture antibodies specific for G-CSF 
(R&D Systems, MCS00) and TPO (R&D Systems, MTP00). For G-CSF, standards 
ranging from 900pg/ml to 14.1pg/ml were used. Samples were used pure or diluted to ½ 
depending on the amount available. For TPO, standards ranging from 4000pg/ml to 
62.5pg/ml were used and plasma samples were diluted 5 times in the diluent provided in 
the kit prior to the assay. Pure or diluted samples and standards were added to the plate in 
duplicate and incubated for 2h at RT. Each well was then washed with 200µl of wash 
buffer; the wash buffer was removed by gently inverting and shaking the plate. The 
operation was repeated an additional three times. The G-CSF or TPO detection antibodies, 
conjugated to horseradish peroxidase (HRP) were added and left to incubate for 2h at RT. 
The washing steps were repeated and the colourimetric HRP substrate was added and 
incubated in the dark for 30min at RT. The reaction was stopped by adding Stop Solution 
and mixing, according to the manufacturer’s instructions. 
 Analysis of ELISA 
Within 30min after stopping the reaction, the optical densities (OD) at 450nm and 570nm 
were measured in a VersaMax ELISA microplate reader (Molecular Devices, Sunnyvale, 
CA, USA). The 450nm OD corresponds to the absorbance of the product from the 
degradation of the substrate from HRP. The OD at 570nm is non-specific and results from 
optical imperfections of the plate or dust, which absorbs equally at the 450nm and 570nm 
wavelengths. The 450nm OD was therefore corrected by subtracting the 570nm OD. 
Duplicates were averaged. The standard curve was plotted and analysed with the 
SigmaPlot software (Systat Software Inc.). A four parameter logistic curve-fit was 
generated using the Standard Curve function of the software. It is a non-linear regression 
model resulting in the following equation: 
𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 = min+	(𝑚𝑎𝑥 −min)1 + 𝑂𝐷𝐸𝐶50;<=>>?>@AB  
Unknown values were computed from the averages of duplicates using this model. A 
control of known concentration provided by the manufacturer was used to assess the 
reliability of the assay. 
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 Neutrophil elastase activity assay 
Bone marrow cells were isolated as described previously. Cells were pelleted and lysed in 
100µl Radioimmunoprecipitation buffer (RIPA; Sigma-Aldrich) per 106 cells. Lysates 
were stored at -80° until use. Neutrophil elastase (NE) activity was measured by a 
colourimetric assay monitoring the degradation of a specific substrate. The substrate is the 
synthetic peptide Methoxysuccinyl-Alanine-Alanine-Proline-Valin-p-nitroaniline (Elastase 
Substrate I, Colorimetric, Calbiochem, La Jolla, CA, USA). 20µl of the lysates were mixed 
with 200µl of reaction buffer containing 0.1 M Tris-HCl and 0.5M NaCl (pH 7.9) and 
1mM substrate in a 96-well plate and place at 37°C. The reaction was monitored by mean 
of the absorbance at 405nm. The values were corrected against the background by 
subtracting the absorbance from wells with RIPA only. One unit of NE activity was 
defined as the quantity of enzyme that liberated 1µmol of p-nitroaniline per hour. The 
following formula was used: 
 𝑈𝑛𝑖𝑡𝑠	𝑝𝑒𝑟	10F	𝑐𝑒𝑙𝑙𝑠= 	 ∆𝐴𝑏𝑠KLM𝐸𝑥𝑡𝑖𝑛𝑐𝑡𝑖𝑜𝑛	𝑐𝑜𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑡A;O=PQ@RO=>=OB	×	𝐿	×	𝑐𝑒𝑙𝑙	𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛>U?RPB		×	𝑠𝑎𝑚𝑝𝑙𝑒	𝑣𝑜𝑙𝑢𝑚𝑒 
  
Where ∆𝐴𝑏𝑠KLM is the slope of the linear regression curve calculated from the linear phase 
of the kinetics, as described in Figure 2-3. The millimolar extinction coefficient of the p-
nitroaniline at 405nm is estimated at 9.62M-1cm-1 in these conditions. The value L 
corresponds to the light path length, estimated at 0.5cm for a volume of 200µl 96-well 
plate. The cell concentration in lysate is expressed in million per ml of lysis buffer. The 
sample volume, expressed in ml, corresponds to the volume of lysate used in the reaction. 
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Figure 2-3. Calculate of neutrophil elastase activity. (A) The reaction rate was determined using 
data points from the linear phase of the reaction. (B) Linear regression computed from the linear 
phase of the reaction. The slope of the linear curve was used to calculate the neutrophil elastase 
activity. 
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 Measurement of mRNA accumulation by RT-qPCR 
 RNA extraction 
Bone marrow cells were isolated as previously described. At least 106 cells were pelleted 
by centrifugation and the supernatant was removed. Cell pellets were stored at -80°C until 
ribonucleic acid (RNA) extraction. Fragments of spleens were cut and put in RNAlaterÔ 
(QIAGEN, Hilden, Germany) then kept at -80°C until RNA extraction. Total RNA was 
extracted using QIAGEN’s mini RNeasy kit, according to the manufacturer’s protocol. 
This kit enables the enrichment of RNA molecules that are longer than 200base-pair (bp).  
Molecules, such as ribosomal RNA (rRNA), transfer RNA (tRNA) and micro RNA 
(miRNA), are smaller than 200bp. Therefore, the kit allows the enrichment of messenger 
RNA (mRNA), which is typically longer than 200bp. To ensure high enough concentration 
of mRNA for the synthesis of complementary deoxyribonucleic acid (cDNA), which 
matters more than higher yields for this application, the membranes were washed twice 
with 50µl the same elution solution. The concentration and purity of RNA was assessed 
with a NanodropÔ spectrophotometer (Thermo Fisher Scientific). The ratios 260/280 and 
260/280 were considered indicators of purity and considered acceptable when close to 2.0 
and 2.2, respectively. 
 cDNA synthesis 
Non-specific cDNA synthesis was performed with a High Capacity cDNA Reverse 
Transcription kit (Applied BiosystemsÔ, Waltham, MA, USA). The mRNA was diluted to 
1µg in 10µl and mixed with 10µl of reverse transcription master mix. The master mix was 
made per sample of 2µl 10X reverse transcription buffer, 0.8µl 100mM deoxynucleotides 
tri-phosphate (dNTP) mix, 2.0µl 10X random primers, 1.0µl of MultiScribeÔ reverse 
transcriptase and 4.2µl H2O. mRNA samples were mixed with the master mix and retro-
transcribed in a thermal cycler. The conditions were set as 25°C for 10min (annealing), 
37°C for 120min (reverse transcription), 85°C for 5min (enzyme inactivation). The 
products were cooled down to 4°C until they were removed from the thermal cycler, after 
what they were transferred to -20°C. Concentrations of cDNA were not measured. Instead, 
it was assumed that the reverse transcription efficacy was of 100%, therefore yielding 1µg 
of cDNA. 
 Quantitative polymerase-chain reaction 
Quantitative polymerase-chain reaction (qPCR) was performed using Fast SYBR Green 
Master Mix (Applied Biosystems). The cDNA sample synthesised previously were diluted 
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to 10ng/µl and 4µl was used per reaction. A master mix was prepared for each primer pair 
and made of 10µl 2X Fast SYBR Green Master Mix, 1µl of 10µM forward and reverse 
primer mix and 5µl H2O per reaction. First the cDNA samples were added inside a 96-well 
plate then 19µl of the master mix were added. The plates were transferred to the real-time 
PCR detection instrument (StepOne Plus, Applied Biosystems) within 30min after all 
reagents were added. The PCR reaction was started with the activation of the AmpliTaq 
Fast DNA polymerase at 95°C for 20sec, then 40 cycles consisting of 95°C for 3sec 
(denaturation) and 60°C for 30 sec (annealing and extension). Specific primers are 
described in Table 2-2. 
 Primer design and melt curve 
Primers were checked for specificity against a mRNA database. Both forward and reverse 
sequences were compared to the Mus musculus RefSeq RNA database using the Basic 
Local Alignment Search Tool (BLAST, US National Library of Medicine) algorithm. To 
avoid amplification of genomic DNA, the primers were chosen in order to cover exon-
exon junction of the mRNA sequence. Primers were ordered as lyophilised oligo DNA and 
suspended in DNase-free water to a stock concentration of 100µM. After the amplification 
steps, a melt curve was done to assess the specificity of primer pairs. The reaction mix was 
exposed to rising temperature and the fluorescence was recoded. Since SYBR Green is 
only fluorescent when incorporated into double-stranded DNA, fluorescence decreases as 
the temperature rises and DNA starts to denature. The derivative of fluorescence shows 
peaks which result from sudden drops in fluorescence, each peak is specific to a PCR 
product. Therefore, the presence of a single peak indicates that only one product has 
formed (i.e. the amplicon) while multiple peaks suggest other double-stranded DNA was 
produced and detected such as primer dimers or contaminating DNA. Examples of melt 
curves for validated and invalidated primers are shown in Figure 2-4. 
 Analysis of RT-qPCR data 
Data were analysed with the StepOneÔ software (Applied Biosystems). A threshold was 
placed automatically and adjusted if needed, intercepting all amplification plots in the 
linear phase of amplification. The number of cycles at which the fluorescence reaches the 
threshold was computed for each sample and termed Ct. Expression of the gene of interest 
was normalised to a housekeeping gene. For each gene and sample analysed, the average 
Ct values of the sample for the housekeeping gene, in this case Hprt, were subtracted from 
the gene of interest’s Ct value. The resulting value was called DCt. The average DCt from a 
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control group was then subtracted from the other groups, giving the value DDCt. Fold-
change for the relative expression of each gene of interest was calculated as 2^(-DDCt). 
 Statistical analyses 
 Comparison between groups 
Data were analysed using GraphPad Prism 5.0 (Prism Software, Irvine, CA, USA). The 
Kolmogorov-Smirnoff test was used to determine if the distributions of values within 
individual groups were normal. When comparing two groups, Student’s t-test or Mann-
Whitney test was used according to the data distribution. Welch’s correction was applied 
for the Student’s t-test in cases of unequal variances between the two groups. In multiple 
comparison, One-way ANOVA or Kruskal-Wallis tests were used according to the data 
distribution followed by Turkey’s or Dunn’s multiple comparison tests, respectively. 
Student’s t-test or one-way ANOVA were used to compare groups distributed normally. If 
one or more group did not follow a normal distribution, a non-parametric test was used. 
When the number of samples in a group was too low, it was assumed the distribution was 
normal and a parametric test was used. 
 Determination of reference interval 
Reference intervals, or normal ranges, were calculated as follow using GraphPad Prism 5.0 
(Prism Software). The Kolmogorov-Smirnoff test was used to determine if the distribution 
of values for a given parameter was normal. The skewness of the data was also calculated. 
The skewness refers to the symmetry of the distribution for a set of values. Non-skewed 
data are symmetrically distributed around the mean and have a skewness of 0, while a 
positive skewness means the distribution is skewed towards the right and a for negative 
skewness towards left. Skewed data can lead to unreliable reference intervals, such as 
negative lower limit224. Arbitrarily the limits to consider a set of values non-skewed was -1 
to 1. Skewness was corrected by transforming the data into a logarithmic (log) scale.  If the 
values were normally distributed, the reference interval was calculated using the standard 
deviation (d) of the mean. The lower limit of the range was calculated as the mean - 2d and 
the upper limit as the mean + 2d224. For log-transformed data, the limits were converted 
back to a linear scale to give the normal range. The reference intervals for data whose 
distribution were not normal was calculate with percentiles. The lower limit was calculated 
as 2.5 centile and the upper limit as the 97.5 centile, so as to determine the interval in 
which 95% of values are expected to fall224. 
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Figure 2-4. Assessment of qPCR-specificity by melt curves. Derivative of the fluorescence curve 
in function of the temperature produces two types of melt curves. (A) Melt curve with a single 
peak, indicating only one amplicon. (B) Melt curve with multiple peaks, two in this example, 
suggesting the presence of non-specific amplicons. 
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Table 2-1. List of antibodies (FC = flow cytometry, IHC = immunochemistry, Neut = cytokine 
neutralisation) 
 
 
  
Target
Fluorophore	/	
conjugation
Manufacturer Application Clone Host Istopye Dilution
BMP4 Purified abcam IHC polyclonal Rabbit IgG 1/100
CD115 PE eBioscience FC AFS98 Rat IgG2a 1/200
CD11b biotin eBioscience IHC M1/70 Rat IgG2b 1/200
CD16/32
(Fc	Block)
purified eBioscience FC 93 Rat IgG2a 1/5000
eFluor	660 eBioscience FC SER-4 Rat IgG2a 1/100
Biotin AbD	Serotec IHC MOMA-1 Rat IgG2a 1/100
CD3 BV421 BioLegend FC 17A2 Rat IgG2b 1/200
CD4 APC BioLegend FC GK1.5 Rat IgG2b 1/200
CD45 APC-Cy7 BioLegend FC 30-F11 Rat IgG2b 1/200
CD45.1 PE-CY5 eBioscience FC A20 Mouse IgG2a 1/200	or	1/400
CD68 AlexaFluor	647 AbD	Serotec IHC FA-11 Rat IgG2a 1/200
PE BioLegend FC 1/200	or	1/400
FITC eBioscience IHC	/	FC 1/100	(IHC);	1/200	(FC)
Primary	antibodies
CD169
CD71 R17217 Rat IgG2a
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FITC eBioscience IHC	/	FC 1/100	(IHC);	1/200	(FC)
Target
Fluorophore	/	
conjugation
Manufacturer Application Clone Host Istopye Dilution
CD8a PerCP-Cy5.5 BioLegend FC 53-6.7 Rat IgG2a 1/200
AlexaFluor	488 eBioscience FC 1/200
AlexaFluor	647 BioLegend IHC 1/100
G-CSF purified R	and	D Neu #	67604 Rat IgG1 see	Methods
Gr-1 PE-Cy7 eBioscience FC RB6-8C5 Rat IgG2a 1/200
Laminin FITC Sigma IHC polyclonal Rabbit IgG 1/100
PE-Cy7 FC 1/200
biotin IHC 1/100
Anti-rabbit	
IgG
Alexa	Fluor	488
Thermo	Fisher	
Scientific
IHC polyclonal Goat IgG 1/100
Alexa	Fluor	488
Thermo	Fisher	
Scientific
IHC 1/100
Alexa	Fluor	647
Thermo	Fisher	
Scientific
IHC 1/100
Streptavidin na na na
Secondary	antibodies/streptavidin
CD71
F4/80
TER119 eBioscience TER119 Rat IgG2b
BM8 Rat IgG2a
R17217 Rat IgG2a
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Table 2-2 List of primers for real-time quantitative polymerase chain reaction 
  
Target
Forward ATCCCGAAGGCTTCCCTGAGTG
Reverse AGGAGACCTTGGTAGAGGCAGA
Forward GGAGGATAGATGTGCTCTGGAAC
Reverse AGTGAGGATGGAGACCGTGGTG
Forward AACCGAGCCTACTCACAGTACG
Reverse GCATCCTTCGTGCTGAAATCGG
Forward ATCTGCGGGAATCCTGTGACTG
Reverse CCATATCTCGTAGCCAACAATGAC
Forward GCTATGAGGATGGAAGACTCTGG
Reverse ACTTGTGCAGCCACCTGAGATC
Forward AGGAGTCCTGTTGATGTTGCCAGT
Reverse GGGACGCAGCAACTGACATTTCTAHPRT
Primer	sequence	5'	-	3'
Csf3	(G-CSF)
Cxcl12
Angpt1
Kitl
Vcam1
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Chapter 3 Visceral leishmaniasis and erythropoiesis 
 Introduction 
Visceral leishmaniasis is a systemic infectious disease responsible for an estimated 20 000 
to 40 000 deaths per year. In contrast to the cutaneous form of the disease, which is self-
healing, the visceral form is a chronic disease, lethal in close to 100% of patients if left 
untreated225. Clinical manifestations of the disease typically include splenomegaly, 
hepatomegaly, cachexia, bleeding disorders and jaundice. Yet patients might only present 
some symptoms and in endemic areas these often overlap with other diseases sharing 
similar clinical signs. Symptoms usually appear months to years after infection when they 
do and vary depending on age or geographical location, especially between the Old World 
(eastern hemisphere) and the New World (America). The variations in species or strains, 
with the emergence of antibiotics-resistant strains make it more challenging to treat 
accordingly226. For these reasons, understanding the immunological and haematological 
bases for blood disorders in the broad context of parasitic infections and specifically in VL 
is essential as it could lead to potential new therapies to relieve the symptoms of the 
disease. 
Anaemia is the decrease of red blood cells in the blood circulation, it has been reported in 
most species naturally infected with L. donovani or L. infantum67,69,72,81. Anaemia has 
systemic consequences. Because red blood cells are responsible for supplying oxygen to all 
and tissues in the body, anaemia can cause a reduction of function in many organs. As a 
consequence, the main overt symptom of anaemia is a general fatigue, known as cachexia. 
Anaemia has never been associated with the lethality of the disease, but its contribution to 
pathogenesis should not be excluded. 
Data from the human disease suggest anaemia is due to the utilisation of heme, an essential 
component of haemoglobin by the parasites95, haemophagocytosis84,227–229 or splenic 
capture62. Iron deficiency has been suggested as a major cause for anaemia of VL4,95. 
However, evidence suggest that the production of red blood cells in the bone marrow is 
also involved. The bone marrow is the tissue inside long bones such as the femur, the 
humerus or the hip bone and is the main site of haematopoiesis in adult mammals. It is a 
complex organ in which HSCs and their daughter cells interact with various non-
haematopoietic cells called stromal cells. With the spleen and the liver, the bone marrow is 
a major site of amastigote replication. A wealth of knowledge regarding the biology of 
parasites in the spleen and liver as well as the tissue-specific immune responses is 
available. But very little is known about the biology of VL in the context of the bone 
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marrow. Ethical challenges render its study difficult in humans because the required 
techniques are invasive. The murine model has been extensively studied for the immune 
response to L. donovani in the spleen and liver, but very few immunological or 
haematological studies in the bone marrow have been reported. In the murine model, it has 
been shown that haematopoietic activity is increased in the bone marrow and the spleen of 
chronically infected BALB/c mice. Infection of stromal macrophages has been suggested 
as a cause for changes in haematopoietic activity19,86. In the human disease, the bone 
marrow shows evidence of myelodysplasia, i.e. ineffective production of blood cells3,4. 
More specifically to erythropoiesis, an experimental model of hamster has been used to 
show that ineffective erythropoiesis caused by VL is linked to a higher rate of apoptosis in 
erythroid precursors through the up-regulation of IFNd and TNF-related apoptosis 
inducing ligand (TRAIL)67.  
Anaemia is a serious complication of VL and appears to be multifactorial. The murine 
model has been hardly studied for haematological changes associated with VL. As a 
consequence, the mechanisms for the reduction of blood cells are still poorly understood. 
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 Aims 
Because murine EVL has a very different outcome from natural human, canine and feline 
infections, as well as EVL in hamsters, it has been poorly studied from a haematological 
perspective. As a consequence, very little is known about the haematological status of 
infected mice. Yet the profusion of biological and technical tools for murine studies allows 
more refined mechanistic studies than it is currently possible in other in vivo models or 
clinical settings. Using mice as an experimental model for the the study of haematological 
alterations would benefit the research into the pathogenesis of VL, provided the model 
proves similar enough to the human disease in this respect. 
 
The aims of the work presented in this chapter therefore were: 
1. To establish the haematological profile of mice chronically infected with L. 
donovani, especially in regards to red blood cells. 
2. To collect and compare clinical data with the murine haematological profile in 
order to find the similitudes and discrepancies between the human disease and the 
experimental murine model. 
3. To quantify erythropoiesis in the bone marrow, the main haematopoietic organ in 
adult mammals. 
4. To determine alterations in the bone marrow potentially underlying the reduction of 
medullar erythropoiesis.  
5. To study the role of the spleen in the anaemia of EVL. 
6. To find out the mechanisms responsible for alteration of erythropoiesis in mice 
infected with L. donovani. 
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 Results 
 Haematological profile of mice chronically infection with L. donovani 
C57BL/6 mice were infected with L. donovani LV9 amastigotes by the intravenous route 
and blood parameters were measured 4 weeks later (Table 3.1). This time point was 
chosen as it has been shown as the beginning of the chronic phase of infection in EVL. The 
first 4 weeks of infection correspond to acute infection in the liver. Hepatic parasite burden 
peaks at 4 weeks post-infection then decreases and parasites are cleared by the 8th week. 
By opposition, parasites number slowly grow over time in the spleen and the bone marrow 
and the infection is chronic230. The 28-day time is therefore commonly used in study of 
EVL as the beginning of chronic infection. Blood was collected by cardiac puncture and 
analysed by an automated blood analyser. Data from 14 naïve mice were used to calculate 
the reference interval, or normal range, for each parameter. No significant change in 
circulating lymphocyte, granulocyte or monocyte was measured between naïve and 
infected mice. A single infected mouse presented both lymphopenia and an eosinophilia 
according to the reference interval. The red blood cell (RBC) count per µl of blood was 
8.11 ± 0.14x106 in naïve mice. In chronically infected mice, the RBC count per volume 
was 19% lower at 56.57 ± 0.0.22x106 RBC/µl. 70% of infected mice had RBC counts 
under the normal range. Similarly, the haemoglobin (Hb) content in the blood of infected 
mice was reduced by 15%, down to 8.17 ± 0.22 g/dl while the baseline was measured at 
9.60 ± 0.21 g/dl in naïve mice. 30% of infected mice had Hb levels below the reference 
interval. The average volume of erythrocytes was unchanged, with a mean corpuscular 
volume (MCV) of 51 femtoliter (fl) in both groups but 3 out of 13 infected mice (23%) had 
developed a macrocytic anaemia, with MCV above the normal range. Contrary to the 
global haemoglobin concentration, the mean corpuscular haemoglobin (MCH), which 
indicates the average content of haemoglobin in individual erythrocytes, was significantly 
increased in infected mice by about 6%. However, all individual mice had MCH within the 
normal range. The mean corpuscular haemoglobin concentration (MCHC), which is 
computed from the MCH and the MCV was unaltered as well. These results all point 
towards development of a normochromic anemia, i.e. a reduction of circulating RBC with 
normal Hb content, in mice infected with L. donovani. Although the comparison group-
wise suggests the anaemia is normocytic, some of the infected mice developed a 
macrocytic anaemia with MCV higher than the normal range. Data regarding platelets are 
discussed in Chapter 4. 
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Table 3-1 Haematological parameters of mice infected with L. donovani. Mice were killed 28 
days after infection. Blood was collected by cardiac puncture under terminal anaesthesia and 
analysed by an automated blood analyser. 
 
  
WBC	(x103 /µl) 6.803 ± 0.864 5.758 ± 0.659 ns Mann	Whitney
NE	(x103 /µl) 1.671 ± 0.309 1.108 ± 0.128 ns t-test
LY	(x103 /µl) 4.486 ± 0.455 4.072 ± 0.626 ns Mann	Whitney
MO	(x103 /µl) 0.296 ± 0.072 0.230 ± 0.017 ns Mann	Whitney
EO	(x103 /µl) 0.259 ± 0.077 0.108 ± 0.058 ns Mann	Whitney
BA	(x103 /µl) 0.077 ± 0.026 0.013 ± 0.003 ns Mann	Whitney
RBC	(x106 /µl) 8.110 ± 0.143 6.572 ± 0.241 <	0.0001 t-test
HB	(g/dl) 9.593 ± 0.213 8.169 ± 0.219 <	0.0001 t-test
HCT	(%) 41.860 ± 0.900 34.020 ± 1.091 <	0.0001 t-test
MCV	(fl) 51.610 ± 0.577 51.990 ± 1.035 ns Mann	Whitney
MCH	(pg) 11.860 ± 0.227 12.520 ± 0.199 <0.05 Mann	Whitney
MCHC	(g/dl) 23.040 ± 0.663 24.130 ± 0.509 ns Mann	Whitney
PLT	(x103 /µl) 583.000 ± 45.680 281.500 ± 26.390 <	0.0001 t-test
MPV	(fl) 4.293 ± 0.143 5.354 ± 0.084 <	0.0001 Mann	Whitney
p TestNaïve	(n=14) Infected	(n=13)
Mean	±	SEM Mean	±	SEM
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Table 3-2. Reference interval of haematological parameters and distribution of infected mice 
in relative to the intervals. Reference interval (or normal range) were calculated from the values 
of naïve mice (n=14). Calculations for the reference intervals are detailed in Chapter 2.  
 
  
Under Within Above
WBC	(x103 /µl) 2.40 - 15.73 0.00% 100.00% 0.00%
NE	(x103 /µl) 0.37 - 5.03 0.00% 100.00% 0.00%
LY	(x103 /µl) 1.96 - 9.01 7.69% 92.31% 0.00%
MO	(x103 /µl) 0.05 - 0.92 0.00% 100.00% 0.00%
EO	(x103 /µl) 0.01 - 0.71 0.00% 92.31% 7.69%
BA	(x103 /µl) 0.00 - 0.26 0.00% 100.00% 0.00%
RBC	(x106 /µl) 7.04 - 9.18 69.23% 30.77% 0.00%
Hb	(g/dl) 8.00 - 11.19 30.77% 69.23% 0.00%
HCT	(%) 35.12 - 48.60 61.54% 38.46% 0.00%
MCV	(fl) 47.30 - 55.92 0.00% 76.92% 23.08%
MCH	(pg) 10.16 - 13.56 0.00% 100.00% 0.00%
MCHC	(g/dl) 18.08 - 28.00 0.00% 100.00% 0.00%
PLT	(x103 /µl) 241.20 - 924.80 38.46% 61.54% 0.00%
MPV	(fl) 3.60 - 5.00 0.00% 23.08% 76.92%
Reference	interval
Distribution	of	haematological	parameters	from	
infected	mice	relative	to	the	reference	interval
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 Medullary erythropoiesis is repressed during EVL 
Decrease in haematocrit can be caused by reduced number of circulating erythrocytes or 
increase in plasma volume. The latter was not investigated here. Reduction of circulating 
erythrocytes can be caused by impairment of erythropoiesis or by peripheral destruction of 
RBC. To determine if erythropoiesis was altered in EVL, the bone marrow of infected 
mice was analysed. Femurs, the more marrow-rich bone and main site of hematopoiesis in 
adult mammals, appeared pale in comparison with naïve mice, in which the femurs have a 
purple-red coloration (Figure 3.1A). Because this phenomenon has been preciously 
associated with impairment of erythropoiesis169,231,232, femurs were sectioned and stained 
with TER119, a marker of erythroid cells in the mouse233 and with DAPI. Nucleated 
TER119+ cells were visibly reduced in the bone marrow of infected mice (Figure 3.1B 
and C). These results indicate that erythropoiesis is reduced in the bone marrow during 
chronic infection with L. donovani. 
 Identification of erythroid precursors 
Erythropoiesis was quantified in the bone marrow by single cell analysis. The bone 
marrow was flushed out of the bone cavity with PBS and the resulting cell suspension 
reflected the colours of complete bones (data not shown). The first observation after 
preparing single cell suspensions is that fewer cells could be recovered from infected bones 
(Figure 3.1D). Erythroid progenitors were identified based on the surface expression of 
CD71 and TER119233. After exclusion of doublets and dead cells, only CD45- cells were 
included in the analysis. It was assumed that the efficacy of RBC lysis was of one hundred 
percent, thus no mature cells were present in the final cell suspensions. Indeed, TER119 is 
also expressed on immature erythroblasts as well as mature reticulocytes and erythrocytes. 
Reticulocytes and erythrocytes can be excluded by a nucleic staining since they are 
enucleated cells but no DNA dye was included in the staining mixes. Control experiments 
have shown that most DNA-negative cells were removed following RBC lysis with the 
ACK buffer (Figure 3-2). Up to four populations of erythroblasts can be identified by flow 
cytometry based on their size and the surface expression of the erythroid marker TER119 
and the transferrin receptor CD71 (Figure 3-3A). The TER19med CD71high population 
corresponds to the pro-erythroblasts. They are the most immature precursors in the 
erythroid-specific lineage identifiable by flow cytometry and differentiate from the BFU-E 
and CFU-E. The TER119high population can be divided into three more populations based 
on CD71 and size. Respectively, pro-erythroblasts differentiate into CD71high FSChigh 
basophilic erythroblasts then CD71high FSClow polychromatic erythroblasts and finally 
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CD71low FSClow orthochromatic erythroblasts and reticulocytes233. Reticulocytes are finally 
released in the blood and mature into erythrocytes. Because all populations of erythroblasts 
could not be consistently resolved, it was decided to group all TER119high cells as a single 
population called erythroblasts (Figure 3-3A). Pro-erythroblasts were defined as 
CD71+TER119low cells and erythroblasts as CD71-/+TER119high (Figure 3-3A). 
Erythroid precursors were measured in the bone marrow of naïve and infected mice 
(Figure 3.-4 A and B). The frequency of pro-erythroblasts in the bone marrow was 1.00 ± 
0.22% in naïve mice and was not significantly different in infected mice (1.03% ± 0.16%; 
Figure 3-4C). On the other hand, the frequency of erythroblasts in infected mice was on 
average reduced by 5-fold compared to the naïve group (Figure 3-3D). The decrease in 
erythroblasts was also reflected in the absolute number of cells (Figure 3-3E and F). A 
single leg (femur + tibia) contains 0.32x106 and 2.66x106 pro-erythroblasts and 
erythroblasts in naive mice respectively, against 0.27x105 and 0.55x106 in infected mice. 
These results all confirm that erythropoiesis, at least in its final stages, is impaired in the 
bone marrow of infected mice 
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Figure 3-1. Signs associated with reduction in medullary erythropoiesis in L. donovani 
infected mice. (A) External view of femurs isolated from naïve (left) and infected (right) mice 
(representative of more than 30 individual mice per group in more than 10 experiments). (B-C) 
Confocal imaging of 5µm femoral sections from naïve (B) and 28d-infected (C) mice stained with 
DAPI (blue) and the erythroid lineage marker TER119 (white; representative of 6 mice per group 
from 2 independent experiments). (D) Quantification of total viable bone marrow cell numbers 
flushed from 1 femur + 1 tibia. Data represent mean + SEM (Mann Whitney test; n=23 mice per 
group from 7 independent experiments). 
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Figure 3-2 Optimal red blood cell lysis takes away the need to use a DNA label to exclude 
mature erythrocytes. (A) Staining of non-lysed bone marrow samples with Hoechst 33342 shows 
DNA- cells, which comprise enucleated reticulocytes and erythrocytes, and DNA+ cells. (B) After 
RBC lysis, the number of anucleate cells is negligible. Therefore, it was judged unnecessary to use 
a DNA stain in conjunction with lysis of the samples.  
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Figure 3-3 Gating strategy to identify subsets of erythroid progenitors. (A) Gating strategy 
used to quantify erythroid progenitors from the bone marrow and the spleen, representative naïve 
mice. Debris were excluded based on their smaller size. Only single cells were included by 
discriminating events with a high pulse width. Analysis was based on live cells which are negative 
for a fixable live/dead staining. Erythroid progenitors are defined as CD45- cells. Pro-erythroblasts 
correspond to the CD71+ TER119low population whereas erythroblasts are defined as CD71-
/+TER119high cells. (B) Isotype control representative for naïve and infected mice. 
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Figure 3-4.  Medullar erythropoiesis is repressed in chronically infected C57BL/6 mice. (A 
and B) Flow cytometry analysis of CD45- bone marrow cells using the erythroid surface markers 
CD71 (transferrin receptor) and TER-119. Pro-erythroblasts are CD45- CD71+ TER119low and 
erythroblasts are CD45- CD71-/+ TER119high. (C) Frequency of pro-erythroblasts in the bone 
marrow. (D) Frequency of erythroblasts in the bone marrow. (E) Absolute number of pro-
erythroblasts and (F) erythroblasts per femur + tibia. (Mann Whitney test; n=14 mice per group 
from 4 independent experiments). Data represent mean + SEM All results were obtained 28 days 
after infection with L. donovani. 
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 L. donovani parasites reside in bone marrow macrophages 
Because erythropoiesis was impaired upon infection with L. donovani, the bone marrow 
was studied in the context of EVL to determine whether the microenvironment was altered. 
Bone marrow sections from naïve and infected mice were stained with haematoxylin and 
eosin to investigate if distinctive features appeared at the tissue level following L. 
donovani infection. Optimisation of the decalcification and sectioning protocol enabled the 
preservation of anatomical details such as the vasculature, cortical and trabecular bones 
(Figure 3-5). Microscopic investigation revealed accumulation of cells resembling 
macrophages (Figure 3-5B, arrow), a feature exclusive to infected mice. These cells were 
characterised by a large cytoplasm and cellular projections similar to the filopodia of 
macrophages234. However, this method did not allow for the identification of intracellular 
amastigotes. The bone marrow, together with the spleen and the liver, is a major site for 
parasite replication. Amastigotes typically reside in mononuclear phagocytes1. In BALB/c 
mice, L. donovani amastigotes reside inside stromal macrophages of the bone marrow 
characterised by the cell surface marker CD16919. To confirm these results, 
immunohistochemistry of bone marrow was performed at day-28 post-infection (Figure 3-
6). For this purpose, mice were infected with a L. donovani LV9 strain expressing a 
membrane-tdTomato fluorescent protein. Unfortunately, chronic infection of C57BL/6 
mice proved harder to achieve with this strain of parasite than the wild-type strain. Instead 
immunocompromised B6 RAG2-/- mice were used. These mice were chosen because of the 
higher parasite burden when compared to wild-type strains infected with the LV9-
tdTomato strain, allowing easier detection of infected cells. CD68, a lysosome-associated 
glycoprotein expressed by macrophages and monocytes was used to identify tissue 
macrophages. Confocal analysis shows a co-localisation of parasites with the CD68 
staining, a marker of macrophages235. The fluorescent parasites and the CD68 staining also 
co-localised CD169 (Figure 3-6A). However, single cells could not be identified from 
these images. The integrin aM (CD11b), a common marker of macrophages but with a low 
expression in bone marrow stromal macrophages147, was undetectable on infected cells 
(Figure 3-6B). Taken together, these results confirm that parasites reside in bone marrow 
macrophages including stromal macrophages described previously as host cells in BALB/c 
mice by Cotterell et al.19. In order to get a better insight into the anatomical localisation of 
parasites within the bone marrow, an approximately 1mm-thick femoral section was 
imaged by multi-photon confocal microscopy and a deep z-stack projection was 
reconstituted. The vasculature was highlighted by staining with an anti-laminin antibody, 
which binds to a family of glycoproteins part of the extracellular matrix surrounding the 
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bone marrow vasculature126,236. It was chosen to study the localisation of parasites in 
relation to the vasculature since the distance to the bone marrow vasculature informs on 
the niche which the cells are part of. The HSC niche in particular has been shown to be 
closely associated with the vasculature126,237. Imaging of parasites in relation to the 
vasculature suggests parasites are localised closed to the vasculature but the distance 
between parasites and blood vessels was not quantified (Figure 3-6C and D). This 
indicates that infected cells are in close proximity to the perivascular niches where most 
HSPCs and stromal cells typically reside126,221 (typically <10µm from blood vessels). 
Because of the difficulty associated with histological studies of long bones, there is no 
report of precise localisation of infected cells in relation to the bone marrow environment.. 
 EVL induces alterations of bone marrow macrophages populations 
Haematopoiesis is a complex process which requires a specific microenvironment and a 
variety of secreted factors127. While HSPCs can be directly affected by multiple conditions, 
perturbations to the microenvironment have also been shown to alter haematopoiesis. We 
focused on two major components of the haematopoietic niche, stromal macrophages and 
CAR cells. CD169+ bone marrow stromal macrophages are essential component of the 
niche for erythropoiesis169 as well as important regulators of the stromal cells in the HSC 
niche147,148. It has been shown here and in a previous study that these cells can be infected 
by L donovani. To identify these cells by flow cytometry, the gating strategy originally 
used by Chow et al.147 was applied. Bone marrow macrophages were identified as Gr-1- 
CD115- F4/80+ low side scatter (SSClow) cells (Figure 3-7A). The surface expression of 
CD169 was then quantified. In naïve mice, two populations of macrophages were resolved 
based on the intensity of CD169 staining; CD169low and CD169high (Figure 3-7B). The 
gating of these two populations was made arbitrarily based on the clear separation in naïve 
mice (green histogram). In naive mice, CD169low macrophages accounted for 2.77±0.59% 
of bone marrow cells or 5.35x105 cells per leg. The CD169high stromal macrophages 
accounted for 1.70±0.29%/3.36x105 (Figure 3-7C). In infected mice, macrophages 
populations were differentially affected. There was no significant change in the absolute 
numbers of CD169low (6.92x105 cells per leg, ns) but the CD169high population was 
significantly reduced by 36% (2.14x105, p<0,01). In spite of the reduction of CD169high 
macrophages, the numbers of total macrophages were similar between the to groups 
(Figure 3-7D), suggesting that a loss of CD169-expression by bone marrow macrophages 
is more likely than an absolute loss of macrophages. The ratio CD169low/CD169high was 
approximately 62/38 in naïve mice. Infected mice showed a distribution of bone marrow 
macrophages skewed towards the left (red histogram), with a ratio of 76/24. 
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Figure 3-5. EVL results in focal accumulation of macrophage-like cells in the bone marrow. 
Haematoxylin-eosin staining of naïve (A) and infected (B) 5µm femoral sections. Unusual 
accumulation of macrophage-like cells is shown in B (arrow). Other notable features include the 
vasculature (1), trabecular bones (2) and cortical bone (3). Representative of 6 mice per group from 
2 independent experiments. 
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Figure 3-6. Markers of bone marrow stromal macrophages co-localise with L. donovani 
amastigotes in B6 RAG2-/- mice. (A and B) Confocal imaging of a 5µm femoral section from a B6 
RAG2-/- mice infected with a membrane tdTomato-expressing strain L. donovani amastigotes 
(tdTomato-LV9, red) and stained with DAPI (blue), CD169 (yellow) and CD68 (green) in (A) and 
with DAPI (blue), CD11b (yellow) and CD68 (green) in (B). (C) Confocal imaging of thick bone 
marrow sections in B6 RAG2-/- mice infected with tdTomato-LV9 (red) and stained with an anti-
Laminin antibody (green). Images represent maximum intensity projection of success confocal 
slices in the z-axis. (D) Enlargement of a portion of image C. 
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Figure 3-7. Bone marrow macrophages populations are altered following L. donovani 
infection. (A) Bone marrow macrophages are identified as Gr-1- CD115- F4/80+ SSClow cells147. 
(B) CD169 expression on bone marrow macrophages of naïve (green) and infected (red) mice. 
Isotype control (blue) is representative of both naïve and infected mice. (C) Absolute numbers of 
macrophages per leg (1 femur + 1 tibia) according to the gating described in A and B. Absolute 
numbers were calculated from the frequencies multiplied by the total bone marrow cells isolated 
from each mouse. Data represent mean + SEM. All experiments were performed 28 days after 
infection. (unpaired t-test; n=10 mice per group from 2 independent experiments) 
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 EVL correlates with repression of the bone marrow stromal support 
The data described here indicate an impairment of erythropoiesis as well as an alteration of 
stromal macrophages. While CD169+ bone marrow macrophages are important for 
erythropoiesis169, their depletion also causes a more general disruption of haematopoiesis, 
characterised by an alteration of the stromal niche retaining HSPCs in the bone marrow147. 
The expression of Kit-ligand (Kitl or Scf), Angiopoietin 1 (Angpt1), vascular cell adhesion 
molecule 1 (Vcam1) and Cxcl12, genes expressed by stromal cells and involved in the 
quiescence and retention of HSCs, was measured140,144,238,239. RT-qPCR analysis of total 
bone marrow cells from chronically infected mice shows no change in expression of Kitl, 
Angpt1 or Vcam1 but a 50% decrease in Cxcl12 expression (Figure 3-8A-D). This can be 
either a result of gene down-regulation or a difference in relative stromal cell frequencies. 
In Cxcl12DsRed mice, fluorescent DsRed protein was inserted inside the Cxcl12 coding 
sequence, so that the expression of DsRed is regulated by the promoter of Cxcl12. This 
model, as described previously221, highlights CXCL12-abundant reticular (CAR) cells, a 
population of mostly perivascular stromal cells, where the HSC-niche is typically located 
(Figure 3-9A). CAR cells were also observed in the bone marrow of day 28-infected 
Cxcl12DsRed mice (Figure 3-9B). An attempt to quantify cells from images of tissue 
sections resulted in a frequency of DsRed-positive cells of approximately 5% (Figure 3-
9C), with no difference between the two groups. This frequency was much higher than the 
reported frequency of CAR cells in the bone marrow, which is estimated at 0.26%145. This 
is most likely due to the morphology of CAR cells. They are fibroblastic cells with 
cytoplasmic projections240 in the 3 dimensions, so a 2-dimensional analysis is likely to 
over-estimate cells by counting the projections as a single cell. The bone marrow was 
therefore flushed and analysed by flow cytometry, a method judged more reliable for 
quantification of CAR cells (Figure 3-10A).  The frequency of CAR cells in control mice 
was then measured at 0.32±0.02% of total bone marrow cells, corresponding to 
4.84±0.49x104 cells per femur. The frequency and absolute number of Ds-Red+ cells were 
reduced in infected mice, down to 0.11±0.01% and 1.36±0.20x104 cells per femur, 
confirming that fewer cells express detectable levels of CXCL12 in the reporter mouse 
model (Figure 3-10B and C). To determine whether this reduction in Cxcl12 in the bone 
marrow at the tissue level was a reflection of lower number of stromal cells or down 
regulation of Cxcl12 expression at the single cell level, I sought to quantify the absolute 
numbers of stromal cells in the bone marrow. It has been shown that CAR cells are mainly 
composed of mesenchymal stem and progenitor cells MSPCs, characterised by their ability 
to produce adherent fibroblastic colonies (CFU-F) in vitro145. A CFU-F assay is accepted 
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as a reflection of the number of MSPCs in the bone marrow. As shown in Figure 3-10D, 
there was also a reduction in the absolute number of CFU-F in the bone marrow of infected 
mice, an average 32.6±3.4 CFU-F could be recovered from 1 million bone marrow cells in 
naïve mice, while only 11.8±4.5 could be recovered from infected mice. Taken altogether, 
these results suggest that chronic EVL leads to a reduction of stromal support in the bone 
marrow. This is characterised by a loss of CXCL12-expressing stromal cells. Molecular 
factors for the reduction of CD169high macrophages and CAR cells was then investigated. 
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Figure 3-8. Effect of L. donovani infection on the expression of HSC niche-essential genes in 
total bone marrow. RNA was extracted from total bone marrow cells and analysed by RT-qPCR 
for the expression of vascular cell adhesion molecule 1 (Vcam1) (A), Angiopoietin 1 (Angpt1, B), 
Kit-ligand (Kitl, C) and Cxcl12 (D). Intra-sample standardisation was done by normalisation to the 
house-keeping gene HPRT and inter-sample standardisation was done by normalisation to the 
average expression of the naïve group. (unpaired t-test; n=3 mice per group from one experiment 
for Vcam1, Angpt1 and Kitl; n=8 mice per group from two experiments for Cxcl12). Data 
represent mean + SEM. All experiments were performed 4 weeks after infection. 
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Figure 3-9. Visualisation of CXCL12-expressing cells using Cxcl12-DsRed reporter mice 
strain. 5µm-thick bone marrow sections from naïve (A) and d28-infected (B) CXCL12-DsRed 
mice were stained with an anti-laminin antibody (green) and DAPI (blue) before confocal analysis. 
Images are representative of 3 mice per group from one experiment. (C) Quantification of DsRed+ 
cells from image-analysis. Data represent mean + SEM (unpaired t-test; n=3 mice per group; 1 
image per mouse). 
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Figure 3-10. The bone marrow stromal compartment is impaired during chronic EVL. (A) 
Flow cytometry analysis of DsRed-positive cells in naïve and infected CXCL12-DsRed reporter 
mice. Dot plots show identical number of cells, gated on live single cells (unpaired t-test). (B) 
Frequency of DsRed+ cells. (C) Absolute number of DsRed+ cells per femur, calculated from the 
frequency of DsRed+ cells in A multiplied by the total bone marrow cell count (Mann Whitney test; 
A and B= Data from 5 naïve mice and 9 infected mice from 2 independent experiments). (D) 
Number of CFU-F per million bone marrow cells. (Unpaired t-test; n=7 mice per group from 2 
independent experiments). Data represent mean + SEM. All experiments were performed 28 days 
post-infection with L. donovani. 
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 G-CSF is up-regulated during EVL 
The regulation of the granulocyte-colony stimulating factor (G-CSF) was investigated. In a 
recent study, G-CSF has been shown to block medullar erythropoiesis by depleting a 
subset of stromal macrophages expressing CD169 in the mouse232. In addition, Petit et al. 
have demonstrated that G-CSF inhibits bone marrow Cxcl12 expression241. Because the 
effects of G-CSF share similarities with events in EVL, the levels of G-CSF were 
measured in the plasma of naïve and L. donovani-infected mice. A 4-fold increase of G-
CSF was detected at the protein level in infected compared to naïve mice (Figure 3-11A). 
Average normal concentration were of 110±6pg/ml with a reference interval calculated 
from 13 naïve mice from 3 experiments of 51pg/ml to 134pg/ml. In 28-day infected mice, 
the average was 599±94pg/ml and 92% (12 out of 13 infected mice) of the mice had values 
above the reference interval. RT-qPCR analysis of Csf3, the gene encoding G-CSF, in total 
bone marrow and spleen cells was performed to identify the source of circulating G-CSF. 
No significant up or down-regulation of Csf3 was detected in the bone marrow (Figure 3-
11B) or the spleen (Figure 3-11C) of infected mice. Hence, increased G-CSF detected in 
plasma may be derived from cellular source residing outside the bone marrow or spleen. 
All organs are virtually capable of producing G-CSF, and the cellular source is thought to 
be endothelial cells, fibroblasts and macrophages242. Microarray data from the 
Immunological Genome Project consortium shows no cell type with a notably high level of 
Csf3 (Figure 3-11E and F). No dataset from the Immgen database showed a cell type with 
a normalised expression value above the 120 threshold. The Immgen consortium 
recommends this value as the threshold for gene expression. Under the 120 value, genes 
have a less than 95% probability of being expressed. The only cell type with a higher 
signal than other types is the blood endothelial cells from subcutaneous lymph nodes (Fig 
3-11F, BEC SLN, in red), in accordance with other studies showing that endothelial cells 
express G-CSF243. To test whether G-CSF up-regulation participates in alterations of 
medullar erythropoiesis, 25µg of a G-CSF neutralising antibody was injected daily into 
mice with EVL. The mice had been infected for 6 weeks prior to treatment, which lasted 1 
week. Treatment with the antibody had no measurable effect on the erythropoiesis when 
compared to the isotype control group. Reduction of erythroblasts was not rescued by 
administration of the anti-G-CSF antibody (Figure 3-12B). Pro-erythroblasts levels were 
unaffected by the infection or the treatment (Figure 3-12A). Interestingly, levels of 
circulating G-CSF were higher in the treated group than in the isotype control, suggesting 
that the treatment may have induced a feedback loop resulting in increased production of 
G-CSF (Figure 3-12C). 
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G-CSF is known to inhibit the CXCL12/CXCR4 signalling axis through the repression of 
CXCL12 expression by stromal cells and by inducing the degradation of extracellular 
CXCL12 by neutrophil elastase241. Therefore, the neutrophil elastase activity in the bone 
marrow of naïve and infected mice was assessed by a biochemical assay monitoring the 
degradation of a specific peptide (Figure 3-11D). Lysates were prepared from bone 
marrow cell pellets and incubated with N-methoxysuccinyl-Alanine-Alanine-Proline-
Valine-p-nitroanilide (Calbiochem). This peptide is specifically cleaved by neutrophil 
elastase and the liberation of 4-nitroaniline can be measured by its specific absorbance. 
The rate of 4-nitroaniline production is considered a reflection of neutrophil elastase 
activity. The peptide was degraded at the same rate in naïve and infected mice, meaning 
there is no difference in neutrophil elastase activity from bone marrow cells (Figure 3-
11D). Systemic neutrophil elastase activity was not measured, so it cannot be excluded that 
neutrophil elastase secreted at a distant site is present in the bone marrow. Indeed, cell 
lysates were used here instead of bone marrow supernatant as done in the original study241. 
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Figure 3-11. EVL induces down-regulation of CXCL12 expression in the bone marrow in 
correlation with up-regulation of systemic G-CSF. (A) Concentration of G-CSF in the blood of 
mice. (Mann Whitney test; n=13 mice per group from 3 independent experiments). (B-C) 
Quantification of G-CSF expression in total bone marrow (B) and spleen (C) cells. G-CSF mRNA 
expression was normalised by RT-qPCR against a housekeeping-gene in each sample and 
expressed relatively to the average expression of the naïve group (Unpaired t-test; n=3 mice per 
group from 1 experiment). (D) Neutrophil-elastase (NE) activity from bone marrow cell lysates. 
Identical numbers of cells were used. NE activity was monitored by a colorimetric assay using a 
specific substrate. One unit of neutrophil elastase activity is defined as the quantity of enzyme that 
liberated 1µmol of substrate per hour. (Unpaired t-test; n=5 mice per group from 1 experiment). All 
data represent mean ± SEM of experiments at day 28 p.i. (E and F) Expression atlas of the Csf3 
gene in the “Key population” and “Stromal cells” panels from the Immunological Genome project.   
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Figure 3-12. Effect of treatment with a neutralising anti-G-CSF antibody (mG-CSF) on 
erythropoiesis and circulating G-CSF in mice infected with L. donovani. Mice were infected 
with L. donovani for 5 weeks. They were then administered 25µg of monoclonal mouse IgG1 
antibody or IgG isotype control i.p. daily for one week before being killed. (A and B) Pro-
erythroblasts and erythroblasts were quantified as described in Fig. 3-2. (C) Quantification of 
circulating G-CSF in the plasma measured by ELISA assay. (One-way ANOVA with Turkey’s 
multiple comparison test; n=3 mice per group from a single experiment). Data represent mean + 
SEM. 
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 Splenic erythropoiesis is increased during EVL 
One of the hallmarks of VL, both in humans and experimental models, is a dramatic 
increase in spleen size. The spleen weight of C57BL/6 mice 4 weeks after infection 
averaged 637±36mg whereas the baseline in naïve mice was measured at 73±3mg, 
corresponding to a 9-fold increase (Fig. 3-13A). This increase in weight correlated with a 
5-fold increase in cellularity (Fig. 3-13B). Spleens were dissociated into single cells 
suspensions and analysed for erythropoiesis in the same way as the bone marrow. Total 
erythroid precursors (pro-erythroblasts + erythroblasts) frequency was quantified in 
infected mice over time. Interestingly, the curves of spleen weight and frequency of 
erythroid precursors followed very similar trends (Fig. 3-13C). The spleen is capable of 
erythropoiesis and it produces erythrocytes in a steady state (Fig. 3-14A). Indeed, pro-
erythroblasts and erythroblasts represented 0.85±0.20% and 0.16±0.06% of total 
splenocytes respectively in naïve mice (Figure 3-14). In infected mice the frequencies of 
both were dramatically increased, by 16 and 45-fold respectively (9.00±1.50% and 
7.19±1.00%) (Figure 3-14). Because splenomegaly was associated with an increase in the 
spleen cellularity (Figure 3-13B), the discrepancies in absolute numbers where even 
higher (Figure 3-14E and F). These results indicate that splenomegaly correlates with 
splenic erythropoiesis, a process in which a specific population of erythropoietic 
precursors, called stress erythroblasts, proliferate in response to anaemia or hypoxia244,245. 
From day 3 after infection with L. donovani to day 21, the frequencies of cumulated pro-
erythroblasts and erythroblasts in the bone marrow were similar between the naïve and the 
infected groups. A significant 70% reduction of medullar erythroblasts in the infected mice 
was measured by day 28 (Figure 3-21A). The frequencies of splenic erythroblasts during 
the course of infection mirrored the trend seen in the bone marrow. Indeed, splenic 
erythropoiesis was similar between the two groups from day 3 to day 21 then a sharp rise 
of splenic erythropoiesis was measured at day 28. This suggests that splenic erythropoiesis 
occurs in response to impairment of medullar erythropoiesis. 
 Splenomegaly correlates with changes of the splenic architecture 
In order to understand the contribution of extramedullary erythropoiesis to splenomegaly, 
spleen tissues were analysed by immunohistochemistry. Spleen weight increases massively 
between day 21 and day 28 post-infection (Figure 3-15A). This corresponds to a 
remodelling of the tissue, characterised by an area-wise increase in F4/80 staining (Figure 
3-15B). Based on the F4/80 staining which highlights red pulp macrophages and the DAPI 
nuclear staining which allows distinction between red pulp and the more cell-dense white 
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pulp, the gross architecture of the spleen was quantified at day 28 post-infection. The white 
pulp area per tissue section did not increase significantly (Figure 3-16A). The red pulp 
was more dramatically dilated with a 5-fold increase in area per tissue section (Figure 3-
16B). This resulted in a ratio red pulp/white pulp of 1.9 in naïve mice vs. 6.4 in infected 
mice (Figure 3-16C). Taken together, these results show that the spleen remodelling is 
characterised by a dilatation of the red pulp more than the white pulp. 
 Extramedullary erythropoiesis occurs in the splenic red pulp 
The spleen sections were then stained with antibodies specific for CD71 and TER119 to 
highlight erythroid precursors. At day 28 post-infection, the spleens from infected mice 
contained visibly more erythroid precursors (Figure 3-17A). Interestingly, the staining 
with CD71 and TER119 revealed that erythroid precursors co-localised exclusively with 
red pulp F4/80+ macrophages, both in naïve and infected mice (Figure 3-17B). These 
results indicate that proliferation of erythroid precursors in the spleen is linked to the 
expansion of the red pulp. Molecular pathways for the induction of extramedullary 
erythropoiesis are known. Indeed, the bone morphogenetic protein 4 (BMP4) is necessary 
to trigger splenic erythropoiesis and mice with a mutation altering the BMP-signalling 
pathway do not develop extramedullary erythropoiesis in response to anaemia244. To 
understand if infection with L. donovani triggers BMP4 signalling in the spleen, the 
expression of BMP4 in the spleen of infected mice was investigated by 
immunohistochemistry. In naïve mice, BMP4 expressing cells were more prominent in the 
red pulp, although BMP4 was also detected in the white pulp (Figure 3-18A). Despite the 
extramedullary erythropoiesis, fewer BMP4-expressing cells could be seen in infected 
mice (Figure 3-18A and B). 
 Reduction of medullar erythropoiesis is independent of splenomegaly 
In our model of EVL, any causality between the alterations of the bone marrow and 
changes in the spleen still needs to be established. It is unclear whether extramedullary 
erythropoiesis is triggered by reduction of erythropoiesis in the bone marrow or the 
opposite. Hypersplenism-induced pancytopenia has been suggested previously since 
haematological parameters return to normal value following splenectomy in VL patients62. 
However direct evidence linking the two have never been reported so far. To understand 
the contribution of the spleen to the anaemia caused by L. donovani, splenectomised 
C57BL/6 mice were infected and analysed for haematological changes. Mice were 
splenectomised or sham-operated prior to delivery. They were allowed to recover for 3 
weeks before being infected with L. donovani and were killed 4 weeks after infection. 
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Infected splenectomised mice had a mild anaemia, similarly to their sham-operated 
counterparts (Figure 3-19A). The nature of anemia was as described in paragraph 1.2.1, 
i.e. normochromic (Figure 3-19B) with a macrocytic tendency in sham-operated infected 
mice (Figure 3-19C). When comparing averages, no difference in MCV was measured. 
However, on an individual level, 7 mice out of 15 sham-operated infected mice showed 
macrocytosis, according to the values in Table 3.1. Only one splenectomised infected mice 
had a MCV above the reference interval. Interestingly, thrombocytopenia was less 
pronounced in splenectomised mice than sham-operated. These data are discussed in 
Chapter 4. The bone marrow was analysed for erythropoiesis to determine if the 
pathogenesis was similar in splenectomised and sham-operated mice. Decolouration of the 
femurs was observed both in the absence and presence of a spleen, indicating that 
erythropoiesis is altered independently of the spleen (Figure 3-20A). The bones from 
splenectomised infected mice were slightly more red in colour than the sham-operated 
infected mice, suggesting erythropoiesis was not as repressed in the former. This was 
confirmed by flow cytometry analysis of total bone marrow stained for erythroid 
precursors. Matching what has been described here before, there was no decrease in 
CD71highTER119low pro-erythroblasts numbers in infected mice (Figure 3-20B). On the 
other hand, a significant decrease in erythroblasts numbers was measured (Figure 3-20C). 
No significant difference was measured between splenectomised infected mice and sham-
operated infected mice but the numbers of erythroblasts dropped less dramatically in 
splenectomised (-59%) than in sham-operated mice (-79%) when compared to their naïve 
counterparts. These results indicate that L. donovani infection can decrease medullar 
erythropoiesis in the absence of a spleen. However, they also suggest that loss of 
erythropoiesis is milder in splenectomised mice, so a partial contribution of the spleen can 
not be excluded. 
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Figure 3-13. Chronic EVL induces splenomegaly. (A) Spleen weight from naïve and infected 
mice (n=20 from 6 independent experiments) (B) Absolute numbers of cells per spleen. Spleens 
were dissociated into single cells suspension and cells were counted with an automatic cells 
counter. Dead cells were excluded from the counts based on Trypan blue inclusion. All mice were 
infected for 28 days (unpaired t-test with Welch’s correction; n=8 mice per group from two 
independent experiments). (C) Total erythroid precursors frequency (pro-erythroblasts and 
erythroblasts) and spleen weight during L donovani infection. (n=3 or 4 mice per time point, from a 
single experiment). Data represent mean ± SEM. 
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Figure 3-14. Chronic EVL induces extramedullary erythropoiesis in the spleen. (A and B) 
Gating strategy for identification of pro-erythroblasts (CD45-CD71highTER119low) and erythroblasts 
(CD45-CD71high/lowTER119high) in the spleens of naïve (A) and infected (B) mice. Plots are gated on 
CD45- live cells and equal number of live cells. (C) Frequency of pro-erythroblasts in the spleen. 
(D) Frequency of pro-erythroblasts in the spleen. (E) Absolute number of erythroblasts per spleen. 
(F) Absolute number of erythroblasts per spleen. Absolute numbers were calculated by multiplying 
the cell frequencies by the total numbers of cells per spleen. All mice were infected for 28 days. 
Data represent mean + SEM (unpaired t-test with Welch’s correction; n=8 mice per group from 
two independent experiments). 
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Figure 3-15. Histological changes in the spleen associated with chronic EVL. (A) Evolution of 
spleen weight in infected mice other time (n=3 mice per time point from one experiment). Data 
represent mean ± SEM. (B) Fluorescent scans of 5µm-thick spleen sections stained with anti-F4/80 
antibody in infected mice at different time points. The naïve control is age-matched with the day-
28 mice (data representative of 3 mice per time point from one experiment). Scale bar = 1mm. 
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Figure 3-16. Chronic EVL induces induces remodelling of the splenic red pulp. (A) Manual 
identification of white pulp and red pulp area based on F4/80 staining (green). The red pulp is 
defined as F4/80+ and the white pulp is F4/80-. Scale bar = 1mm. (B) White pulp area per spleen 
section. (C) Red pulp area per spleen section. (D) Ratio of red pulp/white pulp. Areas were 
measured from a single section per spleen. Data represent mean + SEM (unpaired t-test; n=3 mice 
per group from one experiment).  
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Figure 3-17. EVL-induced extramedullary erythropoiesis is characterised by increase of 
erythroid progenitors in the splenic red pulp. (A) Spleen sections stained with CD71 (red) and 
TER119 (white). (B) Detail of spleen section highlighting the interface between the splenic red 
pulp, F4/80+ (green) and the white pulp F4/80-, together with CD71 and TER119 (scale bar = 
100µm). Representative from 3 mice per group from one experiment.  
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Figure 3-18. Splenic erythropoiesis is not associated with increased BMP4 staining after 28 
day-infection with L. donovani. (A) Confocal imaging of spleen sections staining with anti-F4/80 
(red) and BMP4 (green) antibodies. (B) Automated quantification of BMP4 staining area by the 
Volocity software package (Perkin Elmer). Data from one section per mouse (n=3 mice per group 
from one experiment). 
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Figure 3-19. EVL-induced anaemia is independent of the spleen. Mice were splenectomised 
and allowed to recover before infection with L. donovani. Blood analysis was performed 4 weeks 
after infection. (A) Haematocrit. (B) Mean corpuscular haemoglobin concentration. (C) Mean 
corpuscular volume. Data represent mean + SEM. Absence of statistics means there is no 
significant difference between the four groups (Kruskal-Wallis test with Dunn’s multiple 
comparison test; n=15 mice per group from 3 independent experiments). 
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Figure 3-20. Repression of medullar erythropoiesis is independent of the spleen during L. 
donovani infection. Mice were splenectomised and allowed to recover before infection with L. 
donovani. Experiments were performed 4 weeks after infection. (A) Femurs representative of 15 
mice per group from 3 independent experiments. (B) Quantification of pro-erythroblasts in the 
bone marrow. (C) Quantification of erythroblasts in the bone marrow. The gating strategy in Fig. 3-
2 was used. Absolute numbers were calculated by multiplying frequencies by the total bone 
marrow cell counts. (One-way ANOVA with Turkey’s multiple comparison test; n=10 mice per 
group from 2 independent experiments). Data represent mean + SEM 
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 The onset of medullar erythropoiesis reduction correlates with local 
accumulation of T cells in the bone marrow 
To better understand the pathogenesis EVL, a time-course study was performed. The 
frequencies of T cells, based on the expression of CD3, were measured in parallel with 
erythropoiesis. CD3 is the co-receptor of the T cell receptor and is highly specific to T 
cells246. Erythroid precursors (pro-erythroblasts and erythroblasts) decreased steadily over 
time in infected mice (Figure 3-21A). However, these frequencies have been shown to 
fluctuate, as shown by the control group. Therefore, erythropoiesis in the bone marrow was 
only significantly repressed by day 28. The onset of medullar erythropoiesis repression 
was between day 21 and day 28. No increase in the frequency of CD3+ cells was detected 
in the spleens of infected mice over time (Figure 3-21B). This frequency fluctuated around 
35% of live splenocytes and was never significantly different between the infected and the 
naïve group. On the other hand, the frequency of T cells in the bone marrow increased by 
3-fold between day 21 and day 28 post-infection (Figure 3-21B). The frequency is similar 
to naïve mice during the acute phase of infection, up to day 21, then rises at day 28. The 
frequency of bone marrow T cells was then 3.7 times higher in the infected mice than in 
the control group. The frequency of T cells was also measured in the peripheral blood and 
no difference between infected and control mice was detected during the course of 
infection (Figure 3-21B). Contrary to T cells, data from Ana Pinto show that a decrease in 
B cell frequency, identified on the basis of B220 expression, occurs in the bone marrow of 
chronically infected mice (Figure 3-21C). 
 Visualisation of T cells in the bone marrow 
Single cell analysis revealed an augmentation of CD3+ T cell frequency in the bone 
marrow of infected mice which correlated with the reduction of bone marrow 
erythropoiesis. In order to gain better insights into the role of lymphocytes, hCD2.DsRed 
reporter mice were infected with L. donovani. In these mice, expression of DsRed is 
restricted to T cells222,247, allowing the visualisation of these cells ex vivo. They were killed 
28 days later and the bone marrow was processed to visualise T cells within the medullar 
compartment. Confocal images show sparse DsRed+ cells in the bone marrow of naïve 
mice (Figure 3-22A). This concurs with studies showing the bone marrow harbours T cells 
in a physiological state248–250. DsRed+ cells appeared more numerous in the bone marrow 
of infection mice, with a less diffuse distribution (Figure 3-22B). Image analysis 
confirmed an increase of T cells in the sections scanned (Figure 3-22E). The morphology 
of lymphocytes was also different between the two groups (Figure 3-22C and D). T cells 
from naïve mice were rounder in shape whereas T cells in infected bone marrow had more 
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convoluted shapes. This was confirmed by image analysis and measure of the cell shape 
factor. This value indicates how close to a circle individual cells are, 1 being the maximum 
value (perfect circle). CD2+ bone marrow cells from infected mice had an average shape 
factor of 0.390±0.085 whereas the average shape factor of CD2+ cells from naïve mice was 
0.543±0.121 (Figure 3-22F). The difference was however non-significant. Therefore, bone 
marrow T cells, had irregular shapes, possibly related to the process of cell spreading seen 
during T cell activation251. To investigate if the uneven distribution of T cells was a 
consequence of the migration towards intracellular amastigotes, hCD2-GFP mice were 
infected with tdTomato-LV9 parasites. The bone marrow was then fixed and analysed by 
confocal microscopy. The images suggest some  T cells are close to parasites (Figure 3-
23A and B). 
 Both CD4+ and CD8+ T cells accumulate in the bone marrow of infected mice 
The role of T cells in the pathogenesis of EVL was further investigated by measuring the 
distribution of the two main subsets of T cells, the CD4 and CD8 subsets (Figure 3-24A 
and B). In a physiological state in naïve mice, the frequencies of CD4 and CD8-T cells 
were measured at 0.625±0.85% and 1.143±0.113% of total bone marrow cells, respectively 
(Figure 3-24B). Augmentations of both frequencies were detected on day 28 p.i. in 
infected mice. Of both subtypes, CD4 T cells were the most dramatically increased at 
8.275±0.578%, representing a 13-fold increase. A more moderate 2.6-fold increase was 
measured for the frequency of CD8 T cells at 3.036±0.244% (Figure 3-24B). These results 
show a correlation between the loss of erythropoiesis in the bone marrow and the 
accumulation of T cells in the bone marrow, so the role of adaptive immunity in the 
alteration of erythropoiesis was investigated. 
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Figure 3-21. The onset of medullar erythropoiesis repression corresponds to local 
accumulation of T cells in the bone marrow. (A) Frequency of erythroid precursors (pro-
erythroblasts and erythroblasts) in the bone marrow over time. Precursors were identified on the 
basis of TER119 and CD71 staining. (B) Frequency of CD3+ cells in the bone marrow, spleen and 
blood over time. (unpaired t-test; n=3 mice per group per time point, except naïve spleen analysis 
at day 21 where n=1) (C) Frequency of CD45+B220+ cells in the bone marrow, data from Ana 
Pinto (unpaired t-test with Welch’s correction, n=14 mice per group from 3 independent 
experiments). Data represent mean ± SEM. 
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Figure 3-22. Visualisation of T cells in the bone marrow during EVL. (A) Confocal imaging of 
a bone marrow section from a naïve hCD2-DsRed mouse. (B) Magnification of a detail from A. 
(C) Confocal imaging of a bone marrow section from a 28 day-infected hCD2-DsRed mouse. (D) 
Magnification of a detail from C. (E) Shape factor of DsRed+ cells, determined with the Volocity 
analysis software (Perkin Elmer). 1 corresponds to a cell with a perfect circle shape in a 2D plan. 
(n=3 naive mice and 4 infected mice; cells were analysed from 1 section per mouse from a single 
experiment). Data represent mean ± SEM. 
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Figure 3-23. Imaging of T cells in relation to L. donovani parasites in the bone marrow of 
infected mice. (A and B) Confocal images from a single mouse with T-cell restricted expression of 
GFP (hCD2-GFP, green) and infected for 28d with tdTomato-expressing L. donovani amastigotes 
(red) and stained with DAPI (blue). Images are representative of 2 mice from a single experiment. 
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Figure 3-24. CD4+ and CD8+ frequencies increase in the bone marrow of mice chronically 
infected with L. donovani. (A) Flow cytometry analysis of CD3+CD4+ and CD3+CD8+ cells in the 
bone marrow. Left plots are gated on identical numbers of live single cells. (B) Frequencies of T 
cell subsets in the bone marrow according to the gating strategy described in A. All experiments 
were performed 4 weeks after infection. Data represent mean + SEM (n=4 naïve and 8 infected 
from 2 independent experiments). 
  
 107 
 Absence of overt pathogenesis in chronically infected immunocompromised B6 
RAG2-/- mice 
Because the data reported in the previous paragraphs show a correlation between the onset 
of medullar erythropoiesis repression and accumulation of T cells in the bone marrow, the 
hypothesis that T cells participate in pathogenesis was tested. B6 RAG2-/- mice are 
characterised by a loss-of-function mutation in the Recombination-activating gene 2 which 
is necessary for the V(D)J recombination required to build the antibody repertory. Without 
recombination, the development of lymphocytes is halted and no mature T or B 
lymphocytes are produced252. Therefore, the B6 RAG2-/- strain is devoid of adaptive 
immune response and is a good model to study the effect of L. donovani infection in an 
immune-deficient context. B6 RAG2-/- mice were infected in parallel to WT mice to 
compare the course of infection between the two. Both strains developed a chronic 
infection as determined by the parasite load in the spleen. While the parasite count was 
really high in the spleen of infected B6 RAG2-/- (Figure 3-25A), the LDUs were lower 
when compared to the WT group (Figure 3-25B). However, caution has to be taken in 
comparing LDUs between the two strains since the spleen weight (which is taken into 
account in the calculations of LDUs) differs in the steady state due to different cellular 
composition. Indeed, spleens from B6 RAG2-/- do not contain lymphocytes. No 
splenomegaly was observed in infected B6 RAG2-/- since spleen weight were identical 
between naïve and infected mice (Figure 3-26A). The haematological profile of B6 RAG2-
/- mice showed no alterations in haematocrit (Figure 3-25C). This indicates that visceral 
leishmaniasis in immune-compromised mice does not lead to anaemia. To confirm that no 
pathogenesis was detectable in EVL in B6 RAG2-/- mice, the bone marrow was analysed 
for the erythropoiesis. 
 Erythropoiesis is not altered in B6 RAG2-/- mice 
Erythropoiesis was quantified in the bone marrow of B6 RAG2-/- mice by flow cytometry. 
Infection with L. donovani does not result in a reduction of pro-erythroblasts after 28 days 
in either wild-type or RAG2-/- mice (Figure 3-25D). By contrast to wild-type where L. 
donovani reduces erythroblast in the bone marrow, there was no significant reduction in 
the absolute number of erythroblast either (Figure 3-25E). These results further confirm 
the link between reduction of haematocrit and deficit of RBC production in the bone 
marrow. The data discussed in paragraph 3.2.9 show that extramedullary erythropoiesis 
occurs in the spleen during the chronic phase of infection. Contrary to their wild-type 
counterparts, the RAG2-/- mice had no splenomegaly (Figure 3-26A) and no increase in 
absolute numbers of erythroid precursors in the spleen (Figure 3-26B and C). This further 
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confirms that splenomegaly is induced by the alteration of erythropoiesis in the bone 
marrow. To know whether infection with L. donovani also changes the bone marrow 
microenvironment, the expression levels of Cxcl12 were measured and the stromal 
macrophages analysed in RAG2-/- mice. No reduction of Cxcl12 was detected after 4 
weeks of infection, by opposition to the 50% decrease in wild-type mice (Figure 3-27A). 
Interestingly, this correlated with no up-regulation in circulating G-CSF (Figure 3-27B), 
thus re-affirming the potential role of G-CSF in the alterations seen in wild-type mice, 
Direct evidence is still needed to show that G-CSF is actually causing alterations of the 
bone marrow. In addition, the bone marrow macrophages were unaffected by the infection 
in regards with the expression of CD169 (Figure 3-27C). The numbers of the CD169low 
and CD169high subsets of macrophages were similar between the infected and the control 
groups (Figure 3-27D). 
 Lymphocytes are required for the alteration of the medullar erythropoiesis in 
infected B6 RAG2-/- mice 
The results presented so far suggest a link between the adoptive immune response to L. 
donovani amastigotes and the deficit of RBC production in the bone marrow since 
immune-compromised mice do not have the same defects as the wild-type in regards to 
erythropoiesis. To confirm this, RAG2-/- mice were infected for 4 weeks before 
transferring 107 splenocytes from a naïve mouse. The mice were then killed 1 week later. 
The aim was to determine whether an immune reconstitution would induce the alterations 
described previously in regards to erythropoiesis. A group of naïve RAG2-/- was also 
injected with splenocytes in order to exclude side effects of the immune reconstitution that 
would be independent of the infection. The first observation that was made was that the 
transfer of splenocytes lead to a splenomegaly exclusively in infected mice (Figure 3-
28A). The spleen weight for the infected group with splenocytes reached an average of 
147±7mg whereas in naïve mice with splenocytes and infected mice without splenocytes 
the spleens weighed averages of 41±2mg and 43±8mg, respectively. Erythropoiesis was 
quantified in the bone marrow by flow cytometry (Figure 3-28C). Infection only or 
splenocytes only did not cause a significant drop in pro-erythroblasts or erythroblasts 
numbers in the bone marrow. However, infection together with adoptive transfer of 
splenocytes depleted both pro-erythroblasts and erythroblasts from the bone marrow 
(Figure 3-28D and E). Interestingly, the reduction of medullar erythropoiesis correlated 
with an up-regulation of G-CSF in the plasma, which is another indication that G-CSF may 
be involved in alterations of erythropoiesis in the context of EVL.  
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Figure 3-25. Infection of RAG2-/- mice with L. donovani does not alter medullar 
erythropoiesis. (A) Parasites per 1000 nuclei in the spleen. Spleens impressions were made on 
glass slides and stained with Giemsa. Parasites and nuclei were counted microscopically. (B) 
Leishman-Donovan units calculated from parasite counts in A multiplied by the spleen weight in 
grams (unpaired t-test with Welch’s correction (A) and Mann Whitney test (B); n=8 wild-type and 
B6 RAG2-/- mice from 2 independent experiments). (C) Haematocrit of mice at day 28 post-
infection (Kruskal-Wallis test with Dunn’s multiple comparison test; n=5 wild-type mice per 
group, 3 B6 RAG2-/- naïve and 4 B6 RAG2-/- infected). (D) Pro-erythroblasts per 1 leg (femur + 
tibia). (E) Erythroblasts per leg. Erythroid precursors were identified by flow cytometry as 
described in Fig. 3-2. (Kruskal-Wallis test with Dunn’s multiple comparison test; n=8 wild-type 
mice per group, 5 B6 RAG2-/- naïve and 7 B6 RAG2-/- infected). Data represent mean + SEM. All 
experiments were performed 4 weeks after infection. 
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Figure 3-26. Absence of splenomegaly in RAG2-/- mice infected with L. donovani. (A) Spleen 
weight of wild-type and RAG2-/- mice. (B) Absolute numbers of pro-erythroblasts in the spleen. 
(C) Absolute numbers of erythroblasts in the spleen. Erythroid precursors were identified by flow 
cytometry as described in Fig. 3-12. (one-way ANOVA (A) followed by Turkey’s multiple 
comparison test or Kruskal-Wallis test followed by Dunn’s multiple comparison test (B and C); 
n=8 wild-type mice per group, 5 RAG2-/- naïve and 7 RAG2-/- infected). All experiments were 
performed 4 weeks after infection. 
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Figure 3-27. Absence of G-CSF up-regulation and alteration of the bone marrow 
microenvironment in infected RAG2-/- mice. (A) Cxcl12 expression in total bone marrow cells. 
Intra-sample standardisation was done by normalisation to the house-keeping gene HPRT and 
inter-sample standardisation was done by normalisation to the average expression of the naïve 
group. (n=8 wild-type mice per group, 5 RAG2-/- naïve and 7 RAG2-/- infected from one 
experiment) (B) Concentration of G-CSF in the plasma. (n=5 wild-type mice per group, 3 RAG2-/- 
naïve and 4 RAG2-/- infected from one experiment) (C) CD169 expression on bone marrow 
macrophages of naïve (green) and infected (red) RAG2-/- mice. Isotype control (blue) is 
representative of both naïve and infected mice. (D) Absolute numbers of macrophages per leg (1 
femur + 1 tibia) according to the gating described in C. Absolute numbers were calculated from the 
frequencies multiplied by the total bone marrow cells isolated from each mouse (n=3 naïve and 4 
infected mice from one experiment). All experiments were performed 28 days after infection. 
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Figure 3-28. Adoptive transfer of wild-type splenocytes into chronically infected RAG2-/- 
mice induces repression of medullar erythropoiesis. Mice were infected for 4 weeks before 
being injected with splenocytes from a single wild-type naïve donor. The mice were killed 1 week 
after adoptive transfer. (A) Spleen weight of mice at the experiment’s endpoint. (B) G-CSF plasma 
level determined by ELISA assay. (C) Identification of pro-erythroblasts and erythroblasts by flow 
cytometry. Pro-erythroblasts are CD45- CD71+ TER119low and erythroblasts are CD45- CD71-/+ 
TER119high. (D and E) Quantification of pro-erythroblasts and erythroblasts. Absolute numbers 
were calculated by multiplying frequencies of erythroid precursors (% of live cells) by the total 
bone marrow cell counts. (one-way ANOVA followed by Turkey’s multiple comparison test; n=3 
per group from a single experiment) Data represent mean + SEM. 
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 Discussion 
In the human disease, patients rarely show signs of acute infection and clinical symptoms 
will appear months to year after the initial infection. Therefore, patients diagnosed with VL 
are most often diagnosed when already in the chronic phase of infection, which is why we 
chose to study the chronic phase of EVL. Analysis of the blood from chronically infected 
C57BL/6 mice shows that murine EVL does indeed result in haematological changes. In 
terms of absolute numbers, two lineages were affected, namely RBCs and the platelets. 
Alterations in platelet count are discussed in Chapter 4. Haematocrit as well as 
haemoglobin levels were reduced by 28 days post-infection. Haematocrit reduction can 
arise from fewer circulating RBC or an increase in plasma volume. The latter is called 
dilutional anaemia and has not been investigated here but can not be excluded, especially 
in the context of VL. Indeed, splenomegaly is commonly associated with higher plasma 
volume due to a physiological mechanism involving hypertension of the liver portal vein 
subsequent to the increased splenic blood flow253. Reduction of circulating RBC can also 
participate in reduction of haematocrit. This can be linked to an impairment of 
erythropoiesis in the bone marrow or a peripheral lysis of erythrocytes. Reduction of 
erythropoiesis is discussed further in this chapter. Peripheral haemolysis is a potential 
mechanism for anaemia. In human VL, auto-antibodies against erythrocytes can be found 
in patients and their detection is often associated with anaemia82,254,255. 
The biosynthesis of haemoglobin is a complex process and requires iron. Heme is a 
cofactor essential for many metabolic pathways made of organic ferrous iron Fe2+, by 
opposition to inorganic ferric iron Fe3+, and an organic compound called porphyrin. Iron 
and heme are essential for the growth of Leishmania spp. at the amastigotes and 
promastigotes stages94. However most trypanosomatids have lost the ability to synthesise 
their own heme256. As a result, in vitro growth of parasites requires heme-containing 
media. An exception was found in a trypanosomatid, Strigomonas oncopelti, which does 
not require heme257. Further studies have demonstrated that trypanosomatids that do not 
require exogenous heme rely on betaproteobacterial endosymbiont for the synthesis of 
heme256,258. Others, including Leishmania spp., rely on heme from their hosts. L. donovani 
promastigotes are capable of haemolysis259, a process shared with other species of 
trypanosomes such as T. cruzi207 and T. brucei260. However, free Leishmania promastigotes 
do not enter the circulatory systems of mammalian hosts, contrary to Trypanosoma brucei 
spp. or Trypanosoma cruzi. Anaemia in trypanosomiasis is explained by a complex and 
multifactorial haemolysis, notably by haemolysins from the parasites and by 
erythrophagocytosis by the innate immune system in cattle206 or mouse model261. 
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Haemolysis by Leishmania spp. is more likely to be beneficial for parasite replication 
within the gut of sand flies where promastigotes are in contact with blood from blood 
meals. This mechanism would release heme, from lysed erythrocytes. While haemolysis is 
a potential way for promastigotes to find iron in the sand fly, it is more challenging to find 
iron in parasitophorous vacuoles of macrophages. A membrane iron-transporter, LIT1262, a 
ferric iron reductase, LFR1263, and a plasma membrane heme-transporter, LHR1264, have 
been identified in L. amazonensis.  All three proteins are essential for intracellular growth 
of parasites. In addition, L. amazonensis amastigotes induce iron retention in infected 
macrophages to promote their growth265. Leishmania-induced iron retention involves up-
regulation of hepcidin in macrophages which promotes degradation of ferroportin, a 
transmembrane iron-export protein. Subversion of the host’s iron metabolism has been 
suggested as a cause for anaemia in VL patients95. While Leishmania-specific mechanism 
for iron retention exist, chronic inflammation is also known to trigger iron deficiency 
anaemia. The pro-inflammatory cytokine IL-6 is elevated in VL patients as well as in 
dogs266–268. IL-6 is known to up-regulate hepcidin production in the liver, causing iron 
retention inside macrophages and reduced absorption of nutritional iron213. Therefore, 
chronic VL can potentially cause iron-deficiency anaemia. However, iron deficiency 
anaemia is characterised by a microcytic hypochromic anaemia88,187, i.e. smaller RBC with 
less haemoglobin. Iron metabolism was not investigated in this study. Mild hypochromia 
has been reported in VL patients but associated to a macrocytosis73. Here in the murine VL 
model reduction of haemoglobin was observed in parallel to reduction of RBC so the 
average haemoglobin content per RBC was similar between naïve and infected mice. The 
higher MCV values show that erythrocytes tend to be bigger in infected mice, so the 
anaemia can be qualified of macrocytic normochromic anaemia. Reports of the MCV in 
patients are rare. Cartwright et al. gathered studies on VL anaemia in humans that point 
towards an anisocytosis62, i.e. RBC of unequal size, with a tendency of size distribution 
curves (Price-Jones curve) to be skewed towards the right. Two studies report 
macrocytosis66,73 in children who have developed VL from L. donovani and L. infantum 
infections, respectively. A variety of conditions can cause macrocytic anaemia such as 
vitamin B12 deficiency or primary bone marrow disorders87. Vitamin B12 was not 
measured here but a study of two children with VL presenting myelodysplastic features 
shows none of them had a B12 deficiency4. Because young RBC, the reticulocytes, are 
bigger than mature erythrocytes, an increase in reticulocyte frequency in the blood 
(reticulocytosis), is also known to cause macrocytosis. No record of reticulocytosis, sign of 
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a rapid turnover of RBC, in VL could be found. It was therefore decided to focus on 
erythropoiesis in the bone marrow. 
The infected mice had paler femurs than their naïve counterparts 4 weeks after infection. 
Deletion of CD169+ bone marrow macrophages169 or administration of G-CSF232 have 
been shown to cause pale femurs as well and have been linked to a reduction of 
erythropoiesis in the bone marrow. A similar phenomenon also happens following a local 
irradiation of femur which damages the bone marrow microenvironment231. Here, we have 
shown that infection with L. donovani impaired erythropoiesis in the bone marrow, based 
on the flow cytometry-quantification of pro-erythroblasts and erythroblasts. Previous work 
by Cotterell et al. suggests that L. donovani increases haematopoietic activity in BALB/c 
mice86. This study showed, using a colony-formation assay, that haematopoiesis is 
increased in the bone marrow of infected mice, including erythroid precursors. Similar 
results were shown in hamster infected with L. donovani68. The erythroid colony-forming 
units measured in this study are the BFU-E, representing progenitors upstream of the pro-
erythroblast stage. Since the data reported here indicate an impairment of erythropoiesis at 
the erythroblast stage, these data are not inconsistent with that reported in mice or 
hamsters. In the hamster model of VL, it has been suggested that apoptosis bone marrow 
erythroblasts is increased. However, the analysis of erythroblasts is based on the 
expression of E-cadherin, a marker of erythroid precursors in human that has not yet been 
described in hamster269,270. Many conditions reduce erythropoiesis in the bone marrow, 
such as myelodysplastic syndromes. Additional data from Ana Pinto, show that the number 
of MEP is unchanged at a similar stage of the disease. These progenitors represent the last 
stage of differentiation before an exclusive commitment to the erythroid lineage. This last 
observation indicates that the repression in medullary erythropoiesis only affects the last 
stages of erythropoiesis after the BFU-E stage. 
Because bone marrow resident stromal macrophages are part of the erythroid niche167, 
changes in bone marrow macrophage populations were investigated. Microscopic 
observation of the bone marrow with a non-specific staining reveals cellular alterations 
characterised by an accumulation of cells resembling macrophages. It is possible that these 
macrophages participate in a local inflammation similar to the granulomas formed in the 
liver following infection with visceralising Leishmania species271. However the spatial 
correlation between theses features and amastigotes has not been investigated and they do 
not match the histological description of granulomatous lesions in the bone marrow272. In 
immunocompromised mice, macrophages expressing CD68 and CD169 were shown to be 
infected. Unfortunately, this was not possible to repeat in wild-type C57BL/6 mice because 
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of the low bone marrow parasitemia associated with the tdTomato-LV9 strain. One 
possible explanation for this is that the expression of a tdTomato protein at the surface of 
the parasite is highly immunogenic, resulting in the destruction of many parasites. Flow 
cytometry analysis revealed that the bone marrow of mice infected with L. donovani 
harboured fewer CD169high macrophages. These macrophages are known to be 
indispensable for the retention of HSCs147 and erythroblasts169 in the bone marrow. In 
regards to erythropoiesis, depletion of CD169+ cells has been shown to reduce the number 
of CFU-E, pro-erythroblasts and erythroblasts but not BFU-E169. Stromal macrophages 
regulate the retention of HSCs indirectly through the production of CXCL12 by bone 
marrow stromal cells147. Stromal macrophages interaction with other stromal cells requires 
signalling through the liver X receptor (LXR) and follows a circadian rhythm in the steady 
state148. This rhythm is imposed by the clearance of senescent neutrophils which migrate 
back to the bone marrow. Experimental disruptions of this process, such as depletion of 
CD169-expressing cells, pharmacological inhibition of LXR or depletion of neutrophil, 
have been reported to alter the HSC niche in the bone marrow147,148. Inter-experiment 
variability due to the circadian rhythm was avoided by sampling in between 7am and 9am, 
assuming the infection with L. donovani did not alter the rhythm. 
The cytokine G-CSF is known to be a potent regulator of the bone marrow stromal 
compartment. It is important to note that cytokine concentration values may differ in 
plasma and in serum273. The primary function of G-CSF is to induce granulopoiesis and the 
maturation of neutrophils. Here, despite the increase in levels of circulating G-CSF, 
infected mice did not display neutrophilia at this timepoint (i.e. high number of neutrophils 
in the blood, Table 3-1). G-CSF was investigated here because it has been recently shown 
that administration of G-CSF in mice causes depletion of erythroblastic island 
macrophages expressing CD169 in the bone marrow of mice232. G-CSF is also capable of 
mobilising HSCs from the bone marrow by interfering with the CXCL12-CXCR4 axis. 
The first mechanism to be reported is through the cleavage of secreted CXCL12 in parallel 
with the up-regulation of CXCR4. G-CSF induces neutrophil elastase and other proteases 
in the bone marrow that are in turn responsible for the proteolytic cleavage of CXCL12241. 
The mechanisms of action of G-CSF were subsequently investigated by others who 
demonstrated that down-regulation of CXCL12 still occurred in absence of proteolytic 
activity274. Indeed, G-CSF inhibits the expression of CXCL12 at the mRNA level in the 
bone marrow, indicating that different pathways, protease-dependent and protease-
independent, contribute to the regulation of the HSC niche. Several studies have 
demonstrated that G-CSF was up-regulated in different situations, including 
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infection275,276. Disruption of cholesterol efflux pathways in transgenic mice mobilises 
HSCs correlating with up-regulation of G-CSF and down-regulation of CXCL12277. 
Interestingly, bone marrow stromal cells are able to sense the infection of mice with 
Escherichia Coli (E. coli) through cooperative signalling of the NOD and TLR receptors, 
causing an up-regulation of G-CSF and mobilising HSCs275. Punctual mobilisation of 
HSCs from the bone marrow is thought to be a defence mechanism enabling an increase in 
myelopoiesis in distant site such as the spleen to respond to the infection. In a murine 
breast tumour model, development of anaemia in tumour-bearing mice was correlated with 
up-regulation of G-CSF276. While punctual disruption of the niche has no overt adverse 
effect in the E. coli infection model, EVL is a chronic infection and chronic disruption of 
the HSC niche has potentially more negative effects such as the depletion of the pool of 
HSCs. In addition to higher levels of circulating G-CSF, a 50% reduction of CXCL12 
expression in the bone marrow at day 28p.i. as well as a decrease in the number of 
CXCL12-expressing cells is a notable change associated with EVL. The hypothesis in this 
study was therefore that G-CSF contributes to bone marrow alterations in the context of 
EVL, making it a candidate as a potential target for treatment. Few conditions have been 
linked to elevated G-CSF so reports of G-CSF neutralisation are rare. G-CSF has been 
linked to the severity of inflammatory arthritis in a mouse model278. However, the large 
quantities of antibodies used in this study to neutralise G-CSF, show how difficult 
pharmacological inhibition of G-CSF is. The attempt at neutralising G-CSF in mice 
infected with L. donovani did not alter the pathogenesis. It is unclear whether it is the 
result of a failure to effectively reduce the cytokine or of a feedback loop which would 
explain the higher levels of G-CSF measured in antibody-treated mice compared to the 
isotype-treated group. 
The spleen is an essential organ in regards to the homeostasis of RBC. It filtrates the blood 
and captures aging or damaged RBC279. Red pulp macrophages capture phagocytose RBC 
or part of them280. Splenomegaly is associated with an increased blood flow through the 
spleen253. While this causes physiological changes leading to dilutional anaemia, it is also 
possible then that splenomegaly causes anaemia by depleting the blood of more RBC. In 
mice infected with L. donovani the splenic red pulp is larger and the red pulp/white pulp 
ratio is above 6, while control values approximated 2. Thus, the structure responsible for 
the filtration of RBC is larger. In order to test if splenomegaly is the main cause of 
anaemia in EVL, mice were splenectomised prior to infection. The infection resulted in 
anaemia in both splenectomised and sham-operated mice, indicating that EVL-induced 
anaemia is independent of the spleen. The RBC were slightly different in regards to the 
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presence of the spleen. More mice had MCV above the reference interval in the sham-
operated group than in the splenectomised. This suggests that splenomegaly, although not 
responsible for anaemia, potentially has an effect (most likely physiological) on RBC. 
Here the data suggests that splenomegaly is a response to the loss of erythropoiesis in the 
bone marrow. Progressive splenomegaly correlates with the increase of splenic erythroid 
precursors in the red pulp. The onset of extramedullary erythropoiesis also correlated with 
the reduction of medullar erythropoiesis time-wise. Both events happened between day 21 
and day 28 post infection. Extramedullary erythropoiesis has been reported recently in a 
mouse model of Salmonella enterica infection281. This study confirms that splenic 
erythropoiesis is associated with an increase of F4/80+ cells in the spleen and the 
proliferation of erythroid precursors in the red pulp. However, the authors have not 
addressed the question of what happens to erythropoiesis in the bone marrow in this model, 
it is therefore unclear if splenic erythropoiesis develops independently of the bone marrow. 
The classical molecular mechanism inducing extramedullary erythropoiesis involves the 
production of BMP4 in the spleen244,245,276,282. Spleens did not show an increase of BMP4 4 
weeks after induction of EVL. One possible explanation is that the mice were actually 
recovering at this point. Long-term experiments (post-day28) have sometimes resulted in 
mice clearing the infection and in spleens recovering a normal weight. It is possible in this 
experiment that BMP4 signalling had stopped by day 28. A better time point to consider 
would have been between day 21 and day 28, as it is in this time frame that extramedullary 
erythropoiesis starts according to our data. The other possible explanation is that 
extramedullary erythropoiesis is independent of BMP4. BMP4-independent splenic 
erythropoiesis can be achieve by overexpressing MyrAkt1  in endothelial cells of mice283. 
This erythropoiesis is also independent of anaemia and EPO. One argument in favour of a 
BMP4-induced is a recent study about the remodelling of the spleen in the context of EVL. 
In this study, a population of splenic F4/80highCD11blow macrophages are linked to neo-
vascularisation of the spleen following infection with L. donovani284. The top differentially 
expressed gene when compared to other populations of macrophages is Bmp4 and the third 
is Cxcl12, both involved in extramedullary erythropoiesis244,285,286. 
Haematological data are generally considered clinically relevant when they are associated 
with life-threatening conditions, which is not the case in EVL. Despite a mild anaemia and 
a pronounced thrombocytopenia, no cachexia or excessive bleeding have been observed. 
However previous studies in mice have shown how resilient they can be to alteration of 
erythropoiesis. Systemic suppression of CD169-expressing cell or G-CSF administration 
induce a more than 70% reduction of erythroblasts number but no peripheral 
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anaemia169,232. Compensatory splenic erythropoiesis has been suggested as a rescue 
mechanism in the two studies, but splenectomy following suppression of bone marrow 
macrophages did not induce anaemia169. Splenectomised mice infected with L. donovani 
had the same degree of anaemia as the sham-operated ones. The splenectomy experiments 
done here and the studies mentioned before suggest that more mechanisms, in addition to 
splenic erythropoiesis, cancel the deficit of RBC production in the bone marrow. The liver 
is often overlooked in haematological studies, and it has not been studied here, but 
evidence suggest that Kupffer cells are capable of supporting extramedullary 
erythropoiesis in splenectomised mice with bone marrow failure287. In the CD169-positive 
cell depletion model, mice did not become spontaneously anaemic but recovery from 
chemically-induced anaemia was impaired169. Recovery from anaemia was not 
investigated in this study. 
The data were consistent between individual mice and between independent experiments. 
Clinical data shows that haematological disorders in human VL do not show such 
consistency and patients present with reduced numbers of only some or all of the 
lineages62,64. The basis for these variations is unknown but it is expected that controlled 
experimental conditions as in our study might yield similar haematological profiles. It has 
been demonstrated that genetics play an important part in the response to Leishmania 
infections in mice and only congenic mice were used in this study. Patients infected with 
visceral strains typically develop symptoms months to years after initial infection, thus 
clinical studies include patients who have been infected for different periods of time, 
contrary to the strict 28-day infection used here. In addition, the parasite strain and the 
quantity of parasites in the inoculum were constant. All these factors are very likely to 
explain that the majority of mice developed anaemia and thrombocytopenia only. 
Because experimental data on the haematological alterations induced by VL are rare, the 
mechanisms responsible for alterations of erythropoiesis are unclear. It has been shown 
that haematopoietic activity is increased in BALB/C mice infected with L. donovani but 
not Severe Combined Immune Deficient (scid) mice86. Scid mice like B6 RAG2-/- also lack 
mature B or T lymphocytes. Here the evidence suggest that RAG2-/- mice have no 
repression of medullar erythropoiesis and no splenomegaly despite the high parasite 
burden. Altogether, the data suggest that alteration of haematopoiesis is not a direct 
consequence of the infection but is linked to the adaptive immune response to the parasites. 
Confocal analysis of the bone marrow show that T cells tend to accumulate around 
parasites in the bone marrow. This is probably the bone marrow equivalent of granulomas 
found in the liver. It is likely that T cells infiltrate the bone marrow in order to fight the 
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infection. However, this response seems to have negative collateral effects (i.e. alteration 
of haematopoiesis). Contrary to the liver, the immune response is not protective in the 
bone marrow since intracellular parasites subsist chronically. The role of T cells in bone 
marrow disorders in infectious disease has been studied very little. Contrary to what is 
reported here in EVL, a role for T cells has been excluded in anaemia of trypanosomiasis 
since depletion of both CD4 and CD8 T cells did not change the levels of 
haemoglobin206,261,288. In this regard, anaemia of VL could be closer to aplastic anaemia 
(AA), which is characterised by hypocellular bone marrow and pancytopenia. It has been 
linked experimentally with infiltration of T cells289 in the bone marrow and increase in 
IFNd production290,291. 
In conclusion, this work demonstrates that infection with L. donovani induces alteration of 
RBC homeostasis in mice. The red blood cells numbers were reduced, but haemoglobin 
contents were stable. Infected mice also had a tendency of developing a macrocytic 
anaemia. These alterations reflect closely what has been reported in the human disease. 
Therefore, the mouse model can help provide useful insights into the human disease. The 
anaemia is associated with deep changes in the bone marrow microenvironment, namely 
the reduction of CXCL12-expressing cells and the loss of CD169high macrophages. The 
cytokine G-CSF was up-regulated upon infection and is thought to be in part responsible 
for the bone marrow changes, as it has been shown to affect macrophages of stromal cells 
in other studies. We have strong evidence that splenomegaly is due to extramedullary 
erythropoiesis and is a consequence of the deficit of RBC production in the bone marrow, 
not the cause of it. This initiation of these alterations is dependent on the adaptive immune 
response since erythropoiesis was not affected by infection in immune deficient mice. 
These data all show a novel mechanistic model in which the adaptive immune response to 
L. donovani triggers a cascade of events starting by reduction of stromal support in the 
bone marrow in correlation with reduction of erythropoiesis and anaemia which in turns 
induces extramedullary erythropoiesis and splenomegaly. As the following chapter 
demonstrates, the events originating in the bone marrow causing a splenic reaction have 
further physiological impacts, notably on platelets. 
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Chapter 4 Regulation of platelets during EVL 
 Introduction 
The majority of studies on the pathology of VL focus on the immune response to the 
infection, thus very little is known about the associated haematological alterations in 
general, and about the coagulopathies in particular. Yet excessive bleeding is a common 
feature of VL62 and has been linked to the lethality of disease. Indeed, a recent study 
retrospectively collected data from cases in Brazil from 2007 to 2011 and scored risk 
factors for death from VL77. Apart for the age, the risk factor with the highest score was 
bleeding with an odd ratio of 3.8. This confirmed previous studies linking death from VL 
with bleeding in Brazil75,76 and Sudan79. Coagulopathies can arise from a reduction of 
platelets, the “scaffolds” of blood clots, or anomalies affecting coagulation factors. Clinical 
data suggest haemorrhagic tendencies are primarily linked to a reduction in the number of 
circulating platelets62 that is usually restored to physiological levels after treatment73. 
Auto-immune platelet destruction has been reported in dogs96 but not in humans. It is 
therefore thought that the spleen is responsible for thrombocytopenia. Splenomegaly is 
associated with a multitude of conditions and is known to cause sequestration of 
circulating cells97. Epistaxis (nose bleeding) has been reported in VL clinical studies292 and 
studies of naturally infected dogs293–296. In the human disease, thrombocytopenia correlated 
with epistaxis292. However, no study of haemostasis in humans is available as of today. In 
dogs, epistaxis does not always correlate with thrombocytopenia but dogs infected with L. 
infantum had consistent alterations of haemostasis (longer coagulation time and reduced 
platelet aggregation). It is unclear how VL results in impairment of haemostasis in dogs, 
and if a similar phenomenon occurs in humans, which highlights the need for more studies. 
It is unlikely that treating patients in order to correct haemostasis in the context of VL will 
cure the disease. However, with the emergence of resistant strains of parasites, managing 
symptoms becomes a necessity when antibiotics fail. Because bleeding is associated with 
the lethality of VL in humans, treating haemostatic disorders would help to reduce the 
mortality associated with VL worldwide. 
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 Aims 
Coagulopathies have a negative impact on the prognosis of VL in humans. The statistics 
show haemorrhagic tendencies participates in the lethality of the disease. Correcting or 
preventing the coagulopathies in patients is likely to help reduce the mortality associated 
with VL. To this end, it is essential to understand the mechanisms underlying this 
symptom. Very little is known about the causes for haemorrhages in the context of VL. 
In this study the aims were to: 
1. Determine the nature of thrombocytopenia in infected C57BL/6 mice  
2. Find possible causes for thrombocytopenia. Because the bone marrow and the 
spleen are both involved in the regulation of circulating platelets, the roles of these 
organs were investigated. 
a. Determine if megakaryopoiesis is altered in infected mice. 
b. Determine the role of the spleen in thrombocytopenia by comparing 
platelets in splenectomised vs. sham-operated infected mice. 
3. Determine if L. donovani-induced thrombocytopenia responds to the growth factor 
thrombopoietin (TPO) 
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 Results 
 Chronic L. donovani infection induces thrombocytopenia 
Mice were infected for 28 days with L. donovani before blood was collected and analysed. 
This chapter focuses on platelets. Other haematological parameters, especially RBC, are 
discussed in Chapter 3. The platelet counts (Fig. 4-1A) in naïve mice was of 583±45x103 
platelets per mm3 of blood. Because of quite large standard deviation (170), the normal 
range was quite broad, from 241 to 924 (the normal range is calculated for a normal 
distribution as mean ± 2 standard deviations). The infected group had a much lower 
average platelet count, down to 281±26x103 platelets per mm3 of blood (-52%). 
Thrombocytopenia was defined by values below the reference interval. According to this 
definition, close to 40% of mice were thrombocytopenic. The platelets were also 
significantly bigger in chronically infected mice (Fig. 4-1B), with a mean platelet volume 
of 5.4±0.1 femtoliter (fl). By comparison, naïve mice had an average MPV of 4.3±0.1fl 
and resulting normal range of 3.6 to 5 fl. Thus 76% of mice were considered to have 
abnormally large platelets. Therefore, chronic EVL induces thrombocytopenia 
characterised by an increase in platelet volume. Although infection caused 
thrombocytopenia, no excessive bleeding or epistaxis was ever reported. The 
thrombocytopenia of EVL was not associated with a pathology. 
 Megakaryopoiesis is unaltered during experimental visceral leishmaniasis 
We reported in the previous chapter that anaemia was the result of a deficit of production 
of RBC cells in the bone marrow. Following the same logic, megakaryopoiesis was 
measured in the bone marrow of mice infected with L. donovani in order to determine if 
thrombocytopenia was the consequence of a reduced megakaryopoiesis. To this end, 
femurs were processed, sectioned and stained with haematoxylin and eosin. 
Megakaryocytes, the precursors of platelets, were counted manually, as they are easily 
recognisable. The average numbers of megakaryocytes per field of view were compared 
(Fig. 4-1C). No significant difference was detected between naïve and infected mice, 
despite the drop in platelet counts. Interestingly, no change in plasma TPO levels were 
detected either (Fig. 4-1D). 
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Figure 4-1. L. donovani infection induces thrombocytopenia. (A) Platelet counts (unpaired t-
test, n=14 naïve and 13 infected mice from 3 independent experiments). (B) Mean platelet volume 
(Mann-Whitney test, n=14 naïve and 13 infected mice from 3 independent experiments). (C) 
Average megakaryocytes (MK) counts per field of view from bone marrow sections stained with 
haematoxylin and eosin. MK were manually counted on the basis of their morphology on 5 random 
fields of view per section, 3 sections per animal were analysed. (unpaired t-test, n=4 mice per 
group from one experiment). (C) Circulating TPO levels measured by ELISA from the plasma 
(unpaired t-test, n=3 naïve and 4 infected mice from one experiment). All experiments were 
performed 4 weeks after infection with L. donovani. 
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 Platelet production is stimulated by TPO in infected mice 
Previous data indicate that the thrombocytopenia induced by L donovani infection is not 
the consequence of a reduction of platelet production. The hypothesis is then that 
thrombocytopenia is not aplastic, i.e. megakaryopoiesis is normal and can be stimulated by 
growth factors. To test this hypothesis, mice were treated with recombinant TPO (rhTPO) 
when they were already in the chronic phase of infection and the platelets were counted. In 
a pilot experiment, naïve mice only were infected with L. donovani. 4 weeks later, mice 
were injected with rhTPO ranging from 500ng to 1µg daily i.p. for 5 days. Experiments 
were performed after a resting phase of 5 days. The first five days of treatment aim to 
stimulate the growth of megakaryocytes. It has been shown that platelets continue to being 
release 3 to 5 days after withdrawal of TPO297.   The platelet counts in the treated with 
rhTPO mice were between 1.6 and 1.9 times higher than in the PBS-treated control (Fig. 4-
2A). No difference was measured between the doses. The maximum response was reached 
at the dose of 500ng already. Because rhTPO is not known to have any side effect in mice, 
a dose of 1µg per day for 5 days was chosen for the treatment of infected mice to maximise 
the chances of mice responding to the treatment. Chronic infection resulted in a low 
platelet count in PBS-treated mice (353±32x106 per µl of blood) but rhTPO-treated mice 
had a 2.6-fold increase in circulating platelets (Fig. 4-2B; 725±125x106/µl). However, the 
platelet volume was still expanded in both infected groups (Fig. 4-2C). 
 Thrombocytopenia is associated with splenomegaly 
An interesting observation was made from the treatment of infected mice with rhTPO. 
Although the average platelet counts raised to normal levels compared to PBS-treated 
mice, the efficacy of rhTPO was very uneven. The standard deviation of the platelet count 
was high, resulting in a coefficient of variation (standard deviation/average) of 65%. This 
variability could be partly due to natural variations in sensitivity to rhTPO or technical 
inconsistencies, but possible factors for the variations were also looked for. Individual 
spleen weights of mice treated with rhTPO were therefore plotted against the 
corresponding platelet counts (Fig. 4-2D). A linear model was fit from the data. The 
goodness-of-fit was determined from the R-squared value which was in in this case of 
0.65. This means that the fit explains 65% of the variability of the data. It was considered 
as a good fit for biological data. The resulting line had a negative slope. This indicates that 
the bigger the spleens are, the lower the platelet counts are following rhTPO treatment.  
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Figure 4-2. Treatment of infected mice with recombinant TPO increases circulating platelets. 
(A) Study of dose-response in naïve mice. Mice were injected i.p. daily for five consecutive days 
with rhTPO. Blood was collected 5 days after the last injection and analysed (n=2 mice per dose). 
(B) Platelet counts from infected mice treated with 1µg rhTPO daily rhTPO or PBS, following the 
regime described in A, starting 4 weeks after infection. (Mann-Whitney test, n=7 PBS-treated mice 
and 8 rhTPO-treated mice) (C) Mean volume of platelets from infected mice treated with rhTPO or 
PBS (unpaired t-test, n=7 PBS-treated mice and 8 rhTPO-treated mice). (D) Platelet counts from 
infected mice treated with rhTPO plotted against the spleen weight. The black line corresponds to 
the best-fit linear regression. (n=12, including 4 sham-operated mice) 
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 Splenectomy reduces thrombocytopenia 
The negative correlation between the spleen weight and the efficacy of rhTPO injections to 
correct thrombocytopenia suggests a role for the spleen in the reduction of circulating 
platelets. To investigate this, splenectomised mice were infected with L. donovani (after 
having recovered from the surgery) and the platelets were counted (Fig. 4-3A). In sham-
operated mice, the infection resulted in a 57% reduction of platelets in the blood compared 
to their naïve counterparts (297±16x106 platelets/µl in infected mice vs 685±32x106/µl in 
naive). Splenectomy did not affect the number of circulating platelets in the naïve mice 
compared to sham-operated naïve mice. However, upon chronic infection, the average 
platelet count was only reduced by 33% compared to the naïve splenectomised mice 
(509±42x106 platelets/µl in infected mice vs 756±38x106/µl in naive). When comparing 
the effect of infection between sham-operated and splenectomised mice, the platelet counts 
were in average 70% higher in splenectomised mice than in sham-operated. Altogether, 
these results confirm that the spleen factors into the EVL-induced thrombocytopenia. 
However, there was still a reduction of circulating platelets in splenectomised mice, 
indicating that other mechanisms participate to thrombocytopenia. Again, in infected mice, 
the decrease in platelets was associated with an increase in platelet volume (Fig. 4-3B). 
Sham-operated and splenectomised naïve mice had averages MPVs of 3.7fl and 3.9fl, 
respectively. Their infected counterparts had MPVs of 5fl and 5.4fl respectively 
Unexpectedly, hepatomegaly was present in infected splenectomised mice but was 
consistently lower than sham-operated mice (Fig. 4-4). Splenectomised mice were injected 
with rhTPO along with sham-operated mice. The mice were submitted to the same regime 
described previously. rhTPO was moderately efficient in sham-operated mice with an 
average of 483±91x103 platelets/µl, while the average was measured at 297x103/µl in 
untreated sham-operated mice in previous experiments. By opposition, the treatment 
boosted the platelet counts up to 1953±55x103 platelets/µl in splenectomised mice (Fig. 4-
5A). In addition, the MPV (Fig. 4-5B) returned to values close to what was measured in 
naïve mice (4.12±0.10fl) while it remained high in sham-operated mice with treatment 
(5.35±0.02fl). This result confirms that the spleen counters the efficacy of rhTPO in 
regards to increasing the number circulating platelets and returning the platelet volume to 
normal levels. 
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Figure 4-3. Infection results in higher platelet counts in splenectomised mice. (A) Platelet 
counts. (B) Mean platelet volume. All experiments were performed 4 weeks after infection (n=15 
mice per group from 3 independent experiments). 
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Figure 4-4 Splenectomy results in a reduced hepatomegaly in infected mice. All experiments 
were performed 4 weeks after infection with L. donovani (n=15 from 3 independent experiments). 
 
Figure 4-5. Better response of rhTPO in infected splenectomised mice. (A) Platelet counts. (B) 
Mean platelet volume. Already splenectomised mice or sham-operated mice were infected for 4 
weeks then treated with 1µg rhTPO i.p. daily for 5 days. The blood was analysed 5 days after last 
injection (unpaired t-tests, n=4 sham-operated and 5 splenectomised mice). 
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 Discussion 
In the experimental murine model of VL, chronic infection causes thrombocytopenia and 
an increase in platelet volume. The bone marrow of infected mice had similar numbers of 
megakaryocytes as the naïve mice, indicating that megakaryopoiesis was unaltered. 
However, it is possible that thrombopoiesis (the production of platelets from 
megakaryocytes) is altered at the megakaryocyte stage, i.e. mature megakaryocytes do not 
release platelets. It is still unclear how megakaryocytes release platelets. Two models co-
exist as of today, one involving proplatelets (pseudopodial formations that megakaryocytes 
project into the bone marrow vasculature and are released as platelets) and another in 
which megakaryocytes enter the the circulation and reach the lung vasculature where they 
are fragmented298. Without discussing which of the two models is the most accurate, this 
shows how complex the final stages of thrombopoiesis can be. For this reason, we can not 
definitely exclude that thrombocytopenia is not caused by a deficit of production. 
Interestingly, despite the low platelet counts, circulating levels of TPO were not altered. 
Here we also report that EVL-induced thrombocytopenia is associated with an increase in 
platelet volume. Studies of platelet regulation have shown that thrombocytopenia, 
independently of the cause, generally results in platelets being bigger. Generally speaking, 
the body preserves the total mass of platelets before restabilising the platelet number194. In 
human patients with splenomegaly, the platelet mass was similar to healthy individuals, 
despite the thrombocytopenia97. The same observation was made in experimental rat 
models299. It has been shown that thrombocytopenia causes ultrastructural changes in 
megakaryocytes resulting in an increased volume of platelets300,301. It is very likely that the 
increase of MPV in our model of VL is a compensation mechanism. A non-linear 
correlation between MPV and platelet counts has been reported302, therefore platelet mass 
cannot be calculated by the product of MPV by the total platelets. Therefore, with the 
present data we are unable to determine if the platelet mass is preserved during L. 
donovani infection in mice. 
Thrombocytopenia was not associated with increase in TPO plasma levels. Generally, 
levels of TPO correlate inversely with the number of platelets. Platelets express a high-
affinity receptor for TPO. Platelets regulate TPO by capturing circulating TPO303. As a 
consequence, a decrease of platelets is expected to result in an increase of TPO in the 
blood. However, in contexts of platelet destruction such as immune thrombocytopenic 
purpura, the levels of TPO do not correlate with platelet counts198,304. The two studies 
therefore corroborate our data which show that the cause of thrombocytopenia is a 
peripheral destruction, not a central deficit of 
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up-regulated in patients with aplastic anaemia198,304. The bone marrow produces little TPO 
in physiological conditions, but TPO mRNA has been shown to increase in bone marrow 
stromal cells of patients with thrombocytopenia, including in immune 
thromboctyopenia197. In the eventuality that TPO produced by bone marrow stromal cells 
only has a paracrine action, by opposition to endocrine signalling, then it would not be 
detected in the systemic circulation. Here we only report unchanged systemic levels of 
TPO, but the local regulation of TPO in VL has not been investigated. It cannot be 
excluded that up-regulation of TPO occurs at the tissue level. 
In our mouse model of EVL, thrombocytopenia was not considered aplastic as it responded 
to recombinant human TPO therapy. Eltrombopag is an NHS and FDA-approved drug 
used for the treatment of immune-thrombocytopenia. It is an agonist of Mpl, the main 
receptor of TPO, and has very little side effect. The reconditioning of Eltrombopag for 
treatment of thrombocytopenia in VL patients is an option that we would recommend 
investigating. However, as the data show here, stimulation of platelet production yields 
best results when the splenomegaly is not too severe and reaches a maximum efficacy in 
splenectomised mice. Assuming splenic capture is the main cause for thrombocytopenia in 
VL, it is likely that platelet production has to overcome the rate of splenic capture in order 
to raise platelet counts. In addition, our experimental design for the study of rhTPO in EVL 
did not include time points after treatment. It is possible that experiments were performed 
after the peak of platelet release. In this case, it cannot be excluded that rhTPO worked but 
that platelet counts had dropped faster in mice with the bigger spleens.  
Our data indicate that the decrease in platelets following infection with L. donovani is not 
as severe in splenectomised mice than normal mice. This confirms the involvement of 
splenomegaly in EVL-induced thrombocytopenia. In the steady state, about one-third of 
the platelet mass is sequestered in the spleen and is exchangeable with the circulating 
fraction. The splenic pool of platelets is increased in relation to the splenomegaly. The 
volume of total circulating platelets in human approximate 5 to 10ml, which is quite small 
compared to the total volume of RBC, approximately 25-30ml/kg of body weight305. It is 
estimated that the spleen can pool up to 20% of the RBC in the worst cases of 
splenomegaly. Because the total volume of platelets is so small, the spleen can potentially 
capture a bigger fraction than for the RBC. Liver dysfunction is also a common cause of 
thrombocytopenia218. Viral infection with HCV causes fibrosis of the tissue and liver 
damage in HCV patients is associated with the severity of thrombocytopenia219,220. 
Visceralising species of Leishmania spp. infect Kupffer cells of the liver and induce the 
formation of granulomas223,271. Liver damage has been reported in VL patients306,307. For 
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this reason, the liver may participate in the pathogenesis of thrombocytopenia during VL. 
This would explain why the platelets counts, although higher than in their sham-operated 
counterparts, were still reduced in infected splenectomised mice compared to naïve mice. 
The Salmonella Typhimurium infection model in the mouse has shown that innate 
inflammation can cause local thrombosis and exhaust the pool of circulating platelets via 
the up-regulation of podoplanin on monocytypes and Kupffer cells. Platelets express 
CLEC-2, which binds to podoplanin and causes their activation215–217. Disseminated 
intravascular coagulation of platelets has only been reported once in a dog naturally 
infected with Leishmania infantum but is a unusual finding in VL308. In this work, mice 
infected with L. donovani have never shown signs of intravascular coagulations. 
Another model providing insights into the thrombocytopenia of parasitic infection is 
trypanosomasis309–311. Infection with Trypanosoma brucei or Trypanosoma cruzi leads to 
thrombocytopenia among other symptoms. Trypanosoma cruzi is known to obtain sialic 
acids, complex carbohydrates found on the outer cell membrane, from cells of the host312. 
The trans-sialidase expressed by Trypanosoma cruzi has been shown to induce 
thrombocytopenia313. Indeed, a platelet’s half-life is defined by its content in sialic acids, 
which diminishes over time. Platelets with low sialic acids are phagocytised by Kupffer 
cells in the liver313, which stimulates TPO production via the Ashwell-Morell receptor200. 
This mechanism do not seem to be involved in leishmaniasis since Leishmania species do 
not express a trans-sialidase314. Leishmania  and Trypanosoma parasites have been shown 
to express  platelet activating factors315,316. This is unlikely to cause thrombocytopenia 
since Leishmania parasites are intracellular and not found in the circulation in chronic 
infection. This mechanism appears to help initial infection, since platelet activation has 
been shown to attract monocytes to the sites of Leishmania major infection317, thus 
attracting more potential host cells.  
Epistaxis (nose bleeding) is a clinical symptom often reported as sign of haemorrhagic 
tendencies. Many studies focus on epistaxis because it is a spontaneous phenomenon, 
whereas bleeding tests would require invasive techniques. Contrary to the mouse model, 
epistaxis or mucosal bleeding are common findings in naturally infected dogs. 
Thrombocytopenia is a frequent occurrence in infected dogs, naturally69 or 
experimentally318. However, in some cases, thrombocytopenia has been ruled out as a 
factor for epistaxis. No difference in the frequencies of thrombocytopenia was noted 
between symptomatic dogs with epistaxis and symptomatic dogs without epistaxis295. It is 
also mentioned in this study that thrombocytopenia is not severe enough to explain 
epistaxis. Other studies reports epistaxis in dogs with no thrombocytopenia293. The main 
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factor for epistaxis is not thrombocytopenia but thrombocytopathy, i.e. defect in platelet 
function. Platelet aggregation can be triggered by adenosine di-phosphate (ADP) and 
collagen. Platelet aggregation tests on dogs have shown a reduced aggregation response of 
platelets from the blood of infected dogs294,295,318. The mechanism underlying 
thrombocytopathy in infected dogs is unclear. Here we focused on the thrombocytopenia 
of EVL, which is not always linked to epistaxis. In addition, mice chronically infected with 
L. donovani did not show any spontaneous sign of haemostasis impairment.  If epistaxis is 
taken as a reflection of haemorrhagic tendencies, then treating thrombocytopenia might not 
be clinically relevant. Further studies are required to establish the link between 
thrombocytopenia and clinical symptoms. 
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Chapter 5 General discussion 
 Principal findings and relevance 
 Murine visceral leishmaniasis as a model for haematological studies 
Many experimental studies of VL have used the mouse model and have provided very 
useful insights into the immunobiology of the disease1. The human disease is also 
characterised by profound alterations of the bone marrow and changes in circulating cells 
but very little is known about this aspect of the disease3,62. Much of what is known comes 
from clinical studies and to a certain extent other experimental models such as hamsters. 
The mouse model has often been disregarded because EVL is not associated with lethality 
of overt symptoms. To our knowledge, this is the first report of an extensive 
haematological profile comparing chronically infected and naïve mice. Two types of blood 
cells were reduced during chronic infection, the red blood cells and the platelets. The 
anaemia was mild, normochromic and some mice also showed macrocytic anaemia. 
Reports about VL in humans consistently report a normochromic anaemia with a 
macrocytic tendency. Anaemia did not appear to have a physiological impact on the mice, 
certainly not to the extent of being lethal. Other studies about regulation of erythropoiesis 
in mice show that dramatic decrease in erythropoiesis do not necessarily lead to anaemia. 
Data about thrombocytopenia are rare and there is no experimental study on the 
thrombocytopenia of VL. In the human disease, thrombocytopenia is a common 
occurrence62. The results presented here show that experimentally infected mice and 
human patients have similar haematological alterations. We suggest that the mouse model 
can can be used as a model for haematological disorders in VL, hopefully paving the way 
for more studies. 
 Erythropoiesis is impaired as a consequence of alterations of the bone marrow 
microenvironment 
A decrease in the late stages of erythropoiesis was observed in the bone marrow of infected 
mice chronically infected with L. donovani. The CD71highTER119low pro-erythroblasts 
numbers were unchanged but the CD71high/lowTER119high erythroblasts, which include all 
final stages of erythropoiesis, were reduced. This is the first time erythropoiesis has been 
quantified in detail in the mouse. Previous work by Cotterell et al. has suggested that 
earlier stages of erythropoiesis, the BFU-E, were increased in the bone marrow of infected 
BALB/c mice. Taken together, this suggests that the last stages of erythropoiesis are 
specifically impaired. The microenvironment supporting erythropoiesis was investigated. 
Macrophages are important regulators of erythroid precursors. Here we show that 
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macrophages number are similar upon infection but a relative loss of macrophages 
expressing high levels of CD169 was measured. We and other have demonstrated that 
these macrophages harbour amastigotes, but infection of immunocompromised mice did 
not cause alterations of macrophages. Therefore, the reduction of CD169+ macrophages is 
not a direct consequence of intracellular parasitism. Not only these macrophages are 
known to be essential for erythropoiesis, they have also been linked in previous studies to 
the regulation of the bone marrow microenvironment supporting HSCs. Here, levels of 
CXCL12 were decreased at the mRNA level, corresponding with a decrease in CAR cells. 
These cells have been shown to contain most MSPCs in the bone marrow. The number of 
MSPCs, reflected by the number of CFU-F in the bone marrow was also decreased by L. 
donovani infection, suggesting an actual loss of cells. Previous work has suggested a role 
for stromal macrophages in the pathology of EVL, but here is the first detailed 
investigation into the role of the bone marrow microenvironment in vivo. 
 Cells of the adaptive immune system are required for the onset of 
erythropoiesis repression and alterations of the microenvironment in the bone 
marrow 
One of the major findings in this work is the connection between haematological 
alterations associated with EVL and the immune system. T cells were shown to migrate 
towards parasites in the bone marrow and accumulation of CD3 cells correlated time-wise 
with the decrease of erythropoiesis in the bone marrow. From these observations we 
hypothesised that T cells were responsible for the pathogenesis of VL. The role of adaptive 
immunity in general was confirmed by the lack of alteration in immunocompromised 
RAG2-/- mice. The population of CD169high macrophages, the levels of CXCL12 and G-
CSF as well as erythropoiesis were unchanged. This reinforced the potential link between 
all these alterations. Immune reconstitution resumed the reduction of erythropoiesis in the 
bone marrow together with splenomegaly and higher levels of G-CSF, confirming that the 
adaptive immune response is in part responsible for the defects in erythropoiesis. All these 
findings fit in a model supported by our data and the literature described in Figure 5-1. 
 Alterations of the bone marrow underlie extramedullary erythropoiesis and 
remodelling the spleen 
In other models, the connection between decrease of medullar erythropoiesis and 
splenomegaly has been established. The causes for splenomegaly in VL are unclear. Often, 
splenomegaly and increase in splenic capture of circulating cells is cited as the source for 
haematological alterations. By contrast, we show that changes in the bone marrow 
described above have an impact in the spleen. The alterations in the bone marrow 
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described above were still induced by L. donovani in splenectomised mice. While 
erythropoiesis was decreased in the bone marrow, we measured a dramatic up-regulation 
of splenic erythropoiesis. Histological investigations have shown that erythropoiesis occurs 
exclusively in the red pulp. As a consequence, the red pulp of the spleens from infected 
mice was dilated, especially in comparison to the white pulp. This led to an increase in the 
red pulp/white ratio in 2D image analysis. No up-regulation of BMP4, an essential factor 
inducing extramedullary erythropoiesis, was detected. A recent work by Dalton et al. have 
shown that a population of splenic macrophages is responsible for the splenic remodelling 
during EVL. These macrophages express high levels of Bmp4 compared to other 
populations. Therefore, a role for bone BMP4 signalling cannot be excluded. This is the 
very first report linking alterations of erythropoiesis in the bone marrow and splenic 
remodelling in the context of VL. 
 Thrombocytopenia is caused by splenomegaly and can be rescued by 
recombinant TPO injections 
In addition to anemia, infection with L. donovani resulted in thrombocytopenia. 
Thrombocytopenia was reduced when mice were splenectomised before the infection. No 
deficit of megakaryocyte production was measured as both infected and naïve mice had 
identical number of megakaryocytes in their bone marrow. The production of platelets 
could be stimulated by injections of rhTPO. This treatment was however only efficient is 
rescuing the thrombocytopenia when the splenomegaly was only mild, again indicating 
that the spleen was involved in the reduction of circulating platelets. This was further 
confirmed by injecting rhTPO into splenectomised infected mice, where the platelet counts 
were much higher than what was measured even in naïve mice treated with rhTPO. 
Therefore, the efficacy of rhTPO in driving the platelet count up appears to depend on its 
capacity to stimulate the production of enough platelets to overcome the splenic capture. 
Eltrombopag is a drug used to treat thrombocytopenia. It is an agonist of the c-Mpl 
receptor, the receptor of TPO. This drug is already FDA-approved and associated with 
very little side effect. The demonstration that thrombocytopenia of EVL can be rescued by 
rhTPO suggest that Eltrombopag could be useful in treatment of thrombocytopenia in 
human VL. This work supports the idea that such a drug should be tested in clinical 
settings for the treatment of thrombocytopenia in human VL. 
As a conclusion, we have shown that the adaptive immune response to L. donovani drives 
alterations in the bone marrow, resulting in a loss of erythropoiesis and a mild anaemia. 
These changes are linked to extramedullary erythropoiesis and splenomegaly, which is in 
turns involved in generation of thrombocytopenia, as shown in Figure  5-2. The novelty of 
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this work lies in the demonstration of the complex immunopathogenesis of haematological 
disorders in the context of VL. The individual mechanisms reported in this study have been 
reported previously, but for the first time haematological disorders have been studied not 
in isolation but as part of a whole system, linking anaemia and thrombocytopenia. 
 Outstanding questions and future work 
 Confirm the link between G-CSF up-regulation and repression of 
erythropoiesis 
The concluding model from this work involves G-CSF as a mediator between 
inflammation and repression of erythropoiesis. Absence of G-CSF up-regulation in 
immunocompromised mice correlated with stable expression of CXCL12 and no change in 
CD169-expressing macrophages but it cannot be excluded that these events happen 
independently. The connection between G-CSF and alterations of the bone marrow is 
supported by the literature but experimental data in the context of EVL are still needed. 
Here neutralisation of G-CSF was attempted but was unsuccessful at lowering the levels of 
circulating G-CSF. Further work is therefore needed to confirm the role of G-CSF in the 
pathogenesis of EVL. If a central role for G-CSF in alterations of the bone marrow is 
confirmed, neutralisation of G-CSF could be the base of a novel therapy to relieve 
symptoms of VL. Unfortunately, except for transgenic mouse models, neutralisation of G-
CSF is hard to achieve. Very few conditions have been linked to G-CSF. It has been linked 
to the severity of inflammatory arthritis, but the long treatment and amount of antibody 
used in the study show how difficult G-CSF neutralisation is in vivo278. 
 Functional study of infected macrophages in regards to support of 
erythropoiesis 
We show that infection with L. donovani causes a decrease of CD169high macrophages. But 
the ability of macrophages in mice infected with L. donovani to support erythropoiesis is 
not known. The hypothesis that reduction of CD169high macrophages impairs 
erythropoiesis is supported by the study which shows that depletion of CD169-expressing 
macrophages causes a diminution of erythropoiesis in the bone marrow.  Testing the ability 
of macrophages from infected mice to support erythropoiesis would confirm that 
repression of erythropoiesis in EVL is due in part to the loss of stromal macrophages that 
support erythropoiesis. 
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 Cells of the adaptive immune system responsible for haematological 
alterations 
This work demonstrates a role of the adaptive immune system for the onset of bone 
marrow alterations. Analysis of the bone marrow show that T cells are more numerous in 
infected mice, and images show that T cells come towards infected cells. It is unclear if 
these cells are specifically reacting to parasite antigens, and if they are responsible for the 
defects in haematopoiesis. Immune reconstitution experiments confirm the role for 
adaptive immunity in the pathogenesis of haematological alterations. However, work is 
still needed to demonstrate a) if a specific subset of T or B cell is responsible for the 
alterations of the bone marrow b) if haematological alterations are the result of the local 
inflammation in the bone marrow alone or if immune cells at distant sites also participate. 
 Study the role of the liver in thrombocytopenia 
Thrombocytopenia is a common complication of chronic liver diseases218. VL is associated 
with fibrosis of the liver306,307. The liver has not been studied in this work. The data 
presented here show a contribution of the spleen to thrombocytopenia since the infected 
splenectomised mice have higher platelet counts than there sham-operated counterparts. 
However, a decrease in circulating platelets was still measured in infected splenectomised 
mice, so another mechanism may contribute to thrombocytopenia. Further study is required 
to investigate the role between the liver and thrombocytopenia in the context of VL. 
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Figure 5-1. Hypothetical model for the mechanisms of anaemia in experimental visceral 
leishmaniasis. Infection of the bone marrow (bone marrow) with L. donovani causes CD4 T cells 
mostly, but also CD8 T cells, to infiltrate the tissue. Adaptive immune response drives the up-
regulation of G-CSF in an unidentified source. G-CSF causes alterations of the bone marrow 
microenvironment which consists of CXCL12-secreting fibroblasts and CD169-expressing 
macrophages, the latter also being essential for stimulating CXCL12 production by stromal cells. 
Loss of stromal support for erythropoiesis, especially from stromal macrophages, contributes to the 
decrease of erythropoiesis in the bone marrow and the subsequent anaemia. Dotted arrows 
represent hypothetical connections supported by the literature. 
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Figure 5-2. Hypothetical model for the mechanisms of thrombocytopenia in experimental 
visceral leishmaniasis. In response to anaemia, erythropoiesis is induced in the spleen. The 
proliferation of stress erythroid progenitors in the red pulp of the spleen causes a remodelling of the 
tissue resulting in splenomegaly. The enlarged spleens capture more circulating platelets, which 
eventually leads to thrombocytopenia.  
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List of abbreviations 
 
 
°C   degree Celsius 
Angpt1  angiopoietin 1 
BFU-E   erythroid-burst forming unit 
BSA   bovine serum albumin 
CAR   CXCL12-abundant reticular 
CD”x”   cluster of differentiation “x” 
cDNA   complementary deoxyribonucleic acid 
CFU-E   erythroid-colony forming unit 
CFU-F   fibroblast-colony forming unit 
CL   cutaneous leishmaniasis 
CLEC-2  C-type lectin-like receptor 
CLP   common lymphoid progenitor 
CMP   common myeloid progenitor 
DAPI   4',6-diamidino-2-phenylindole 
DC   dendritic cell 
DCL   diffuse cutaneous leishmaniasis 
DNA   deoxyribonucleic acid 
E. coli   Escherichia coli 
ELISA   enzyme-linked immunosorbent assay 
Emp   erythroblast macrophage protein 
EVL   experimental visceral leishmaniasis 
FSC   forward scatter 
G-CSF   granulocyte-colony stimulating factor 
G-CSF   granulocyte-colony stimulating factor 
GPVI   glycoprotein VI 
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GM-CSF  granulocyte monocyte-colony stimulating factor 
Hb   haemoglobin 
HSC   haematopoietic stem cell 
IL   interleukin 
LT-HSC  long-term haematopoietic stem cell 
LXR   liver X receptor 
M   mole/litre (mM: millimole/litre) 
MCH   mean corpuscular haemoglobin 
MCV   mean corpuscular volume 
MEP   megakaryocyte-erythrocyte progenitor 
MK   megakaryocyte 
Mpl   myeloproliferative leukaemia protein 
MPV   mean platelet volume 
MSC   mesenchymal stem cell 
MSPC   mesenchymal stem and progenitor cell 
NK   natural killer 
nm   nanometre 
NO   nitric oxide 
OD   optical density 
PBS   phosphate-buffered saline 
pg   picograms 
PKDL   post kala-azar dermal leishmaniasis 
RAG2   recombination-activating gene 2 
RBC   red blood cells 
rhTPO   recombinant human thrombopoietin 
RIPA   radioimmunoprecipitation buffer 
RNA   ribonucleic acid 
RT   room temperature 
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Scf   stem cell factor 
SLAM   signalling lymphocytic activation molecules 
SNARE  soluble N-ethylmaleimide attachment protein receptor 
SSC   side scatter 
SSG   stibogluconate 
ST-HSC  short-term haematopoietic stem cell 
STAT   signal transducers and activators of transcription 
TGFb   transforming growth factor beta 
TH1   type 1 helper T cell 
TNF   tumour necrosis factor 
TPO   thrombopoietin 
TRAIL  TNF-related apoptosis inducing factor 
Vcam1   vascular cell adhesion molecule 1 
VL   visceral leishmaniasis 
µl   microliter 
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